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Although most of the cells in an organism have the same genome, they clearly
present different gene expression patterns according to their functions. This is an
evidence of the fact that cell function depends not only on genetic properties, but also
on mechanisms of regulation of gene expression. Gene regulation is of critical
importance, not only for cell differentiation, but also for normal cellular homeostasis
and survival. Cells can indeed adapt to environmental changes by turning on and off
the expression of specific genes in response to certain stimuli. Regulation of gene
expression occurs at different levels, from DNA to transcription and translation, and
involves various mechanisms including chemical and structural alternation of DNA,
recruitment of transcription factors and mRNA processing.
Epigenetic modifications have been recognized as an important factor in
controlling gene transcription. The term epigenetics was originally coined by C.H.
Waddington in 1940s.1 Over the years, several definitions have been proposed and
the term epigenetic has been used in various senses. Today, epigenetics can be
defined as the study of reversible heritable changes in gene function that occur
without a change in the sequence of nuclear DNA.2 Epigenetic modifications control
gene expression in a potentially heritable but still reversible way. This allows cells to
perpetuate information and at the same time be responsive to environmental
changes. The two major epigenetic mechanisms are methylation of DNA and
posttranslational modifications of chromatin-associated proteins, specifically,
histones (figure 1.1). DNA methylation is generally associated with gene repression,
whereas histone modifications can have both repressive and activating functions.3
The importance of epigenetics for cellular development and homeostasis is reflected
by the observation that alterations of epigenetic events play a key role in the
pathogenesis of human diseases. Proteins controlling epigenetic events are therefore
of increasing interest in drug discovery.
HISTONE ACETYLTRANSFERASES
The organization of the eukaryotic DNA into chromatin allows its packaging into the
cell nucleus and plays an important role in regulation of gene expression. The
fundamental repeating unit of chromatin is the nucleosome (figure 1.1), which
consists of 147 base pairs of DNA wrapped around an octameric histone core
containing two copies of each of the four histone proteins (H2A, H2B, H3 and H4).4
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Histones are subject to a wide variety of posttranslational modifications, such as
methylation, acetylation, phosphorylation and ubiquitination.5 These
posttranslational modifications modify histones-DNA interactions and change the
chromatin structure to expose promoter regions for binding of transcription factors.
Furthermore, they mediate specific interactions with multiprotein complexes, which
initiate or inhibit gene transcription.6
Figure 1.1: epigenetic modifications and chromatin packing.
Histone acetylation has been recognized as an important epigenetic control
mechanism in gene expression. Reversible acetylation of histones is modulated by
the activity of histone acetyltransferases (HATs) and histone deacetylases (HDACs).
These enzymes catalyze the introduction or removal of acetyl groups from ε-amino
functionalities of specific lysine residues, respectively. Interestingly, many HATs
and HDACs are also active on non-histone protein substrates.
HATs are classified based on their cellular localization in nuclear HATs (type A)
and cytoplasmic HATs (type B).7 Whereas little is known about cytoplasmic HATs,
several nuclear HATs have been identified and divided into three major families
based on their primary structure homology: the GNAT (GCN5-related N-
acetyltransferase) family, represented by GCN5 (general control nonderepressible 5)
and PCAF (p300/CBP associated factor); the p300/CBP family, including p300 and
CBP (CREB binding protein); the MYST family, which includes Tip60 (TAT
interacting protein 60) and MOZ (monocytic leukemia zinc finger protein). Although




ROLE OFHATS IN INFLAMMATION
Inflammation is a physiological response, triggered by physical, biological or
chemical stimuli, that is necessary for cell survival. Under certain circumstances,
however, the inflammatory response is inappropriate or excessive, which leads to a
pathological state. Abnormal and chronic inflammatory responses have been
associated with various diseases including asthma, cancer, diabetes and
neurodegenerative diseases. It has been demonstrated clearly that post-translational
modifications of proteins play a crucial role in regulating the intensity, the duration
and the specificity of inflammatory responses.
Role of acetylation in NF-κB-mediated inflammation
The nuclear factor κB (NF-κB) transcription factors encompass a family of inducible
transcription factors that play a critical role in the expression of numerous genes
that are involved in immune and inflammatory responses and in cell survival.8
NF-κB transcription factors exist in homo- or heterodimeric complexes
consisting of different members of the Rel family proteins. The most prevalent and
best studied of these complexes is the p50-p65 heterodimer. In resting cells, p50-p65
is present in the cytoplasm in an inactive form, bound to inhibitory proteins, known
as IκBs (figure 1.2). Upon stimulation by specific inducers such as inflammatory
cytokines (tumor necrosis factor, interleukin-1), bacterial products
(lipopolysaccharide) or oxidative stress (H2O2), the IκBs are phosphorylated,
ubiquitinated, and degraded. Degradation of IκBs results in the release of the p50-
p65 dimer, which is free to translocate into the nucleus. Subsequently, the
transcription factor p50-p65 binds to κB target promoters and activates expression of
specific genes. Due to the central role of NF-κB in inflammation, the NF-κB pathway
has been recognized as a target for therapeutic intervention.
Acetylation of NF-κB complex
Several regulatory mechanisms control the NF-κB response to specific stimuli.
Among these, post-translational modifications play an important role and regulate
different functions of NF-κB. Post-translational modifications mutually influence
each other, which results in a complex pattern of modifications that determine the
output and the duration of responses upon specific stimulations of NF-κB. Recently,
it has been described that acetylations of specific lysine residues of NF-κB subunits
play distinct roles in the regulation of its transcriptional capacity, its DNA-binding
ability and duration of its action (figure 1.2).
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Figure 1.2: acetylation plays an important role in NF-κB mediated inflammation. In resting
cells, the p50-p65 subunits are present in the cytoplasm in an inactive form, bound to the
inhibitory protein Ikβα. Upon stimulation Ikβα is phosphorylated, ubiquitinated, and degraded.
The p50-p65 dimer is released and translocates into the nucleus, where both subunits are
acetylated at different positions. Acetylations of the p50-p65 dimer regulate its transcriptional
capacity, its DNA-binding ability and the duration of its action. The p50-p65 subunits recruit
HATs to the target genes. Gene-specific histone acetylations by HATs change the chromatin
structure to expose promoter regions for binding of p50-p65.
It has been shown that the p65 NF-κB subunit (also known as RelA) is
acetylated at specific sites by different HATs. Chen et al. reported acetylation at
lysine residues 218, 221 and 310 by the HATs p300 and CBP.9 Acetylation at Lys
221 increases the binding affinity of the NF-κB complex to the DNA κB enhancer.
Furthermore, acetylation at Lys 221, alone or in combination with Lys 218, impairs
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assembly of NF-κB with newly synthesized IκBα, which extends the duration of the
NF-κB activity. On the contrary, deacetylation by HDAC3 stimulates IκBα binding,
which promotes NF-κB export from the nucleus to the cytoplasm.10 Acetylation at
Lys 310 is required for full transcriptional activity of p65, but does not affect the
DNA binding or its assembly with IκBα. In a subsequent study, it was shown that
acetylation on this position provides a binding site for binding of the bromodomain of
the transcriptional coactivator Brd4.11 Recent work by Yang et al. showed that
acetylation at Lys 310 enhances the transcriptional activity of p65 by impairing the
methylation of lysine residues 314 and 315, which is important for the
ubiquitination and degradation of chromatin-associated p65.12 The HDAC SIRT1
deacetylates p65 at Lys 310 and thus terminates NF-κB dependent gene
expression.13 Thus, acetylations of NF-κB on residues 218, 221 and 310 increase its
transcriptional activity.
In contrast, acetylation at other positions decreases the NF-κB transcriptional
activity. Acetylation on the lysine residues 122 and 123 by both p300 and PCAF
reduce binding of NF-κB to the DNA κB enhancer and facilitate binding to IκBα and
subsequent export from the cytoplasm.14 Others acetylations have no direct effect on
transcriptional activity. Acetylation at lysine residues 314 and 315 by p300 do not
affect the general transcriptional activity of the NF-κB complex.15,16 Nevertheless,
these acetylations modulate the expression of specific sets of genes, which indicate
that site-specific acetylations of p65 regulate the specificity of the NF-κB dependent
gene expression.
The p50 subunit of NF-κB is also subject to stimulus-induced acetylation. In
vitro, p50 is acetylated at lysine residues 431, 440 and 441.17 It has been shown that
acetylation by p300 increases binding of p50 to the DNA and enhances the
transcriptional activation by NF-κB.18
Further evidence for the importance of direct acetylations of NF-κB subunits as
regulatory mechanisms is the observation that diverse cofactors are able to regulate
NF-κB transactivation by modulating p50/p65 acetylation levels. For example, the
transcriptional repressor Daxx impairs the transcriptional activity of NF-κB by
binding to p65 and interferes with its acetylation.19 In contrast, the transcription
coactivator Stat3 maintains constitutive NF-κB activity in inflammation-induced
cancers by promoting p300-mediated acetylation of the p65 subunit.20
Taking these data together it is concluded that direct acetylation and
deacetylation of specific lysine residues in the p50 and p65 subunits of NF-κB play a
crucial role in the regulation of different NF-κB functions. Acetylations on different
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sites have different effects on NF-κB transcriptional activity and NF-κB dependent
gene expression. Several studies show that inhibition of deacetylation extents NF-κB
transcriptional activity in response to specific stimuli, whereas other studies
demonstrate that inhibition of deacetylation decreases NF-κB transcriptional
activity.8,21,22 This indicates that the resulting effect of both HAT and HDAC
inhibition depends on the selectivity for specific NF-κB acetylation sites. The critical
role of NF-κB acetylation and deacetylation in the regulation of NF-κB mediated
gene expression raises the idea to modulate inflammatory responses by modulating
NF-κB acetylation levels with HAT and HDAC inhibitors. It has been shown that
NF-κB acetylations are mediated by the HATs such as p300, CBP and PCAF, which
indicates that small molecule inhibitors of these HATs will modulate NF-κB
signaling via direct inhibition of NF-κB acetylation as well as via modulation of
histone acetylation.
Acetylation of co-activators of NF-κB
Several cofactors that are involved in the regulation of the NF-κB transactivation
are subject to direct acetylations by HATs. These acetylations modulate their
interactions with the NF-κB subunits. Such acetylations have been described for
Poly(ADP-ribose) polymerase-1 (PARP-1), Stat1 and the glucocorticoid receptors.
PARP1 is a coactivator of NF-κB that has been demonstrated to play a role in
inflammatory disorders. PARP-1 is acetylated upon inflammatory stimulation on
specific lysine residues by p300 and CBP and deacetylated by HDACs 1-3.22
Acetylation of PARP-1 is required for the interaction with p50, which results in
coactivation of NF-κB in response to inflammatory stimuli. Stat1 is a transcription
factor that is able to modulate NF-κB activity. Acetylation of Stat1 by HATs, such as
CBP, results in binding to the p65 subunit of NF-κB and consequently reduction of
NF-κB signalling.23 The action of glucocorticoids involves acetylation of the
glucocorticoid receptor. The deacetylated form of the glucocorticoid bound
glucocorticoid receptor is able to suppress NF-κB activity.24
Acetylation of histones in NF-κB mediated gene transcription
Dynamic acetylation and deacetylation of histones play an important role in the
regulation of gene transcription resulting from activation of the NF-κB pathway.
Upon DNA binding the NF-κB subunits are able to recruit HATs and HDACs to the
target gene promoter in order to change the acetylation profiles of the histones. It
has been shown that the transcriptional activation domain of p65 interacts with both
the N-terminal and C-terminal domain of the HATs CBP and p300.25 These HATs
function as co-activator for gene transcription. It has been demonstrated that the
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presence of HATs, such as CBP, p300 and PCAF, at the gene promoter is essential
for NF-κB-mediated gene expression.26 In contrast, it has also been shown that p65
interacts with HDACs, such as HDAC-1 and SIRT6, which function as repressors of
gene transcription by deacetylating histones at promoters of NF-κB target genes.27,28
The importance of promoter-specific histone acetylation by HATs has been
demonstrated for many NF-κB target genes (table 1.1). HATs are involved in gene
transcription of granulocyte-macrophage colony-stimulating factor (GM-CSF), which
is a protein that is involved in physiological and pathological inflammatory processes.
IL-1β stimulates GM-CSF production through activation of the NF-κB pathway. The
GM-CSF production is associated with increased acetylation at Lys 8 and 12 of
histone H4 connected to the GM-CSF promoter.29 Another example is CCL11 (also
known as eotaxin-1), which is an eosinophil chemo-attractant with relevance in
allergic diseases such as asthma. CCL11 transcription is increased upon stimulation
with TNF-α. NF-κB is the key transcription factor for CCL11. In the TNF-α-induced
CCL11 transcription, PCAF is recruited, upon phosphorylation, to the CCL11
promoter. PCAF increases histone H4 acetylation at Lys 5 and 12, which promotes
the p65 association with the DNA and the transcription of CCL11 gene. Histone H4
acetylation is markedly reduced after treatment with β2-agonists and glucocorticoids.
This suggests that one of the mechanisms of actions of these medicines is indirect
decrease of histone acetylation, which inhibits inflammatory gene transcription.30,31
IL-6 is another important mediator of inflammatory responses. Overexpression
of CBP and p300 potentiate basal and TNF-α induced IL-6 promoter activation via
interactions with the NF-κB subunit p65. A similar mechanism is proposed for the
endothelial leukocyte adhesion molecule (ELAM), which is another NF-κB-
dependent promoter.32 Interferon-γ-inducible protein-10 (CXCL10) is a chemokine
implicated in the pathophysiology of asthma and COPD. Stimulation of asthmatic
airway smooth muscle cells with TNF-α or IFN-γ induces recruitment of CBP and
acetylation of histone H4, but not H3 at the CXCL10 promoter, which consequently
increases its transcriptional activity.33 Another gene that is expressed upon
inflammatory stimulation is E-selectin. E-selectin is an adhesion molecule that is
rapidly expressed by endothelial cells activated upon inflammatory stimulation.
Induction of E-selectin gene expression by TNF-α is associated with hyperacetylation
of histones H3 and H4 connected to the E-selectin promoter by the HATs PCAF and
p300.34 Another gene whose expression is induced in response to inflammation is
cyclooxygenase 2 (COX-2). Transactivation of COX-2 gene expression involves
selective hyperacetylation of histone H4 connected to the COX-2 promoter in a
stimulus-specific manner. Stimulation with bradykinin causes acetylation at Lys 5,
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8, and 16 whereas stimulation with IL-1β causes only acetylation at Lys 8.35 This
demonstrates that specific stimuli induce a distinct histone acetylation pattern,
which regulates distinct gene transcription patterns in response to specific
inflammatory stimuli.
Table1.1: promoter-specific hyperacetylation of NF-κB-dependent genes.
Gene Stimulus Cell type Acetylation site HAT
involved
Ref.
GM-CSF IL-1β A549 Histone H4Lys 8, 12 unknown 26
Eotaxin-1 TNF-α HASMC Histone H4Lys 5, 12 PCAF 28
Interleukin-8 Legionella Human lungepithelial Histone H3 Lys 14Histone H4 p300/CBP 33
Listeria HUVEC Histone H3 Lys 14,
Histone H4 Lys 8
CBP 34
LPS HUT-78,Jurkat,monocytes
Histone H4 unknown 35
H2O2,PM10






ELAM TNF-α L929sAHEK293T Global histoneacetylation p300/CBP 29
CXCL10 TNF-α,INF-γ ASM Histone H4 CBP 30
E-selectine TNF-α HUVECs Histone H3Lys 9, 14
Histone H4Lys 5, 8, 12
PCAF,p300 31
Cox-2 Bradykinin ASM Histone H4Lys 5, 8, 16 unknown 32
IL-1β ASM Histone H4 Lys 8 unknown 32
Histone acetylation in IL-8 gene expression
Histone acetylation plays an important role in the activation of interleukin 8 (IL-8)
gene expression in immune responses triggered by bacterial infections. For example,
IL-8 expression in Legionella pneumophila infected lung cells involves increased
recruitment of p300 and CBP, as well as enhanced acetylation of histones H3 and H4
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at the IL-8 gene promoter.36 The same is observed upon infection by intracellular
Listeria monocytogenes, which also induces acetylation of histone H3 and H4 at the
IL-8 promoter, which consequently increases IL-8 expression. In contrast, Listeria-
induced IFN-γ gene expression does not require changes in the histone acetylation at
the IFN-γ promoter. Furthermore, the HDAC inhibitor Trichostatin A increases
Listeria-induced expression of IL-8, but not of IFN-γ induced IL-8 expression. This
demonstrates that histone acetylation regulates the gene expression patterns in
response to specific stimuli.37 Another stimulus that increases IL-8 expression is
LPS. LPS-induced IL-8 gene transcription is associated with acetylation of histone
H4 at the IL-8 promoter. Interestingly, glucocorticoids suppress IL-8 expression,
which is accompanied by reduction of histone acetylation of the IL-8 promoter.38 In
contrast, IL-8 expression and release is also increased upon oxidative stress induced
by H2O2 and environmental particulate matter (PM10). It has been shown that H2O2
and PM10 augment the intrinsic HAT activity in alveolar epithelial cells leading to
increased histone H4 acetylation at the IL-8 gene promoter.39 These findings
demonstrate that IL-8 expression is positively correlated with histone acetylation
and that the importance of histone acetylation for IL-8 expression depends on the
input stimulus.
Role of acetylation in inflammatory diseases
Asthma and COPD
Inflammatory lung diseases, like asthma and COPD (chronic obstructive pulmonary
disease) are associated with the expression of multiple inflammatory genes in the
lungs. Increasing evidence demonstrates that the balance between HAT and HDAC
activity is altered in these diseases. A recent study showed significant reduction of
HDAC activity and increased HAT activity in peripheral blood mononuclear cells of
children with allergic asthma. The intensity of these alterations was positively
correlated to bronchial hyperresponsiveness.40 In another study, it has been shown
that bronchial biopsies from subjects with asthma contain reduced HDAC 1 and 2
expression and decreased HDAC activity. In contrast, HAT activity was increased,
although no difference in expression of HATs (PCAF and CBP) was found.41
Furthermore, it has been found that HAT activity is increased and HDAC activity is
decreased in alveolar macrophages of subjects with asthma compared to healthy
subjects.42 The HAT activity was reduced to normal levels in patient that were
treated with glucocorticoids, which indicates that glucocorticoids regulate
inflammatory responses indirectly by reduction of HAT activity.
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The inflammatory lung disease COPD is also characterized by a disturbed
HAT/HDAC balance. A study with lung tissue samples of COPD patients showed
reduced HDAC activity and expression, and increased histone H4 acetylation at the
IL-8 promoter. In contrast to asthma, HAT activity in COPD patients was not
increased in comparison with healthy subjects.43 The reduced HDAC expression and
activity measured in COPD are also responsible for the steroid resistance associated
with this disease.24 Taken together, these findings indicate that a shift of the
HAT/HDAC balance towards HAT activity may underlie the increased expression of
inflammatory genes in inflammatory lung diseases, which is a mechanism that has
been described in several review articles.44-46 This demonstrates that inhibition of
HAT activity has potential for treatment of such inflammatory diseases.
Diabetes
Inflammatory processes play a role in the pathogenesis of diabetes. This has been
shown in experiments with high glucose conditions, which mimic diabetes. These
experiments demonstrated activation of NF-κB-dependent gene transcription of
inflammatory genes in monocytes in vitro. This activation proceeds through
recruitment of p65 and HATs to the TNF-α and COX-2 promoters, with concomitant
increases in histone H3 and H4 acetylation. Furthermore, increased histone H3
acetylation at TNF-α and COX-2 promoters has been found in human blood
monocytes from type 1 and type 2 diabetic subjects in comparison with non-diabetic
subjects.47 A study in endothelial cells and vascular tissue demonstrated that glucose
causes upregulation of p300 accompanied by increased histone acetylation and
expression of extracellular matrix proteins and vasoactive factors. These proteins are
responsible for alterations of endothelial and vascular structure and function in
organs, which are affected by chronic diabetic complications.48 These results suggest
that inhibition of histone acetylation might be a valuable strategy to suppress
inflammatory responses in diabetes.
Neurodegenerative diseases
Neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease and
amyotrophic lateral sclerosis, are characterized by slow and progressive dysfunction
and loss of neurons in the central nervous system. Several findings support the
theory that inflammation contributes to the development of the neurodegeneration
by activating chronic immune responses, in particular by microglia and astroglia.
Highly activated glial cells express pro-inflammatory cytokines and chemokines that
increase excito-toxicity on neurons and are responsible for neuronal apoptosis.49,50
The inflammatory response of glial cells involves the activation of different signaling
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pathways, including NF-κB, which is accompanied by histone hyperacetylation.51-53
There are many examples in the literature of small molecules that provide protection
against glial cell induced neurodegeneration by blocking the NF-κB pathway.54,55
These findings raise the idea that HAT inhibitors could find a therapeutic
application also in this field.
ROLE OFHATS IN CANCER
Epigenetic events are crucial in the onset and progression of numerous cancer types.
The aberrant gene expression observed in cancer has been often connected to
alterations of histone acetylation; however, the detailed roles of HATs are unclear.
Several studies indicate that HATs act as tumor suppressors. On the contrary,
increasing evidences suggest a role as tumor promoters. For example, it has been
shown that p300 plays a major role in prostatic cancer cell proliferation. High levels
of p300 in biopsies from patients with prostatic cancer are predictive for larger
tumor volumes and aggressive cancer progression.56 A marked increase in p300
mRNA levels has been detected in patient with colorectal cancer and correlated with
poor prognosis.57 Bandyopadhyay et al. showed that downregulation of p300 activity
resulted in activation of a senescence checkpoint in human melanocytes, which
suggests that p300 could be a potential target for novel approaches in the treatment
of melanoma.58
Other HAT family enzymes have also been described to play a role in cancer
manifestation. The HAT MOZ forms fusion genes by chromosome translocation with
p300 in acute myeloid leukemia. The fusion transcript has two acetyltransferase
domains and could be involved in leukemogenesis through aberrant regulation of
histone acetylation.59 It has been described that Tip60 and PCAF are overexpressed
in cisplatin-resistant cells and that knockdown of Tip60 expression renders cells
sensitive to cisplatin.60 Cancer cells overexpressing PCAF showed resistance also to
other chemotherapeutic agents. Downregulation of PCAF sensitized cells to
chemotherapeutic agents and induced cell cycle arrest and apoptosis.61 These results
suggest that PCAF and Tip60 are critical for cancer cells and represent potential
targets for cancer treatment.
In addition, HATs are linked to cancer through their crucial functions in cell
cycle progression. For example, CBP and p300 have an essential function during the
G1/S transition and are required for cell proliferation.62,63 It has been shown that
acetylation of cyclin A by PCAF is essential in order to allow mitosis progression.64
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Acetylation of the cell-division cycle (CDC)-6 protein by GCN5 seems to be crucial for
proper S-phase progression during the cell cycle.65
Changes in global levels of histone acetylation are often associated with different
type of cancer. Seligson et al. described high levels of acetylation at Lys 18 of histone
H3 and Lys 12 of histone H4 in tissue samples from patients with prostate cancer.66
It has been shown that histones H3 and H4 are hyperacetylated in hepatocellular
carcinoma cells compared with cirrhotic and normal livers cells.67 Histone H3 has
been described to be highly acetylated in oral squamous cell carcinoma patient
samples.68 The commonly observed hyperacetylation in cancer suggests that small
molecule inhibitors of HATs have potential to suppress cancer development.
Acetylations of non-histone target proteins play an important role in cancer
development. The transcription factor c-MYC is one of the most frequently
overexpressed oncogenes in human cancer. Acetylation of c-MYC by either
GCN5/PCAF or Tip60 increases protein stability, contributing to cancer
progression.69 In a similar way, acetylation of androgen receptor by p300, PCAF or
Tip60 is critical for prostate cancer cell growth.70,71
Taken together, these studies indicate that, in certain circumstances, increased
HAT activity is associated with cancer development. HATs inhibitors could serve as
tools to unravel the detailed functions of HATs in cancer and might ultimately lead
to therapeutic applications.
HAT INHIBITORS
Small molecule HAT inhibitors that are subtype selective and cell-permeable are
essential tools to evaluate the role of HATs in inflammation and cancer. Several
classes of HAT inhibitors have been described. The most potent and selective HAT
inhibitors are the so-called bisubstrate inhibitors, which include both the histone
peptide and CoA (figure 1.3). These inhibitors are remarkably selective and potent
but their lack of cell-permeability limits their applicability.72,73 High-throughput
screening led to the identification of isothiazolones as potent HAT inhibitors.74 It has
been suggested that the chemical reactivity of these compounds might be important
for their mechanism of action. It is likely that isothiazolone covalently capture a
cysteine thiol group in the HAT active site. This property could be employed for the
development of probes for activity-based protein profiling (ABBP). However, a better
knowledge of isothiazolone structure-activity relationship is necessary to develop
them as ABPP probes for HATs.
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Figure 1.3: synthetic inhibitors of histone acetyltransferases.
Recently, a promising HAT inhibitor (C646) was discovered using a virtual
ligand screening.75 This compound is a potent and selective inhibitor of p300 and it is
able to reduce histone acetylation and cancer cell growth. Alkylidenemalonates, 4-
hydroxyquinolines and α-methylene-γ-butyrolactones have also been described to
inhibit HAT activity. Unfortunately, the low potency and specificity has limited their
applications in cell-based studies.76,77
The screening of natural products has led to the identification of several HAT
inhibitors (figure 1.4). Interestingly, these compounds originate from plants known
in the traditional medicine to have anti-inflammatory effects. For example,
anacardic acid (AA) has been described as inhibitor of the HATs p300/CBP and
PCAF.78 AA is also known to possess anti-inflammatory properties. Sung et al.
reported that AA inhibits acetylation of p65, and suppresses both inducible and
constitutive NF-κB activation with consequent reduction of NF-κB-dependent gene
expression. The down-regulation of p300 by siRNA abrogated the effects of AA on the
NF-κB pathway, which suggests that the HAT inhibitory effect is essential for the
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Figure 1.4: natural product inhibitors of histone acetyltransferases.
Another natural product, which has recently been described to inhibit the HAT
p300, is Plumbagin.80 Plumbagin also suppresses NF-κB activation induced by
different inflammatory stimuli and down-regulates NF-κB-dependent gene
expression.81 Interestingly, the intensively investigated natural product Curcumin is
an inhibitor of p300/CBP.82 Its synthetic derivative hydrazinocurcumin (figure 1.3),
inhibits HATs also.68 Curcumin reduces NF-κB activation induced by a variety of
stimuli and down-regulates NF-κB dependent expression of many inflammatory
genes via suppression of TNF-α-induced p65 acetylation.83 Furthermore, the natural
products Gallic acid and Epigallocatechin-3-gallate also possess anti-inflammatory
properties. Recently, these compounds were described as non-selective inhibitors of
HATs.84,85 They suppress p65 acetylation and abrogate NF-κB activation in response
to different inflammatory stimuli. It should, however, be noted that
Epigallocatechin-3-gallate also inhibits phosphorylation of several proteins like for
example MAP kinases.86 Finally, the natural product Garcinol is a potent inhibitor of
p300 and PCAF and also possesses anti-inflammatory properties.87 It has been
showed that Garcinol inhibits constitutive and induced NF-κB activity and down-
regulates NF-κB-dependent genes.88 Microarray analysis showed that Garcinol
inhibited the expression of many disease related genes.89 Taking these data together
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it is tempting to speculate that the anti-inflammatory and HAT inhibitory properties
of these natural products are directly connected. However, the development of
selective inhibitors for HAT isoenzymes that could specifically downregulate
expression of distinct genes, remain a major challenge.
SCOPE OF THE THESIS
HATs have been extensively studied in recent years and an increasing number of
functions in cell physiology and pathology have been identified. Nevertheless, the
detailed roles and interactions of HAT isoenzymes remain to be elucidated. Small
molecule modulators of HAT activity are effective tools to investigate cellular HAT
functions and their implications for pathology. Furthermore, these molecules
represent starting points for the design of new drugs. For example, the commonly
observed hyperacetylation in inflammation demonstrates that small molecule
inhibitors of HATs have potential to suppress inflammation. Moreover, several
studies suggest that HAT hyperactivity may be associated with tumorigenesis and
therefore it is expected that HAT inhibitors may serve as potential anticancer
agents.
The currently described HAT inhibitors, however, suffer from low potency, lack
of specificity or low cell-permeability, which hampers their use in pharmacological
studies. The development of novel HAT inhibitors therefore is urgently required. The
aim of the studies described in this thesis is to develop potent and selective small
molecule inhibitors of HATs that can effectively inhibit histone acetylation in cells.
Ultimately, the aim is to provide novel probes for pharmacological and ABPP studies
on HATs.
The studies described in chapter 2 aim at the design of new covalent
isothiazolone-based HAT inhibitors, which could be used as ABPP probes. In this
chapter we aim to resolve the structure-activity relationships (SAR) for inhibition of
HATs by isothiazolones in order to clarify the structural requirements for biological
activity. For this purpose, we investigate the in vitro inhibitory activities of different
isothiazolone derivatives on the recombinant HAT PCAF. To assess the toxicity of
these compounds, we explore the growth inhibition of different cancer cell lines upon
treatment with isothiazolones.
In chapter 3 we continue our studies on isothiazolones as HAT inhibitors. We
investigate new synthetic modifications of the isothiazolone ring in order to
modulate its reactivity and establish whether changes in chemical reactivity are
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correlated to changes in the biological properties. Furthermore, we analyze the
reactivity of 5-chloroisothiazolones and 5-chloroisothiazolone-1-oxides towards thiols
and thiolates to elucidate the reaction mechanism of these compounds.
The work described in chapter 4 aims at the design on new non-covalent HAT
inhibitors based on the natural product AA, which could be used as tools for
pharmacological studies. Using a combination of molecular modeling and organic
synthesis, new AA derivatives are developed. We investigate the in vitro inhibitory
potency of these compounds for the recombinant HAT PCAF activity in order to
resolve the SAR. Furthermore, we study the inhibition of histone acetylation in HEP
G2 cells upon treatment with AA derivatives to prove their efficacy in cell-based
studies.
Chapter 5 extends our investigation on AA derivatives as HAT inhibitors. We
aim to develop compounds that are selective towards different recombinant HAT
isoenzymes. For this purpose, we synthesized several salicylate derivatives and
screen them for the in vitro inhibition of three different recombinant HATs.
Furthermore, we aim to elucidate the HAT inhibitory mechanism of this class of
compounds using enzyme kinetics studies. We also evaluate the inhibitory properties
of salicylate derivatives on HAT activity of nuclear extract from cell cultures and
tissue samples in order to prove their efficacy in biological samples.
In chapter 6 the results from the studies described in this thesis are
summarized and discussed, together with future perspectives.
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Small molecule HAT inhibitors are useful tools to unravel the role of histone acetyl
transferases (HATs) in the cell and have relevance for oncology. We present a
systematic investigation of the inhibition of the HAT p300/CBP Associated Factor
(PCAF) by isothiazolones with different substitutions. 5-chloroisothiazolones proved
to be the most potent inhibitors of PCAF. The growth inhibition of 4 different cell
lines was studied and the growth of two cell lines (A2780 and HEK 293) was
inhibited at micromolar concentrations by 5-chloroisothiazolones. Furthermore, the 5-
chloroisothiazolone preservative KathonTM CG that is used in cosmetics inhibited
PCAF and the growth of cell lines A2780 and HEK 293, which indicates that this
preservative should be applied with care.
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INTRODUCTION
Posttranslational modifications of histone proteins play a crucial role in gene-specific
transcription regulation in eukaryotes.90 These histone modifications occur in
distinct patterns that mediate specific interactions with multiprotein complexes,
which initiate or inhibit gene transcription via the so-called ‘histone-code’.91-93 There
is increasing evidence that the histone code plays a crucial role in normal and
aberrant cell function and differentiation. Small molecule modulators of histone
modifying enzymes are useful tools to unravel the functions of these enzymes and
might ultimately lead to therapeutic applications.
The histone acetyltransferases (HATs) form a disparate group of enzymes that
mediate acetyl transfer to histones or other proteins.7,94 The GNAT (Gcn5 related N-
acetyltransferase) family HATs include the closely related enzymes PCAF
(p300/CBP associated factor) and GCN5 (general control of amino-acid synthesis 5).95
PCAF acetylates histone H3 on lysine 14 and less efficiently histone H4 on lysine 8.96
The GNAT family HATs have been recognized as potential anticancer and antiviral
targets.94,97 The HAT GCN5 plays a key role in EGF mediated gene transcription,
which is relevant for cancer therapy.98 Furthermore, GCN5 is crucial for cell cycle
progression 99.Deregulation of the activity of GNAT and p300 family HATs plays an
important role in a number of human cancers.100,101
Despite the potential therapeutic relevance of the GNAT family HATs, very few
small molecule inhibitors for GCN5 and PCAF have been described so far. Lau et al.
described bisubstrate inhibitors for p300 and PCAF by coupling the histone H3
peptide to CoA.72 However, this provided compounds with poor membrane
permeability. The natural products Curcumin, Garcinol and Anacardic acid show
HAT inhibitory activity, however their potency is low.78,82,87 GCN5 and PCAF are
inhibited by α-methylene-γ-butyrolactones and isothiazolones, which covalently
capture the active site thiol of these enzymes.74,102
The isothiazolones provide an interesting starting point for structure based
design of PCAF and GCN5 inhibitors. The isothiazolone functionality is readily
available via organic synthesis and can easily be decorated with diverse
substitutions to enhance binding to the enzyme active site.103 The crystal structure
and the catalytic mechanism of GCN5 and PCAF provide inspiration for inhibitor
design.104-107 The crystal structure of the enzyme GCN5 in complex with a
bisubstrate inhibitor shows that the pyrophosphate and the pantothenic acid moiety
make extensive hydrogen bonding interactions with the enzyme.108 The same is
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observed in the crystal structure of the enzyme PCAF in complex with CoA (PDB
entry 1CM0).104 This suggests that hydrogen bonding interactions are relevant for
binding to the enzyme active site. Thus, inhibitors with hydrogen bond
donor/acceptors may show improved binding to the enzyme active site.
In this study we investigated structure activity relationships for inhibition of the
enzyme PCAF by isothiazolones. The (5-chloro)isothiazolone scaffold was used to
target the active site thiol and the substitution was explored to enhance binding by
providing specific interactions with the enzyme. A series of 19 compounds was
synthesized and tested for inhibition of PCAF activity. 5-Chloroisothiazolones
showed the most potent inhibition of PCAF. 5-Chloroisothiazolone 2e showed a
slightly increased potency compared to the other 5-chloroisothiazolones. Cell lines
A2780 and HEK 293 showed growth inhibition upon treatment with micromolar
concentrations N-aliphatic substituted 5-chloroisothiazolones, whereas the cell lines
WiDr and HEP G2 were much less affected.
RESULTS AND DISCUSSION
Chemistry
A collection of N-functionalized isothiazolones was synthesized using procedures
shown in Scheme 2.1.103,109-111 Different amines were reacted with 3,3′-
dithiodipropanoyl chloride 1 to give the dithiodipropionic amides in moderate to high
yields. The dithiodipropionic amides were treated with sulfuryl chloride (3 equiv) at
0 ºC in dichloromethane to give the 5-chloroisothiazolones 2 and isothiazolones 3 in
ratios between 3:1 and 2:1, which were readily separated using column
chromatography. 5-chloroisothiazolones were obtained in yields between 50% and
70% and isothiazolones were obtained in yields around 20% from the same reaction
mixture. Surprisingly, 2d yielded only 23% of the 5-chloroisothiazolone and the
corresponding isothiazolone could not be isolated from the same reaction mixture. 5-
Chloroisothiazolone 2e was oxidized by mCPBA to yield 5-chloroisothiazolone-1-
oxide 4e.109 Treatment of 5-chloroisothiazolone 2e with POCl3 and ammonia
provided 5-chloroisothiazol-3-amine 5e.103 4-acylamino-isothiazolone 7e was
obtained using a modified procedure published by Nádel et al.111 Cbz protected L-
Cystin 6 was coupled to an amine HCl-salt using DCC, HOBt and triethylamine as a
base followed by treatment with sulfuryl chloride to yield the 4-carbamoyl-5-
chloroisothiazolone 7e.
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Scheme 2.1: synthesis of a focused compound collection. Reagents and conditions: (a) R-NH2,
Et3N, CH2Cl2, (b) SO2Cl2, CH2Cl2, (c) mCPBA, CH2Cl2, (d) POCl3, (e) NH3, CH3CN, (f) DCC,
HOBt, Et3N, R-NH3+Cl-, CH2Cl2.
Structure–activity relationships for PCAF inhibition
Structure–activity relationships for inhibition of the HAT PCAF by a series of (5-
chloro)isothiazolones were investigated in order to explore the binding properties of
these compounds (table 1.1). Binding studies were performed using a procedure
published by Trievel et al.112 The enzyme activity was measured by detection of CoA-
SH by the fluorescent dye 7-(diethylamino)-3-(4’-maleimidylphenyl)-4-
methylcoumarin (CPM). The CoA-SH concentrations measured with no inhibitor
present were around 50 μM. Enzyme inhibition was measured by determination of
the residual enzyme activity after 15 min incubation with the inhibitor. The
inhibitor concentrations were maximal 10 μM, so inhibitory effects of more than 20%
at 10 μM inhibitor concentration cannot be explained by direct reaction of the
inhibitors with CoA-SH, but result from inhibition of the enzyme. Compounds that
showed more than 50% inhibition at 10 μM (n = 3) were subjected to IC50
determination (n = 3). A representative example is shown in figure 2.1A.
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Table 2.1: inhibition of the HAT PCAF and proliferation of cell lines by (5-
chloro)isothiazolones. Inhibition concentration 50% (IC50) determination n = 3, growth














3.0 ± 0.6 2.0 ± 0.2 5.0 ± 0.4 6.0 ± 1.2 1.4 ± 0.1
2b 3.0 ± 0.3 >10 >10 >10 5.6 ± 0.4
2c 2.9 ± 0.3 2.3 ± 0.2 >10 6.4 ± 0.2 1.7 ± 0.1
2d 2.9 ± 0.7 >10 >10 >10 >10
2e 1.8 ± 0.2 3.3 ± 0.3 7.5 ± 0.3 10 ± 1 2.8 ± 0.3
2f 2.5 ± 0.3 3.0 ± 0.4 >10 7.0 ± 0.8 1.5 ± 0.6
2g 2.8 ± 0.3 5.2 ± 0.1 >10 8.0 ± 0.4 0.7 ± 0.1
2h 3.2 ± 0.2 7.0 ± 0.8 5.6 ± 0.5 9.4 ± 0.3 2.9 ± 0.8
2i 2.0 ± 0.2 3.0 ± 0.1 >10 >10 >10
2j 2.5 ± 0.1 >10 >10 >10 >10
2k 2.6 ± 0.1 8.1 ± 0.7 >10 >10 3.0 ± 0.4
3b >10 >10 >10 >10 >10
3c >10 >10 >10 >10 >10
3e >10 >10 >10 >10 >10
3f >10 >10 >10 >10 >10
3h >10 >10 >10 >10 >10
3j 4.2 ± 0.6 >10 >10 >10 >10
4e 5.6 ± 0.2 >10 >10 >10 >10
5e >10 >10 8.6 ± 1.0 2.0 ± ± 0.3 4.7 ± 0.4
7e 4.9 ± 0.9 5.8 ± 0.6 >10 >10 10
The compounds were designed to evaluate the PCAF inhibition of 5-
chloroisothiazolones and isothiazolones with different N-substitutions. The 5-
chloroisothiazolone core with only an N-ethyl substitution 2b shows a potent PCAF
inhibition. The PCAF inhibition of 2b is equal to the commercially available
preservative KathonTM CG 2a/3a, which is a mixture of N-methyl-5-
chloroisothiazolone and N-methylisothiazolone 3:1. An N-pentyl substitution 2c did
not improve binding compared to 2b. A series of N-substitutions with a methyl ester
at different numbers of carbon atoms distance to the (5-chloro-)isothiazolone 2d–h
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was studied. Compound 2e showed a slightly increased potency compared to the
other 5-chloroisothiazolones, which suggests that the N-substitution provides
additional interaction with PCAF. Based on compound 2e a molecular modeling was
performed to suggest a binding pose to aid future optimizations of the PCAF
inhibition (figure 2.2).
Figure 2.1: panel A shows the concentration dependence for inhibition of the PCAF enzyme
activity by 5-chloroisothiazolone 2e (n = 3, standard deviation shown) and panel B shows the
concentration dependence for growth inhibition of the cell line A2780 by 2e (n = 8, standard
deviation shown).
There is a pronounced difference in potency between N-aliphatic substituted 5-
chloroisothiazolones 2 and isothiazolones 3. 5-Chloroisothiazolones 2b–i,k inhibit
PCAF with IC50 values around 2–3 μM, whereas isothiazolones 3b,c,e,f,h, showed
less than 50% inhibition at 10 μM. The difference in potency for the N-aromatic
substituted 5-chloroisothiazolone 2j and isothiazolone 3j is much less pronounced.
The same in observed in the data provided by Stimson et al. in which the difference
in PCAF inhibitory potency between N-aromatic 5-chloroisothiazolones and
isothiazolones is a factor 2 or less.74
Compounds with modifications directly on the isothiazolone scaffold were
synthesized and the consequences for PCAF inhibition were studied. 5-
chloroisothiazolone-1-oxide 4e inhibited the PCAF activity at micromolar
concentrations. The 5-chloroisothiazol-3-amine 5e did not inhibit PCAF. Substitution
of the 5-chloroisothiazolone scaffold in the 4-position with an amino acyl substituent
7e reduced the PCAF inhibition compared to compound 2e. Nevertheless, compound
7e provides an interesting starting point for further optimization of the PCAF
inhibition by variation of the 4-amino acyl substituent.
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Reports on the reactivity of N-methylisothiazolones and N-methyl-5-
chloroisothiazolones indicate a high reactivity of 5-chloroisothiazolones. 5-
chloroisothiazolones are prone to nucleophilic substitution in the 5-position and
reductive cleavage of the N–S bond.113 In contrast, for isothiazolones only reductive
cleavage of the N–S bond by sulfides is observed and no nucleophilic addition in the
5-position. This study supports the idea that the potent inhibition of 5-
chloroisothiazolones is due to their reactivity. Interestingly, isothiazolone 3j with a
N-aromatic substitution shows an IC50 of 4.2 μM for PCAF inhibition. This indicates
that N-aromatic isothiazolones are either more prone to nucleophilic addition in the
5-position of the isothiazolone or that they are more prone to reductive cleavage of
the N–S bond, compared to N-aliphatic substituted isothiazolones.
Figure 2.2: binding pose for 2e in the PCAF active site (PDB entry 1CM0) that was proposed by
a molecular modeling study. Cys 574 is the active site cysteine. Hydrogen bonds are formed to
valine 576 and Glutamine 581 and to the pyrophosphate binding pocket formed by the backbone
amides of Glutamine 581,Valine 582, Lysine 583, Glycine 584 and Tyrosine 585.
Molecular modeling
Modeling studies were performed to propose a binding pose for inhibitor 2e to aid
future optimization of the inhibitors. The crystal structure of PCAF complexed with
CoA (PDB entry code 1CM0) was used for docking studies.104 The molecular
modeling study suggested a binding pose in which the methyl ester is hydrogen
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bonded to a pocket in which the pyrophosphate is bound in the PCAF crystal
structure 1CMO (figure 2.2). The pyrophosphate binding pocket is formed by the
backbone of amides of Glutamine 581, Valine 582, Lysine 583, Glycine 584 and
Tyrosine 585. The carbonyl from the 5-chloroisothiazolone is hydrogen bonded to
Glutamine 581 and Valine 576. Docking of 5-chloroisothiazolone-1-oxide 4e provided
a similar binding pose as observed for 2e. Docking of 7e provided also a binding pose
comparable to 2e. These results suggest that the PCAF inhibitory potency of 2e, 4e
and 7e might be improved by variations in the substitution in the 4-position of the
isothiazolone core. In conclusion, compounds 2e, 4e and 7e provide starting points to
design inhibitors with an improved PCAF inhibitory potency.
Growth inhibition of cell lines
Inhibition of cancer cell lines was studied in order to explore the relevance of (5-
chloro)isothiazolones as research tools to study the biological mechanisms
underlying cell proliferation.114 The growth inhibition of the human cancer cell lines
A2780 (ovarian), WiDr (colon) and HEP G2 (liver) and the human embryonic cell line
293 (kidney) was studied. Growth inhibition was determined using a crystal violet
assay. The compounds were screened at 10 μM inhibitor concentration for growth
inhibition (n = 8) and compounds with more than 50% growth inhibition were
subjected to growth inhibition 50% determination (GI50) (n = 8) (table 2.1). A
representative example is shown in figure 2.1B. The N-aliphatic substituted 5-
chloroisothiazolones are the most potent compounds for growth inhibition of cell
lines A2780 and HEK 293. The growth of cell lines WiDr and HEP G2 were not
inhibited or required higher concentrations for inhibition compared to cell lines
A2780 and HEK 293, which might be due to differences in the growth rate or
differences in cellular biochemistry. Western blots on histone acetylation in cell lines
that are treated with optimized inhibitors are required to proof a connection between
the PCAF HAT inhibition and the cellular activity.
It is remarkable that compounds 2j and 3j do not inhibit the growth of the four
cell lines that were studied. This indicates that N-aromatic isothiazolones like 2j are
less potent inhibitors of cell proliferation. Compound 5e with a 5-chloroisothiazol-3-
amine scaffold showed no inhibitory effect on PCAF but shows a potent inhibition of
WiDr, HEP G2 and HEK 293 cell lines. This is the first time that a biological effect
is described for a compound with a 5-chloroisothiazol-3-amine scaffold.
The commercially available preservative KathonTM CG 2a/3a showed a potent
PCAF inhibition and a potent growth inhibition of the four cell lines studied (table
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2.1). This is remarkable because the mixture has been used as a preservative in
rinse-off cosmetics such as shampoos and conditioners for more than 25 years.
KathonTM CG is claimed to be safe and effective, however skin sensitization have
been reported.113,115 The growth inhibition of cell lines shows that KathonTM CG
2a/3a is cell-permeable and acts on intracellular targets. The inhibition of PCAF
indicates that this preservative might modify the epigenetic regulation of gene
transcription. Taking these data together we conclude that KathonTM CG should be
applied with care.
CONCLUSION
In conclusion, N-aliphatic substituted 5-chloroisothiazolones inhibit the enzyme
PCAF with an IC50 around 2–3 μM, whereas N-aliphatic substituted isothiazolones
show less than 50% inhibition at 10 μM. The difference in PCAF inhibitory potency
between N-aromatic substituted 5-chloroisothiazolones and isothiazolones is much
less pronounced. N-Aromatic and N-aliphatic substituted 5-chloroisothiazolones
showed a comparable potency for PCAF inhibition. N-Aliphatic substituted 5-
chloroisothiazolones inhibited the growth of the cell lines A2780 and HEK 293 in the
low micromolar range, whereas growth inhibition of WiDr and HEP G2 required
higher concentrations or was not observed. N-Aromatic substituted 5-
choroisothiazolones, N-aromatic and N-aliphatic substituted isothiazolones showed
less than 50% inhibition of the cell proliferation at 10 μM. Finally, it has been shown
that the preservative KathonTM CG inhibits the HAT PCAF and inhibits the cell
growth of A2780, WiDr, HEP G2 and HEK 293 cell lines.
EXPERIMENTAL PROCEDURES
Organic synthesis
General: Chemicals were obtained from commercial sources (Sigma–Aldrich, Acros
Organics) and used without previous purification, except dichloromethane that was
distilled over CaH2 before use. Thin-layer chromatography (TLC) was performed on
aluminum sheets of Silica Gel 60 F254. Spots were visualized under ultraviolet light,
with I2 vapor, KMnO4 solution or ninhydrin solution. Column chromatography was
performed with MP Ecochrom Silica Gel 32–63, 60 Å. 1H and 13C NMR spectra were
recorded on a Varian Gemini-200 (50.32 MHz). Chemical shift values are reported as
part per million (δ) relative to residual solvent peaks (CHCl3, 1H δ = 7.26, 13C δ =
77.16 or CD3OD, 1H δ = 3.31, 13C δ = 49.00). The coupling constants (J) are reported
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in Hertz (Hz). 13C spectra were recorded using the attached proton test (APT) pulse
sequence. Electrospray ionization mass spectra (ESI-MS) were recorded on an
Applied Biosystems/SCIEX API3000-triple quadrupole mass spectrometer. High-
resolution mass spectra (HR-MS) were recorded using a flow injection method on a
LTQ-Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany) with a
resolution of 60,000 at m/z 400. Protonated testosterone (lock mass m/z = 289.2162)
was used for internal recalibration in real time. Melting points were determined on
an Electrothermal digital melting point apparatus and are uncorrected.
Scheme 2.2: general procedure 2-3 and chemical structure of compounds 8a-f and 10b-k.
General procedure 1
The dithiobispropanamide (8 mmol) was dissolved in dry CH2Cl2 (50 mL) at 0 ºC.
SO2Cl2 (24 mmol) was added dropwise to the solution, and the mixture was stirred at
0 ºC for 2 h. Subsequently, the mixture was washed with water (2 times 200 mL) and
brine (1 time 200 mL), dried with Na2SO4 and filtered. The solution was
concentrated under reduced pressure and purified using column chromatography.
General procedure 2
SOCl2 (30 mmol) was added dropwise to a suspension of the amino acid (25 mmol) in
methanol (25 mL) at 0˚C. The mixture was stirred for 2 hours at 0˚C. The solvent
was removed under reduced pressure to give the title compound.
General procedure 3
A mixture of 3,3’-dithiodipropionic acid (15 mmol) was suspended in SOCl2 (10 mL).
The suspension was heated to 60 oC until the starting material dissolved and
subsequently the SOCl2 was distilled off leaving 3,3'-dithiodipropanoyl chloride as a
dark orange oil behind. The orange oil was dried under vacuum. A mixture of
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cooled to 0˚C and 3,3'-dithiodipropanoyl chloride was added dropwise. After 1 h. the
cooling is removed and the mixture was stirred at room temperature overnight. The
resulting precipitate was filtered off and the filtrate was extracted with saturated
Na2CO3 (3 times 50 mL), 1 N HCl (3 times 50 mL), and brine (1 time 50 mL). The
organic layer was dried (Na2SO4), and concentrated under reduced pressure to give
the dithiopropionamide
5-Chloro-2-ethylisothiazol-3(2H)-one (2b)
The product was obtained using procedure 1 starting from 10b. Purification was
performed using column chromatography with hexane/EtOAc 3:1 (v/v) as eluent.
Yield 46%. Brown gum. Rf = 0.44 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, CDCl3): δ
1.32 (t, J = 7.2 Hz, 3H), 3.81 (q, J = 7.2 Hz, 2H), 6.36 (s, 1H). 13C NMR (50 MHz,
CDCl3): δ 15.0, 39.4, 114.8, 146.3, 167.0. HPLC: purity >99%, retention time 6.6 min
(column C8 mobile phase H2O/CH3CN/TFA 60:40:1). HRMS (m/z) 163.9933 [M+H]+,
calcd 163.9937 C5H7ClNOS.
2-Ethylisothiazol-3(2H)-one (3b)
After elution of 2b product 3b was eluted from the column using EtOAc eluent. Yield
10%. Brown gum. Rf = 0.38 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, CDCl3) δ 1.60
(m, 3H), 3.88 (m, 2H), 6.36 (m, 1H) 8.20 (m, 1H). 13C NMR (50 MHz, CDCl3) δ 15.3,
39.8, 114.9, 140.4, 168.9. GC–MS purity >99%, retention time 2.69 min, (EI) [M+]
m/z 129. HRMS (m/z) 130.0323 [M+H]+, calcd 130.03266 C5H8NOS.
5-Chloro-2-pentylisothiazol-3(2H)-one (2c)
The product was obtained using procedure 1 starting from 10c. Purification was
performed using column chromatography with hexane/EtOAc 8:1 (v/v) as eluent. An
extra column chromatography step was required to obtain the pure product. Yield
55%. Orange oil. Rf = 0.53 (CH2Cl2/MeOH 94:6). 1H NMR (200 MHz, CDCl3) δ 0.88 (t,
J = 6.8 Hz, 3H), 1.24-1.38 (m, 4H), 1.59-1.73 (m, 2H), 3.71 (t, J = 7.3 Hz, 2H), 6.25 (s,
1H). 13C NMR (50 MHz, CDCl3) δ 14.1, 22.4, 28.8, 29.6, 44.0, 115.0, 145.8, 167.1. GC-
MS RT 5.2 min, purity >99%, MS(EI) (m/z) 205, calcd 205. HRMS (m/z) 206.0402
[M+H]+, calcd 206.04064 C8H13ClNOS.
2-pentylisothiazol-3(2H)-one (3c)
After elution of 2c product 3c was eluted from the column using hexane/EtOAc 1:1
(v/v) as eluent. An extra column chromatography step was required to obtain the
pure product. Yield 25%. Brown gum. Rf = 0.29 (CH2Cl2/MeOH 94:6). 1H NMR (200
MHz, CDCl3) δ 0.89 (t, J = 6.5 Hz, 3H), 1.24-1.37 (m, 4H), 1.51-1.79 (m, 2H), 3.79 (t,
J = 7.3 Hz, 2H), 6.32 (d, J = 6.2 Hz, 1H), 8.1 (d, J = 6.2 Hz, 1H). 13C NMR (50 MHz,
Inhibition of the HAT PCAF by isothiazolones
37
CDCl3) δ 14.2, 22.6, 28.8, 29.7, 44.5, 114.7, 139.7, 169.1. GC-MS RT 4.8 min, purity
>95%, MS(EI) (m/z) 171, calcd 171. HRMS (m/z) 172.0792 [M+H]+, calcd 172.0796
C8H14NOS.
Methyl 2-(5-chloro-3-oxoisothiazol-2(3H)-yl)ethanoate (2d)
The product was obtained using procedure 1 starting from the 10d. Purification was
performed using column chromatography with hexane/EtOAc 3:2 (v/v) as eluent.
Yield 23%. Dark brown gum. Rf = 0.76 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz,
CDCl3) δ 3.78 (s, 3H), 4.48 (s, 2H), 6.32 (s, 1H). 13C NMR (50 MHz, CDCl3) δ 44.1,
53.0, 112.9, 148.2, 167.3, 168.0. GC–MS rt 4.88 min, MS (EI) gave anomalous
results. MS (ESI) (m/z) 208.0 [M+H]+, calcd 208.0. HRMS (m/z) 207.9831 [M+H]+,
calcd 207.9835 C6H7ClNO3S.
Methyl 3-(5-chloro-3-oxoisothiazol-2(3H)-yl)propanoate (2e)
The product was obtained using procedure 1 starting from 10e. Purification was
performed using column chromatography with hexane/EtOAc 1:2 (v/v) as eluent.
Yield 49%. Orange oil. Rf = 0.58 (CH2Cl2/MeOH 10:1). 1H NMR (200 MHz, CDCl3) δ
2.67 (t, J = 6.2 Hz, 2H), 3.66 (s, 3H), 3.95 (t, J = 6.2 Hz, 2H), 6.19 (s, 1H). 13C NMR
(50 MHz, CDCl3) d 33.9, 39.8, 52.3, 114.3, 147.0, 167.1, 171.8. GC– MS RT 5.97 min,
purity >99%, MS(EI) (m/z) 221 [M], calcd 221. HRMS (m/z) 221.9987 [M+H]+, calcd
221.9992 C7H9ClNO3S, (m/z) 243.9805 [M+Na]+, calcd 243.9811 C7H8ClNNaO3S.
HPLC purity >99%%, rt 5.0 min, (column C8 mobile phase H20/CH3CN/TFA 60:40:1).
Methyl 3-(3-oxoisothiazol-2(3H)-yl)propanoate (3e)
After elution of 2e product 3e was eluted from the column using hexane/EtOAc 1:20
(v/v) as eluent. Yield 23%. Brown oil. Rf = 0.49 (CH2Cl2/MeOH 10:1). 1H NMR (200
MHz, CDCl3) δ 2.76 (t, J = 6.5 Hz, 2H), 3.70 (s, 3H), 4.09 (t, J = 6.5 Hz, 2H), 6.31 (d,
J = 6.4 Hz, 1H), 8.10 (d, J = 6.2 Hz, 1H). 13C NMR (50 MHz, CDCl3) δ 33.9, 40.2,
52.2, 114.2, 140.4, 169.1, 171.6. GC–MS RT 6.36 min, purity >99%, MS (EI) (m/z)
187 [M], calcd 187. HRMS (m/z) 188.0378 [M+H]+, calcd 188.0381 C7H9ClNO3S,
(m/z) 210.01961 [M+Na]+, calcd 210.0201 C7H9NNaO3S.
Methyl 4-(5-chloro-3-oxoisothiazol-2(3H)-yl)butanoate (2f)
The product was obtained using procedure 1 starting from 10f. Purification was
performed using column chromatography with hexane/EtOAc 1:1 (v/v) as eluent.
Yield 67%. Brown solid. Mp = 47.9 °C. Rf = 0.83 (CH2Cl2/MeOH 9:1). 1H NMR (200
MHz, CDCl3) δ 1.92–2.06 (m, 2H), 2.38 (t, J = 7.2 Hz, 2H), 3.66 (s, 3H), 3.78 (t, J =
7.1 Hz, 2H), 6.19 (s, 1H). 13C NMR (50 MHz, CDCl3): δ 24.9, 30.7, 42.9, 51.9, 114.8,
146.1, 167.1, 173.0. GC–MS RT 6.69 min, purity >99%, MS(EI) (m/z) 235 [M]+, calcd
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235. HRMS (m/z) 236.0143 [M+H]+, calcd 236.0148 C8H11ClNO3S, (m/z) 257.9962
[M+Na]+, calcd 257.9968 C8H10ClNNaO3S.
Methyl 4-(3-oxoisothiazol-2(3H)-yl)butanoate (3f)
After elution of 2f product 3f was eluted from the column using hexane/EtOAc 1:7
(v/v) as eluent. Yield 9%. Brown oil. Rf = 0.78 (CH2Cl2/MeOH 9:1). 1H NMR (200
MHz, CDCl3) δ 2.02 (t, J = 7.1 Hz, 2H), 2.37 (t, J = 7.2 Hz, 2H), 3.66 (s, 3H), 3.87 (t, J
= 7.1 Hz, 1H), 6.28 (d, J = 6.2 Hz, 1H), 8.1 (d, J = 6.2 Hz, 1H). 13C NMR (50 MHz,
CDCl3) δ 25.1, 30.8, 43.1, 51.9, 114.8, 139.2, 173.2, 180.3. GC–MS RT time 6.36 min,
purity >99%, MS (EI) (m/z) 201 [M]+, calcd 201. HRMS (m/z) 202.0534 [M+H]+,
calcd 202.0538 C8H12NO3S, (m/z) 224.0352 [M+Na]+, calcd 224.03573 C8H11NNaO3S.
Methyl 4-(5-chloro-3-oxoisothiazol-2(3H)-yl)pentanoate (2g)
The product was obtained using procedure 1 starting from 10g. Purification was
performed using column chromatography with hexane/EtOAc 3:1 (v/v) as eluent.
Yield 62%. Brown oil. Rf = 0.52 (CH2Cl2/MeOH 94:6). 1H NMR (200 MHz, CDCl3) δ
1.60–1.90 (m, 4H), 2.35 (t, J = 7.2 Hz, 2H), 3.65 (s, 3H), 3.75 (t, J = 7.1 Hz, 2H), 6.32
(s, 1H). 13C NMR (50 MHz, CDCl3) δ 21.9, 29.2, 33.5, 43.7, 51.9, 114.9, 146.4, 167.3,
173.6. GC–MS RT 7.58 min, purity >99%, MS (EI) (m/z) 249, calcd 249. HRMS
(m/z) 250.0300 [M+H]+, calcd 250.0305 C9H13ClNO3S, (m/z) 272.0119 [M+Na]+,
calcd 272.0124 C9H12ClNNaO3S.
Methyl 4-(3-oxoisothiazol-2(3H)-yl)pentanoate
After elution of 2g the product was eluted from the column using hexane/EtOAc 1:8
(v/v) as eluent. Yield 12%. Brown oil. Rf = 0.39 (CH2Cl2/MeOH 94:6). The compound
was not pure enough for biochemical characterization and was thus excluded from
the study.
Methyl 6-(5-chloro-3-oxoisothiazol-2(3H)-yl)hexanoate (2h)
The product was obtained using procedure 1 starting from 10h. Purification was
performed using column chromatography with hexane/EtOAc 3:1 (v/v) as eluent.
Yield 61%. Yellow oil. Rf = 0.56 (EtOAc/hexane 6:1). 1H NMR (200 MHz, CDCl3) δ
1.30–1.42 (m, 2H), 1.56–1.71 (m, 4H), 2.29 (t, J = 7.2 Hz, 2H), 3.63 (s, 3H), 3.71 (t, J
= 7.2 Hz, 2H), 6.24 (s, 1H). 13C NMR (50 MHz, CDCl3) δ 24.4, 26.0, 29.4, 33.8, 43.5,
51.6, 114.8, 145.7, 166.9, 173.9. GC-MS RT 8.36 min, purity >99%, MS (EI) (m/z)
263, calcd 263. HRMS (m/z) 264.0456 [M+H]+, calcd 264.04612 C10H15ClNO3S.
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Methyl 6-(5-chloro-3-oxoisothiazol-2(3H)-yl)hexanoate (3h)
After elution of 2h product 3h was eluted from the column using hexane/EtOAc 1:5
(v/v) as eluent. Yield 25%. Yellow oil. Rf = 0.30 (EtOAc/hexane 6:1). 1H NMR (200
MHz, CDCl3) δ 1.30– 1.74 (m, 6H), 2.29 (t, J = 7.2 Hz, 2H), 3.63 (s, 3H), 3.76 (t, J =
7.2 Hz, 2H), 6.23 (d, J = 6.5 Hz, 1H), 8.04 (d, J = 6.5 Hz, 1H). 13C NMR (50 MHz,
CDCl3) δ 24.5, 26.1, 29.6, 33.9, 43.8, 51.7, 114.8, 139.0, 169.0, 174.0. GC–MS RT 7.98
min, purity >99%, MS (EI) (m/z) 229, calcd 229. HRMS (m/z) 230.0846 [M+H]+,
calcd 230.08509 C10H16NO3S.
Ethyl 3-(5-chloro-3-oxoisothiazol-2(3H)-yl)propanoate (2i)
The product was obtained using procedure 1 starting from 10i. Purification was
performed using column chromatography with hexane/EtOAc 2:1 (v/v) as eluent.
Yield 51%. Brown solid. Mp = 73.2 ºC. Rf = 0.67 (CH2Cl2/MeOH 9:1). 1H NMR (200
MHz, CDCl3) δ 1.26 (t, J = 7.2 Hz, 3H), 2.70 (t, J = 6.2 Hz, 2H), 4.00 (t, J = 6.2 Hz,
2H), 4.16 (q, J = 7.1, 7.3 Hz, 2H), 6.24 (s, 1H). 13C NMR (50 MHz, CDCl3) δ 14.4,
34.2, 39.9, 61.4, 114.3, 147.1, 167.2, 171.4. GC–MS RT 6.43 min, purity >99%, MS
(EI) (m/z) 235, calcd 235. HRMS (m/z) 236.0143 [M+H]+, calcd 236.0148
C8H11ClNO3S.
5-Chloro-2-(3-chloro-4-fluorophenyl)isothiazol-3(2H)-one (2j)
The product was obtained using procedure 1 starting from 10j. Purification was
performed using column chromatography with EtOAc/hexanes 1:10 (v/v) as eluent.
Yield 62%. White solid, Mp = 116.9 °C; Rf = 0.66 (EtOAc/cyclohexane 1:1). 1H NMR
(200 MHz, CDCl3) δ 6.36 (s, 1H), 7.10–7.21 (m, 1H), 7.43–7.36 (m, 1H), 7.63 (dd, J =
2.6, 6.5 Hz, 1H). 13C NMR (50 MHz, CDCl3) δ 114.8, 117.2, 117.6, 124.9, 125.0, 127.6,
146.5, 154.8, 159.8, 165.4. GC–MS purity >99%, RT 7.8 min, MS (EI) (m/z) 263,
calcd 263. HRMS (m/z) 263.9448 [M+H]+, calcd 263.9453 C9H5Cl2FNOS.
2-(3-Chloro-4-fluorophenyl)isothiazol-3(2H)-one (3j)
After elution of 2j product 3j was eluted from the column using EtOAc/hexanes 1:2
as eluent. Yield 23%. Orange oil, Rf = 0.18 (EtOAc/cyclohexane 1:1). 1H NMR (200
MHz, CDCl3) δ 6.33 (d, J = 6.3 Hz, 1H), 7.10–7.21 (m, 1H), 7.47–7.41 (m, 1H), 7.68
(dd, J = 2.6/6.5 Hz, 1H), 8.19 (d, J = 6.3 Hz, 1H). 13C NMR (50 MHz, CDCl3) δ 114.8,
117.0, 117.5, 125.0, 127.4, 140.1, 154.7, 159.7, 167.7. GC–MS purity >95%, RT 7.7





The product was obtained using procedure 1 starting from 10k. Purification was
performed using column chromatography with EtOAc/hexanes 3:1 (v/v) as eluent.
Yield 29%. Yellow gum, Rf = 0.35 (EtOAc/hexane 3:1), 1H NMR (200 MHz, CDCl3) δ
3.45–3.47 (m, 2H), 3.86 (t, J = 6 Hz, 2H), 5.01 (s, 2H), 6.25 (s, 1H), 7.35 (m, 5H). 13C
NMR (50 MHz, CDCl3) δ 41.1, 43.5, 66.9, 114.3, 128.1, 128.2, 128.6, 136.4, 152.4,
156.9, 160.8. HPLC purity >94%%, RT 12.3 min, (column C8 mobile phase
H20/CH3CN/TFA 60/40/1). HRMS (m/z) 313.0414 [M+H]+, calcd 313.0408
C13H14ClN2O3S. (m/z) 335.0233 [M+Na]+, calcd 335.0228 C13H13ClN2NaO3S.
Methyl 3-(5-chloro-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate (4e)
Compound 2e (1 mmol) was dissolved in CH2Cl2 (15 mL) and m-chloroperbenzoic
acid was added in several portions. The mixture was stirred at room temperature for
16 h. Several crystals Na2S2O3·5H2O and H2O (5 mL) were added and the mixture
was stirred for 10 min. A saturated solution of NaHCO3 (50 mL) was added, this
mixture was stirred for 5 min and the phases were separated. The organic layer was
washed with saturated NaHCO3 (50 mL), brine (50 mL) and dried with Na2SO4 and
the solvent was evaporated under reduced pressure. The residue was purified by
column chromatography with EtOAc/hexanes 1:2 as eluent. Yield 50%, yellow oil, Rf
= 0.72 (EtOAc/hexane 10:1). 1H NMR (200 MHz, CD3OD) δ 2.70–2.77 (m, 2H), 3.68
(s, 3H), 3.99 (t, J = 6.8 Hz, 2H), 6.98 (s, 1H). 13C NMR (50 MHz, CDCl3) δ 34.5, 38.3,
52.4, 125.4, 158.6, 166.5, 173.7. GC–MS RT 6.1 min, purity >99%, MS (ESI) (m/z)
206, calcd 206 (M-OMe). HRMS (m/z) 237.9936 [M+H]+, calcd 237.9941
C7H9ClNO4S.
Methyl 3-[(5-chloroisothiazol-3-yl)amino]propanoate (5e)
Compound 2e (0.74 mmol) was dissolved in POCl3 (1.5 mL) and stirred overnight at
room temperature. The next morning an orange-brown precipitate was observed.
Isopropylether (20 mL) was added and the precipitate intensified. The suspension
was centrifuged (4000 rpm, 10 min), the supernatant was discarded and the residue
washed with isopropylether. Subsequently, the residue was suspended in CH3CN (10
mL), cooled to 0 ºC and NH3 gas was bubbled through the solution for 30 min. The
red-white suspension turned into a brown solution with a white precipitate. The
suspension was filtered and the filtrate was concentrated under reduced pressure
and purified using column chromatography EtOAc/hexanes 1:6 as eluent. Yield 44%,
Yellow solid, Mp = 73.2 °C, Rf = 0.33 (EtOAc/hexane 3:1), 1H NMR (200 MHz, CDCl3)
δ 2.64 (t, J = 6.2 Hz, 2H), 3.61 (t, J = 5.9 Hz, 2H), 3.68 (s, 3H), 6.34 (s, 1H). 13C NMR
(50 MHz, CDCl3) δ 33.9, 38.5, 51.9, 112.3, 151.8 163.6, 173.2. GC–MS RT 5.9 min,
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The product was obtained using procedure 1 starting from 9. Purification was
performed using column chromatography with EtOAc/hexanes 1:1 (v/v) as eluent.
Yield 70%. Off-white gum. Rf = 0.38 (EtOAc/cyclohexane 2:1). 1H NMR (200 MHz,
CDCl3) δ 2.67 (m, 2H), 3.70 (s, 3H), 3.96 (m, 2H), 5.15 (s, 2H), 7.34 (m, 5H). 13C NMR
(50 MHz, CDCl3) δ 33.6, 40.5, 52.2, 67.9, 119.1, 128.3, 128.4, 128.6, 135.7 153.2,
163.0 171.6. HPLC purity >99%. HRMS (m/z) 371.0463 [M+H]+, calcd 371.0469
C15H16ClN2O5S.
Methyl 2-aminoethanoate•HCl (8a)
The product was obtained employing procedure 2 in 98% yield. White solid. M.p =
135.4 °C. Rf = 0.59 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, D2O) δ 3.85 (s, 3H), 3.96
(s, 2H). 13C NMR (50 MHz, D2O) δ 40.2, 53.5, 161.3. ESI-MS (m/z) 90.0 [M+H]+, calc.
90.1.
Methyl 3-aminopropionate•HCl (8b)
The product was obtained employing procedure 2 in quantitative yield. White solid,
M.p. = 101.0 oC, Rf = 0.50 (triethylamine/methanol/dichloromethane 1:10:90). 1H
NMR (200 MHz, D2O) δ 2.86 (t, J = 6.5 Hz, 2H), 3.30 (t, J = 6.4 Hz, 2H), 3.76 (s, 3H).
13C NMR (50 MHz, D2O) δ 31.2, 35.2, 52.7, 162.2. MS(ESI) (m/z) 104.1 [M+H]+, calc.
104.1.
Methyl-4-aminobutanoate•HCl (8c)
The product was obtained employing procedure 2 in quantitative yield. White solid.
M.p = 120.0 °C. Rf = 0.26 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, D2O) δ 1.85 (m,
2H), 2.42 (t, J = 7.2 Hz, 2H), 2.93 (t, J = 7.8 Hz, 2H), 3.59 (s, 3H). 13C NMR (50 MHz,
D2O) δ 22.2, 30.7, 38.9, 52.5, 175.8. MS(ESI) (m/z) 118.1 [M+H]+, calc. 118.1.
Methyl-4-aminopentanoate•HCl (8d)
The product was obtained employing procedure 2 in quantitative yield. White solid.
M.p = 146.3 °C. Rf = 0.19 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, D2O) δ 1.65-1.73
(m, 4H), 2.46 (t, J = 6.9 Hz, 2H), 3.02 (br.t, 2H), 3.70 (s, 3H). 13C NMR (50 MHz, D2O)




The product was obtained employing procedure 2. Yield 94%. White solid. M.p =
123.1 °C. Rf = 0.38 (CH2Cl2/MeOH/Et3N 90:10:1). 1H NMR (200 MHz, D2O) δ 1.33-
1.42 (m, 2H), 1.56-1.70 (m, 4H), 2.41 (t, J = 7.4 Hz, 2H), 2.98 (t, J = 7.5 Hz, 2H), 3.68
(s, 3H). 13C NMR (50 MHz, D2O) δ 23.8, 25.2, 26.5, 33.5, 39.4, 52.3, 170.8. MS(ESI)
(m/z) 146.1 [M+H]+, calc. 146.1.
Ethyl 3-aminopropanoate•HCl (8f)
The product was obtained employing procedure 2, in which methanol was replaced
for ethanol, in quantitative yield. White solid. M.p = 68.2°C. Rf = 0.38 (CH2Cl2/MeOH
9:1). 1H NMR (200 MHz, D2O) δ 1.29 (t, J = 7.1 Hz, 3H), 2.84 (t, J = 6.7 Hz, 2H), 3.32
(t, J = 6.5 Hz, 2H), 4.24 (q, J = 7.0 Hz, 2H). 13C NMR (50 MHz, D2O) δ 13.4, 31.4,
35.2, 62.5, 171.7. MS(ESI) (m/z) 118.1 [M+H]+, calc. 118.1.
Cbz-Cystin-NHC2H4COOMe (9)
Cbz-Cystin (4 mmol) was suspended in dry DMF (5 mL) and stirred at room
temperature. HOBt (8 mmol) and DCC (8 mmol) were added subsequently and the
mixture is stirred for 15 min at room temperature. HCl salt 8b (8 mmol) and
triethylamine (8 mmol) were added subsequently and the mixture was stirred for 45
min at room temperature. The reaction mixture was diluted with ethylacetate (50
mL) and filtered. The ethylacetate was extracted with 1N aqueous HCl solution (50
mL, 2 times), saturated aqueous Na2CO3 (50 mL, 2 times), brine (50 mL) and dried
(Na2SO4). The organic solvent was evaporated to yield the product with sufficiently
high purity (>90%, TLC) for the next reaction step. Yield 75%. Brown-white solid.
M.p = 120.9 °C. Rf = 0.38 (CH2Cl2/MeOH/acetic acid 90:10:1). 1H NMR (200 MHz,
CDCl3): δ 2.49 (t, J = 6.2 Hz, 4H), 2.92 (d, J = 6.2 Hz, 4H), 3.48 (t, J = 6.5 Hz, 4H),
3.64 (s, 6H), 3.75 (m, 2H), 5.11 (s, 4H), 7.34 (m, 10H). 13C NMR (50 MHz, CDCl3): δ
(m/z) 679.4 [M+H]+, calc. 679.2.
3,3’-dithiobis(N-ethylpropanamide) (10b)
The product was obtained following procedure 3 starting from ethylamine. Yield
37%. Brown gum. Rf = 0.57 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, CDCl3) δ 1.16 (t,
J = 7.2 Hz, 3H), 2.62-2.71 (m, 2H), 2.96-3.24 (m, 4H).13C NMR (50 MHz, CDCl3) δ
14.8, 34.8, 36.0, 61.9, 172.6. MS(ESI) (m/z) 265.2 [M+H]+, calc. 265.1, (m/z) 287.1
[M+Na]+, calc. 287.1.
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3,3'-dithiobis(N-pentylpropanamide) (10c)
The product was obtained following procedure 3 starting from pentan-1-amine. Yield
80%. Brown-white brown solid. M.p = 121.4 °C. Rf = 0.4 (CH2Cl2/MeOH 94:6). 1H
NMR (200 MHz, CDCl3) δ 0.88 (t, J = 6.6 Hz, 3H), 1.25-1.32 (m, 4H), 1.43-1.57 (m,
2H), 2.57 (t, J = 7.1 Hz, 2H), 2.97 (t, J = 7.1 Hz, 2H), 3.18-3.28 (m, 2H), 6.38 (br. 2H)
13C NMR (50 MHz, CDCl3) δ 14.2, 22.6, 29.3, 29.4, 34.6, 35.9, 40.0 171.3. MS(ESI)
(m/z) 349.2 [M+H]+, calc. 349.2, (m/z) 371.2 [M+Na]+, calc. 371.2.
3,3'-dithiobis[N-(methyl 2-aminoethanoate)propanamide] (10d)
The product was obtained following procedure 3 starting from 8a. Yield 27%. Dark
brown solid. M.p = 65.5 °C. Rf = 0.59 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, CDCl3)
δ 2.65-3.28 (m, 4H), 3.76 (s, 3H), 4.06 (d, J = 5.0 Hz, 2H). 13C NMR (50 MHz, CDCl3)
δ 34.6, 35.4, 41.4, 52.6, 166.0, 171.1. MS(ESI) (m/z) 353.2 [M+H]+, calc. 353.1, (m/z)
375.1 [M+Na]+, calc. 375.1.
3,3'-dithiobis[N-(methyl 2-aminopropionate)propanamide] (10e)
The product was obtained following procedure 3 starting from 8b. Yield 42%. Brown
gum. Rf = 0.38 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, CDCl3) δ 2.51-2.58 (m, 8H),
2.90-2.97 (t, J = 6.9 Hz, 4H), 3.47-3.56 (m, 4H), 3.68 (s, 3H). 13C NMR (50 MHz,
CDCl3) 33.9, 34.0, 35.1, 35.9, 52.0, 171.0, 173.0. MS(ESI) (m/z) 381.2 [M+H]+, calc.
381.1, (m/z) 403.2 [M+Na]+, calc. 403.1.
3,3'-dithiobis[N-(methyl 2-aminobutanoate)propanamide] (10f)
The product was obtained following procedure 3 starting from 8c. Yield 62%. Brown
solid. M.p. = 102.1 oC. Rf = 0.50 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, CDCl3) δ
1.83 (m, 2H), 2.37 (t, J = 7.4 Hz, 2H), 2.56 (t, J = 6.9 Hz, 2H), 2.96 (t, J = 6.9 Hz, 2H),
3.26 (m, 2H), 3.65 (s, 3H). 13C NMR (50 MHz, CDCl3) 24.7, 31.6, 34.4, 35.8, 39.2,
51.9, 171.4, 174.0. MS(ESI) (m/z) 409.2 [M+H]+, calc. 409.2, (m/z) 431.2 [M+Na]+,
calc. 431.2.
3,3'-dithiobis[N-(methyl 2-aminopentanoate)propanamide] (10g)
The product was obtained following procedure 3 starting from 8d. Yield 45%. Brown
solid. M.p. = 60.8 oC. Rf = 0.39 (CH2Cl2/MeOH 94:6). 1H NMR (200 MHz, CDCl3) δ
1.50-1.73 (m, 8H), 2.33 (t, J = 6.8 Hz, 4H), 2.53-2.69 (m, 4H), 2.97 (t, J = 7.1 Hz, 4H),
3.26 (m, 4H), 3.65 (s, 6H). 13C NMR (50 MHz, CDCl3) 22.2, 29.1, 33.7, 34.5, 36.0,





The product was obtained following procedure 3 starting from 8e. Yield 62%. Brown
solid. M.p. = 97.3 oC. Rf = 0.63 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, CDCl3) δ
1.29-1.66 (m, 6H), 2.30 (t, J = 7.2 Hz, 2H), 2.57 (t, J = 7.0 Hz, 2H), 2.97 (t, J = 6.9 Hz,
2H), 3.24 (m, J = 6.5 Hz, 2H), 3.64 (s, 3H), 6.44 (br. t). 13C NMR (50 MHz, CDCl3) δ
24.5, 26.4, 29.2, 33.9, 34.4, 35.8, 39.5, 51.7, 171.2, 174.2. MS(ESI) (m/z) 465.3
[M+H]+, calc. 465.2, (m/z) 487.3 [M+Na]+, calc. 487.2.
3,3'-dithiobis[N-(ethyl 2-aminopropionate)propanamide] (10i)
The product was obtained following procedure 3 starting from 8f. Yield 83%. Brown
solid. M.p = 93.3 °C. Rf = 0.64 (CH2Cl2/MeOH 9:1). 1H NMR (200 MHz, CDCl3) δ 1.24
(t, J = 7.1 Hz, 3H), 2.54 (m, 4H), 2.94 (t, J = 7.0 Hz, 2H), 3.51 (m, 2H), 4.31 (q, J = 7.1
Hz, 2H), 6.60 (br s, 1H). 13C NMR (50 MHz, CDCl3) δ 14.3, 34.1, 34.4, 35.2, 35.8, 59.9,
171.2, 172.6. MS(ESI) (m/z) 409.2 [M+H]+, calc. 409.2, (m/z) 431.2 [M+Na]+, calc.
431.2.
3,3'-dithiobis[N-(3-chloro-4-fluorophenyl)propanamide] (10j)
The product was obtained following procedure 3 starting from 3-chloro-4-
fluoroaniline. Yield 76%. Orange solid, M.p. = 133.7°C; Rf = 0.44 (ethyl
acetate/cyclohexane 1:1). 1H NMR (200 MHz, CDCl3/CD3OD 1:1) δ 2.57 (t, J = 4.5 Hz,
4H), 2.79 (t, J = 4.5 Hz, 4H), 6.85 (t, J = 5.9 Hz, 2H), 7.13 (m, 2H), 7.54 (d, J = 4.5
Hz, 2H). 13C NMR (50 MHz, CDCl3/CD3OD 1:1): δ 33.6, 35.9, 115.9, 116.4, 119.4,
119.5, 121.9, 151.9, 156.8, 170.4. MS(ESI) (m/z) 465.3 [M+H]+, calc. 465.0.
3,3'-dithiobis[N-(benzyl(2-aminoethyl)carbamate)propanamide] (10k)
The product was obtained following procedure 3 starting from benzyl (2-
aminoethyl)carbamate. Yield 55%. Brown gum, Rf = 0.51 (CH2Cl2/MeOH 9:1), 1H
NMR (200 MHz, CDCl3) δ 2.50-3.20 (m, 8H), 3.23-3.70 (m, 8H), 5.08 (s, 4H), 7.10-7.40
(m, 10H). 13C NMR (50 MHz, CDCl3) 32.9, 34.1, 41.5, 58.8, 67.0, 128.3, 128.8, 129.1,
129.2, 136.6, 165.0, 171.9.
Modeling
Molecular dockings were performed using the program Molegro Virtural Docker
2007 (MVD) from Molegro ApS, Aarhus, Denmark. The crystal structure from PCAF
(PDB entry 1CM0) chain B, was prepared for dockings using the default settings in
MVD. The water molecules were removed before docking. The ligands were geometry
optimized using HYPERCHEM 7.5 Professional (Hypercube, Inc) using molecular
mechanics with the Amber force field and Polar-Ribiere (conjugate gradient)
algorithm. The optimized ligands were prepared for docking using the default
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settings in MVD.116 The 5-chloroisothiazolones, isothiazolones and 5-chloro-
isothiazolones-1-oxide were docked with a distance constraint of 6 Å between the Cys
574 thiol and the carbon atom 5 in the isothiazolone scaffold. Docking solutions were
calculated within a sphere of 15 Å from the Cys 574 thiol. Docking solutions were
selected based on the MOLDOCKSCORE and the docking solutions were evaluated
manually and the amino acid side chain in a radius of 10 Å from the ligand were
energy minimized, followed by energy minimization of the ligand.
Enzyme inhibition studies
A fluorescent histone acetyl transferase assay described by Trievel et al. was used for
enzyme inhibition studies.112 The human recombinant histone acetyl transferases
PCAF (p300/CREB-binding protein Associated Factor) was purchased from Biomol
International. The histone H3 peptide (Ac-QTARKSTGGKAPRKQLATKNH2) was
purchased from Pepscan (Lelystad, NL) (purity >98%, m/z 1034.9 [M+2H]2+ calcd
1035.2).The other chemicals were purchased from Sigma–Aldrich. The assay buffer
contained 100 mM HEPES/NaOH, pH 7.5, 0.8% Triton-X. 10 μL inhibitor solution
(variable concentration) in assay buffer and 10 μL of the histone acetyl transferase
(0.25 μM) in assay buffer containing 0.1% N-ethylmaleimide (NEM)-treated BSA
were mixed in incubated for 15 min. 10 μL AcCoA (400 μM) in assay buffer and 20
μL Histone H3 peptide solution (200 μM) in assay buffer were added. The enzymatic
reaction was allowed to proceed for 15 min followed by subsequent addition of 50 μL
isopropanol and 100 μL 7-diethylamino-3-(4’-maleimidylphenyl)-4-methylcoumarin
(CPM) 25 μM in assay buffer. The mixture was incubated for 15 min and the
fluorescence was read with an excitation of 360 nm and an emission of 460 nm. The
signal with no inhibitor present was set to 100% and the signal with no Histone H3
peptide present was set to 0%. Inhibitor solutions were prepared as 10 mM stock
solution in DMSO and subsequently diluted to the desired final concentration using
assay buffer. Calculations were performed using the Excel 2003 and the Microcal
Origin 7 software. Screenings were performed at 10 μM inhibitor concentration (n
=3, two times) and compounds showing more than 50 % inhibition at 10 μM were
subjected to IC50 determination. IC50 determinations were performed using two-fold
dilutions of the inhibitor starting from 10 μM. The IC50’s were derived by non-linear
curve fitting of the data.
Cell growth inhibition
Cell culture
The growth inhibition of the human cancer cell lines A2780 (ovarian), WiDr (colon)
and HEP G2 (liver) and the human embryonic cell line 293 (kidney) was studied. The
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cells were maintained in Dulbecco’s modified Eagles Medium with 10% heat-
inactivated fetal calf serum, 50 IU/mL penicillin and 50 mg/mL streptomycin at 37
ºC in a humidified 5% CO2 incubator. All cell culture reagents were purchased from
invitrogen.
Cell proliferation
Cell proliferation was measured by a Crystal Violet assay. For this assay, cells were
seeded at 5000 cells per well into 96-well plates, grown for 24 h, and treated for an
additional 48 h with the different inhibitors. After this, the medium was aspirated
and the cells were fixed with 50 μL 1% crystal violet in 70% ethanol for 30 min.
Subsequently, the cells were washed with water and the staining was solubilized by
addition of 100 μL 1% SDS in water. The plates were read at 550 nm. A blank
extinction value in which no cells were seeded was subtracted from all
determinations and cell growth with no inhibitor present was set to 100%. All
concentrations were tested in 8-fold on one plate and the GI50 values of most potent
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Development of small molecule inhibitors of the histone acetyltransferase p300/CBP
associated factor (PCAF) is relevant for oncology. The inhibition of the enzyme PCAF
and proliferation of the cancer cell line HEP G2 by a series of 5-chloroisothiazolones
was compared to a series of 5-chloroisothiazolone-1-oxides. The PCAF inhibitory
potency of 5-chloroisothiazolones and 5-chloroisothiazolone-1-oxides is influenced by
substitution in the 4-position. A study on the reactivity of the HAT inhibitors towards
thiols and thiolates indicates that 5-chloroisothiazolones reacted quickly with
propane-1-thiolate to provide many products, whereas 5-chloroisothiazolone-1-oxides
provide only one defined product. Growth inhibition studies indicate that 5-
chloroisothiazolones inhibit proliferation of HEP G2 cells at concentrations between
8.6 and 24 µM, whereas 5-chloroisothiazolone-1-oxides required higher concentrations
or showed no inhibition.
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INTRODUCTION
Histone acetylation and deacetylation play a crucial role in regulation of gene
transcription in eukaryotes.90 These histone modifications are regulated by two
classes of enzymes: histone acetyltransferases (HATs) and histone deacetylases
(HDACs), which respectively catalyze the addition to and the removal of acetyl
groups on specific lysine residues.7 Small molecule inhibitors are useful tools to
study the functions of these enzymes and have potential therapeutic
applications.107,117
HATs are grouped into different families according to their sequence
similarity.94 The GNAT (Gcn5 related N-acetyltransferase) family HATs include the
closely related enzymes PCAF (p300/CBP associated factor) and GCN5 (general
control of amino-acid synthesis 5).95 The members of this family play a key role in
endothelial growth factor (EGF) mediated gene transcription and in cell cycle
progression and have therefore been recognized as potential anticancer targets.97-99
Furthermore, deregulation of the activities of GNAT and p300 family HATs plays an
important role in human immunodeficiency virus (HIV) and chronic obstructive
pulmonary disease (COPD).89,118
Despite significant efforts, very few small molecule and cell-permeable inhibitors
for GCN5 and PCAF have been described until now. Potent and selective bisubstrate
inhibitors for p300 and PCAF have been reported but their lack of cell-permeability
limits their application.72 The natural products curcumin, garcinol and anacardic
acid show HAT inhibitory activity, however their potency is low.78,82,87 A promising
class of inhibitors is represented by isothiazolones, which inhibit HATs with IC50’s in
the micromolar range.74,119,120
The PCAF inhibition of isothiazolones is expected to derive from their reactivity
towards the enzyme’s active site thiol. The reaction of isothiazolones with a thiolate
involves nucleophilic attack at the sulfur atom with concomitant cleavage of the S–N
bond to give a ring opened product that can react further.113 For 5-
chloroisothiazolone-1-oxides the reactivity towards thiolates is unknown.
Previously, we have reported a significant difference in PCAF HAT inhibition
between N-aliphatic substituted 5-chloroisothiazolones and isothiazolones.120 The
most potent derivative is denoted isothiazolone A (figure 3.1). We also found that
PCAF is inhibited by the 5-chloroisothiazolone-1-oxide denoted isothiazolone oxide A
(figure 3.1). Furthermore, we have demonstrated that 5-chloroisothiazolones inhibit
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the growth  of  cancer cell lines in the micromolar range, whereas isothiazolones
showed no inhibition at 10 µM.
Figure 3.1: inhibitors of the HAT PCAF with an isothiazolone or isothiazolone-1-oxide core
structure.
In this study we investigated synthetic modifications of 5-chloroisothiazolones
and 5-chloroisothiazolone-1-oxides and studied their reactivity to thiols and thiolates
using HPLC and NMR. We studied also their inhibition of the enzyme PCAF and
inhibition of cell proliferation. Chloro and methyl substituents were introduced in
the 4-position of the 5-chloroisothiazolone and 5-chloroisothiazolone-1-oxide core in
order to study the effect of substituents on the inhibition of the enzyme PCAF.
Finally, the growth inhibition of HEP G2 liver cancer cells upon treatment with 5-
chloroisothiazolones and 5-chloroisothiazolone-1-oxides was investigated to explore
the toxicity of these molecules.
CHEMISTRY
Synthesis of isothiazolones and isothiazolone-1-oxides
A series of 5-chloroisothiazolones and 5-chloroisothiazolone-1-oxides was synthesized
in order to explore synthetic modifications of the isothiazolone ring and their effects
on inhibition of the enzyme PCAF and cell proliferation. Synthesis was performed
according to previously published procedures.103 Amines were reacted with 3,3´-
dithiobispropionyl chloride to yield the corresponding 3,3´-dithiobispropionic amides.
The 3,3´-dithiobispropionic amides were treated with 3 equivalents sulfuryl chloride
in dichloromethane. This provided reaction mixtures in which the 5-
chloroisothiazolones were the main products (40–60%) and the isothiazolones the
minor product (10–20%). According to the literature, 4,5-dichloroisothiazolones 7 and
8 can be obtained in one step from 3,3´-dithiobispropionic amides by treatment with
5 equivalents of sulfuryl chloride in yields between 10% and 40%. We hypothesized
that chlorination of the purified 5-chloroisothiazolones in the 4-position would
provide the 4,5-dichloroisothiazolones with higher yields. Indeed, treatment of 1 and
3 with sulfuryl chloride gave the 4,5-dichloroisothiazolones 7 and 8 in yields of 55%
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and 90%, respectively (Scheme 1). Compound 2 was synthesized according to the
procedure described by Yue et al.121 However, product 2 was obtained with a yield of
10% instead of the reported 30–70%. The lower yield may be explained by the steric
hindrance for formation of the S–N bond when the N is tert-butyl substituted.
Scheme 3.1: reagents and conditions: (a) mCPBA, CH2Cl2, (b) SO2Cl2, CH2Cl2, (c) CH3-(CH2)11-
SH, Et3N, CH2Cl2.
The 5-chloroisothiazolones were oxidized by mCPBA to yield the corresponding
5-chloroisothiazolone-1-oxides 4–6 as racemic mixtures in yields between 60% and
80% after purification. Combs et al. demonstrated that comparable S-oxides can be
resolved using chiral HPLC and that the stereochemistry is stable.122 However,
attempts to separate the enantiomers of 5-chloroisothiazolone-1-oxides 6 using chiral
HPLC failed.
Attempts were made to chlorinate the 5-chloroisothiazolone-1-oxides 4 and 6 in
the 4-position using sulfuryl chloride. However, overnight treatment with 3
equivalents of sulfuryl chloride at room temperature did not show conversion of the
starting materials into the desired products 9 and 10. Apparently, it is not possible
to chlorinate 5-chloroisothiazolone-1-oxides in the 4-position under these conditions.
Compounds 9 and 10 were obtained via oxidation of 7 and 8 using mCPBA in yields
around 80%.
Thiol substitution on the 5-chloroisothiazolone-1-oxides 5 and 6 was studied
using dodecane-1-thiol as a reagent. The thiol (–SH) did not react with the 5-
chloroisothiazolone-1-oxides, whereas a very quick reaction (<30 min) with the
Chapter 3
52
thiolate (–S-) was observed. Products 11 and 12 were obtained by reaction of 5 and 6
with dodecane-1-thiol in the presence of triethylamine in yields around 60% after
purification. Compound 12 was chlorinated in the 4-position using sulfuryl chloride
as a reagent to give 13 in 58% yield.
Scheme 3.2: reagents and conditions: (a) Thioacetic acid, cyclohexane, reflux, (b) 6 N HCl in
H2O, reflux (c) aqueous 35% H2O2, (d) SOCl2, reflux, (e) R-NH2, Et3N, CH2Cl2, (f) SO2Cl2, CH2Cl2
(g) mCPBA, CH2Cl2.
5-chloro-4-methylisothiazolones 19 and 20 were synthesized using the procedure
shown in Scheme 2.113,123 Methacrylic acid (14) was subjected to Michael addition
with thioacetic acid to give the 3-(acetylthio)-2-methylpropanoic acid (15) as a
racemic mixture in 50% yield. Deacetylation was achieved by treatment with 6 N
HCl, and the resulting thiol was oxidized using H2O2 to yield the 3,3´-dithiobis(2-
methylpropanoic acid) (16) that was pure enough to continue to the next step. The
diacid 16 was converted to the diacylchloride and coupled to different amines to give
the crude 3,3´-dithiobispropionic amides 17 and 18 in yields around 30% over 3 steps.
The crude 3,3´-dithiobispropionic amides were treated with 3 equivalents of sulfuryl
chloride at 0 ºC in dichloromethane to give the 5-chloro-4-methylisothiazolones 19
and 20 in yields of 38% and 52%, respectively. Compounds 19 and 20 were oxidized
by mCPBA to the corresponding 1-oxide derivates 21 and 22 in yields around 75%.
Reactivity of isothiazolones and isothiazolone-1-oxides
The biological activity of isothiazolones and their derivatives originates from both
their binding to proteins and their reactivity towards thiolates.124,125 It has been
described that isothiazolones react with thiolates on the sulfur atom, with
concomitant cleavage of the S–N bond. A study on N-methylisothiazolone 25, with N-
Acetyl-Cys as thiolate, showed formation of intermediate 27 (figure 3.2).113 The
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reaction between 5-chloro-N-methylchloroisothiazolone 23 is expected to proceed
through the same mechanism, however intermediate 28 has not been identified. This
might be due to the increased reactivity of intermediate 28 due to the presence of the
chlorine atom. Another line of evidence for this inhibitory mechanism has been
provided by a study on inhibition of p56lck tyrosine kinase by isothiazolones.125
Morley et al. have studied the reactivity of (5-chloro)isothiazolones towards 2-
methyl-2-propanethiol at pH 4 in aqueous environment. They have found kinetic
rate constants in the order 23 >24> 25> 26 (figure 3.2).126
Figure 3.2: reactivity of the isothiazolone core.
The reactivity of 5-chloroisothiazolones and 5-chloroisothiazolone-1-oxides
towards thiols and thiolates was studied using comparable methods as published
previously.127 HPLC analysis showed that 3 did not react with propane-1-thiol in
acetonitrile as a solvent after 24 h treatment at room temperature. In contrast,
treatment with sodium propane-1-thiolate in acetonitrile resulted in a quick
conversion into many new products. Treatment with 0.1 equivalent thiolate resulted
in 10% conversion of the starting material. Treatment with 0.5 equivalents resulted
in 50% conversion and many new products were observed. After treatment with 1.0
equivalent thiolate the starting material disappeared and many new peaks were
observed. These results show that 5-chloroisothiazolones do not react with thiols,
whereas they react quickly with thiolates providing many products that could not be
identified.
The thiol reactivity of 5-chloroisothiazolone-1-oxide 6 was investigated. No
reaction was observed between 6 and propane-1-thiol after treatment overnight. On
the contrary, 6 reacted quickly with sodium propan-1-thiolate in acetonitrile to
provide one new product. Treatment with 0.1 equivalent resulted in one new product
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with a conversion of about 10%. Treatment with 0.5 equivalent resulted in about
50% conversion into one new product. After treatment with 1.0 equivalent, the
starting material was completely converted into one new product. NMR data showed
that this product derives from addition-elimination in the 5-position. Treatment of 5-
chloroisothiazolon-1-oxide with more than 1.0 equivalent of sodium propan-1-thiolate
provided substitution in the 5-position, followed by substitution in the 4-position.
These data show that 5-chloroisothiazolone-1-oxides do not react with thiols,




Inhibition of the HAT PCAF by 5-chloroisothiazolones and 5-chloroisothiazolone-1-
oxides was investigated in order to explore the binding properties of these
compounds. The PCAF HAT inhibition studies were performed using a fluorescent
assay as described previously.112,120 5-Chloroisothiazolones 1 and 3 showed PCAF
inhibition with IC50 values of 3.0 and 1.8 µM, respectively (table 3.1). The effects of
substitutions in the 5-chloroisothiazolone 4-position on PCAF inhibition were
studied. Introduction of a chlorine in the 4-position provided compounds 7 and 8 with
an IC50 of 2.4 and 2.6 µM, whereas introduction of a methyl group in the 4-position
provided compounds 19 and 20 with less than 50% inhibition at 10 µM.
The inhibitory properties of these molecules derive both from their binding to
the enzyme active site and from their chemical reactivity. Chloro- or methyl-
substitution in the 4-position of 5-chloroisothiazolones could change the binding
configuration to the active site of the enzyme and thus influence the inhibitory
properties.
Substitution of the 5-chloroisothiazolones in their 4-position changes their
reactivity. The methyl group is an electron donating group (EDG) due to inductive
effects, whereas the chlorine is a net electron-withdrawing group (EWG) due to
inductive effects partially counteracted by an electron donating contribution through
resonance. Introduction of an EDG like a methyl group (20) causes loss of potency,
which suggests that an EDG in the 4-position adds electron density to the
isothiazolone ring and thus stabilizes it for nucleophilic attack. On the contrary, the
introduction of an EWG like a chlorine atom (8) does not affect the inhibitory
properties. This datum suggests that the isothiazolone reactivity on the 1-position
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towards thiolates is already at its maximum and cannot be increased further by an
EWG.
The effect of substitution in the 4-position of 5-chloroisothiazolone-1-oxides on
inhibition of PCAF activity was studied. The compounds were tested as racemic
mixtures. Compound 4, with an N-ethyl substitution, showed less than 50%
inhibition at 10 µM. Introduction of either a chlorine (9) or a methyl group (21) in
the 4-position, provided compounds that did not show any inhibition at 10 µM.
Compound 6 with a methyl ester in the N-substitution showed PCAF inhibition with
an IC50 value of 5.6 µM. Introduction of either a chloro (10) or a methyl substituent
(22) provided compounds that showed less than 50% PCAF inhibition at 10 µM.
These differences in binding could derive from changes in binding to the enzyme
active site as well as from changes in reactivity.
Table 3.1: inhibition of HAT PCAF and proliferation of cell lines by 5-chloroisothiazolinone and
isothiazolone-1-oxide.




1 Cl H Ethyl 3.0 ± 0.3 12 ± 0.5
7 Cl Cl Ethyl 2.4 ± 0.1 12 ± 2
19 Cl CH3 Ethyl > 10 9.1 ± 0.9
3 Cl H (CH2)2CO2Me 1.8 ± 0.2 24 ± 3
8 Cl Cl (CH2)2CO2Me 2.6 ± 0.6 16 ± 3
20 Cl CH3 (CH2)2CO2Me > 10 8.6 ± 1
4 Cl H Ethyl > 10 > 100
9 Cl Cl Ethyl > 10 > 100
21 Cl CH3 Ethyl > 10 > 100
6 Cl H (CH2)2CO2Me 5.6 ± 0.2 > 100
10 Cl Cl (CH2)2CO2Me > 10 > 100
22 Cl CH3 (CH2)2CO2Me > 10 > 100
5 Cl H tert-Butyl > 10 27 ± 9
11 S(CH)11CH3 H tert-Butyl >10 > 50
12 S(CH)11CH3 H (CH2)2CO2Me > 10 > 100
13 S(CH)11CH3 Cl (CH2)2CO2Me > 10 > 100
[a] Inhibition concentration 50% (IC50) determination n = 3.
[b] Growth inhibition 50% determinations n = 8.
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The 5-dodecylthioisothiazolone-1-oxides 11 and 12 and 5-dodecylthio-4-
chloroisothiazolone-1-oxide 13 showed no detectable PCAF inhibition at 10 µM. The
lack of activity of these compounds might derive both from their binding properties
to the enzyme active site as well as their reactivity towards thiolates.
Growth inhibition
Growth inhibition of cancer cells was studied in order to explore how modifications of
the isothiazolone core influence the inhibition of cell proliferation. The growth
inhibition of the human cancer cell line HEP G2 (liver cancer) was studied using a
crystal violet assay as described previously.120 The 5-chloroisothiazolones inhibited
the growth of HEP G2 cells with IC50 values between 8.6 and 24 µM (table 3.1). The
differences in PCAF inhibitory potency are not reflected in the inhibition of cell
proliferation. Other mechanisms might be involved in the inhibition of cell
proliferation by these compounds like for example binding to other proteins or
reactions with cellular glutathione. Western blot on inhibition of histone acetylation
upon treatment of this cell line with the inhibitors is required to investigate if the
molecules inhibit histone acetylation in cell-based assays.
5-Chloroisothiazolone-1-oxides showed less than 50% inhibition of cell
proliferation at 100 µM, with the exception of compound 5. In general, 5-
chloroisothiazolone-1-oxides are less lipophilic then 5-chloroisothiazolones, which
might hamper their cellular permeability. The partition coefficient (log P) for
isothiazolone-1-oxide 6 was determined to be 0.08, whereas for isothiazolone 3 a log
P value of 0.69 was measured. The low log P value of isothiazolone-1-oxide 6 might
hamper the inhibition of cell proliferation.
CONCLUSION
A series of 5-chloroisothiazolones and 5-chloroisothiazolone-1-oxides with chlorine
and methyl substitutions in the 4-position was synthesized. 5-chloroisothiazolones
were readily chlorinated in the 4-position by sulfuryl chloride, whereas the 5-
chloroisothiazolone-1-oxides could not be chlorinated in the 4-position under the
applied conditions. 5-Chloroisothiazolones do not react with thiols whereas they
react quickly with thiolates. Upon reaction, multiple products were observed which
hampers the elucidation of the reaction mechanism. 5-chloroisothiazolone-1-oxides
do not react with thiols, whereas they react quickly with thiolates in the 5-position.
The reaction occurs via an addition-elimination mechanism to give 5-
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alkylthioisothiazolone-1-oxides. The resulting 5-alkylthioisothiazolone-1-oxide was
chlorinated in the 4-position using sulfuryl chloride.
N-aliphatic substituted 5-chloroisothiazolones (1 and 3) showed PCAF inhibition
at micromolar concentrations (2–3 µM). Chlorine substitution in the 4-position
yielded products which retained PCAF inhibition, whereas methyl substitution
provided compounds that showed no inhibition at 10 µM. 5-Chloroisothiazolone-1-
oxide 6 with a methyl ester in the N-substitution shows an IC50 of 5.6 µM whereas 4
shows an IC50 higher than 10 µM. These data indicate that the methyl ester
contributes to PCAF inhibition. Methyl or chlorine substitution in the 4-position and
thiol substitution in the 5-position of 5-chloroisothiazolone-1-oxides provides
compounds with IC50 values higher than 10 µM. 5-chloroisothiazolones inhibit the
growth of HEP G2 cancer cells in concentrations between 8.6 and 24 µM, whereas
little or no growth inhibition was observed for 5-chloroisothiazolone-1-oxides.
EXPERIMENTAL PROTOCOLS
General procedures
Chemicals were obtained from commercial suppliers (Sigma–Aldrich, Acros
Organics) and in most cases used without further purification. Dichloromethane was
dried by distillation over CaH2 before use. Aluminum sheets of Silica Gel 60 F254
were used for Thin-layer chromatography (TLC). Spots were visualized under
ultraviolet light or stained with KMnO4 solution. MP Ecochrom Silica Gel 32–63 60
Å was used for column chromatography. Melting points were determined on an
Electrothermal digital melting point apparatus and are uncorrected. 1H and 13C
NMR spectra were recorded on a Varian Gemini-200 (50.32 MHz) spectrometer.
Chemical shift values are reported relative to residual solvent peaks (CD3OD, 1H δ =
3.31, 13C δ = 49.00 or CHCl3, 1H δ = 7.26, 13C δ = 77.16). The coupling constants (J)
are reported in Hertz (Hz). 13C spectra were recorded using the attached proton test
(APT) pulse sequence. HPLC analyses were performed with a Waters 510 pump,
equipped with an ISCO 2360 gradient programmer and a Waters 486 UV detector
(254 nm). The column was a 25 cm x 4.6 mm (5 µm) Discovery C18, with a flow of 0.5
mL/min. Electrospray ionization mass spectra (ESI-MS) were recorded on an Applied
Biosystems/SCIEX API3000-triple quadrupole mass spectrometer. High-resolution
mass spectra (HR-MS) were recorded using a flow injection method on an LTQ-
Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany) with a
resolution of 60,000 at m/z 400. Internal recalibration in real time was performed




The starting material (1.0 mmol) was dissolved in dichloromethane (10 mL), and m-
chloroperbenzoic acid (70%) (1.2 mmol, 0.29 g) was added in several portions over 20
min. The mixture was stirred for 3 h at room temperature. A few milligrams of
sodium metabisulfite were added to quench the excess mCPBA, and the mixture was
stirred for 5 min. The solvent was evaporated under reduced pressure, and the
residue was dissolved in EtOAc (15 mL), and extracted with saturated NaHCO3
solution (3 x 15 mL) and brine (1 x 15 mL). The organic layer was dried over Na2SO4,
filtered and the solvent was evaporated under reduced pressure. The crude product
was purified by column chromatography.
Synthetic procedure 2
The starting material (1.0 mmol) was dissolved in dichloromethane (10 mL). Sulfuryl
chloride (3.0 mmol, 0.24 mL) was added slowly and the solution was stirred
overnight at room temperature. H2O (1.0 mL) was added to the solution, and the
mixture was stirred for 5 min. The mixture was extracted with water (3 x 10 mL)
and brine (1 x 10 mL), dried over Na2SO4, and filtered. The solvent was evaporated
under reduced pressure, and the product was purified by column chromatography.
Synthetic procedure 3
The dithiobispropanamide (1.0 mmol) was dissolved in dry dichloromethane (5 mL)
and cooled to 0˚C. Sulfuryl chloride (3.0 mmol, 0.24 mL) was added dropwise, and
the mixture was stirred for 2h at room temperature. H2O (1.0 mL) was added, and
the mixture was stirred for 5 min. Subsequently, the mixture was extracted with
water (3 x 10 mL) and brine (1 x 10 mL), dried over Na2SO4, and filtered. The solvent
was evaporated under reduced pressure, and the product was purified by column
chromatography.
5-chloro-2-ethylisothiazol-3(2H)-one-1-oxide (4)
The product was obtained using procedure 1 starting from 1 and purified using
column chromatography with EtOAc/Hex 1:2 (v/v) as eluent. The compound was
obtained as a yellow oil (100 mg, 56%): Rf = 0.38 (EtOAc/Hex, 1:2); 1H NMR (200
MHz, CDCl3): δ = 1.33 (t, J = 7.1 Hz, 3H), 3.65-3.89 (m, 2H), 6.67 ppm (s, 1H); 13C
NMR (50 MHz, CDCl3): δ = 14.8, 36.8, 124.4, 156.9, 169.4 ppm; HPLC: purity > 98%,
RT = 9.6 min, mobile phase: H2O:CH3CN:TFA 60:40:0.1; HRMS: m/z [M+H]+ calcd
for C5H735ClNO2S: 179.9988, found: 179.9876.
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2-tert-butyl-5-chloroisothiazol-3(2H)-one 1-oxide (5)
The product was obtained using procedure 1 starting from 2 and purified using
column chromatography with EtOAc/Hex 1:2 (v/v) as eluent. The compound was
obtained as a colorless oil ( 62 mg, 30%): Rf = 0.6 (EtOAc/Hex, 1:1); 1H NMR (200
MHz, CDCl3) : δ 1.63 (s, 9H), 6.55 ppm (s, 1H); 13C NMR (50 MHz, CDCl3): δ 29.4,
59.7, 125.8, 136.3, 165.6 ppm; HPLC: purity 98%, RT = 11.1 min, mobile phase:
H2O:CH3CN:TFA 50:50:0.1; MS (ES, 70 eV): m/z 207.9 [M+H]+.
4,5-dichloro-2-ethylisothiazol-3(2H)-one (7)
The product was obtained using procedure 2 starting from 1 and purified using
column chromatography with EtOAc/Hex 1:1 (v/v) as eluent. The compound was
obtained as a yellow oil (109 mg, 55%): Rf = 0.51(EtOAc/Hex 1:2); 1H NMR (200
MHz, CDCl3): δ = 1.32 (t, J = 7.2 Hz, 3H), 3.86 ppm (q, J = 7.0 Hz, 2H); 13C NMR (50
MHz, CDCl3): δ = 14.7, 40.4, 138.4, 161.8, 168.0 ppm; HPLC: purity 99%, RT = 12.2
min, mobile phase: H2O:CH3CN:TFA 60:40:0.1; HRMS: m/z [M+H]+ calcd for
C5H635Cl2NOS: 197.9542, found: 197.9543.
Methyl 3-(4,5-dichloro-3-oxoisothiazol-2(3H)-yl)propanoate (8)
The product was obtained using procedure 2 starting from 3 and was purified using
column chromatography with EtOAc/Hex 1:1 (v/v) as eluent. The compound was
obtained as a yellow oil (233 mg, 91 %): Rf = 0.40 (EtOAc/Hex 1:1); 1H NMR (200
MHz, CDCl3): δ = 2.75 (t, J = 6.1 Hz, 2H), 3.71 (s, 3H), 4.07 ppm (t, J = 6.0, Hz 2H);
13C NMR (50 MHz, CDCl3): δ = 33.6, 41.0, 52.3, 114.5, 139.7, 162.1, 171.7 ppm;
HPLC: purity > 98%, RT = 10.5 min, mobile phase: H2O:CH3CN:TFA 50:50:0.1;
HRMS: m/z [M+H]+ cald for C7H835Cl2NO3S: 255.9597, found: 255.9596.
4,5-dichloro-2-ethylisothiazol-3(2H)-one-1-oxide (9)
The product was obtained using procedure 1 starting from 7 and purified using
column chromatography with EtOAc/Hexane 1:3 (v/v) as eluent. The compound was
obtained as a pale yellow solid (165 mg, 77 %): Rf = 0.58 (EtOAc/Hex, 1:2); 1H NMR
(200 MHz, CDCl3): δ = 1.32-1.40 (m, 3H), 3.72-3.91 (m, 2H) ppm. 13C NMR (50 MHz,
CDCl3): δ = 14.7, 38.0, 131.0, 148.7, 159.8 ppm; HPLC: purity 98%, RT = 12.2 min,
mobile phase: H2O:CH3CN:TFA 50:50:0.1; HRMS: m/z [M+H]+ calcd for
C5H635Cl2NO2S: 213.9491, found: 213.9491.
Methyl 3-(4,5-dichloro-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate (10)
The product was obtained using procedure 1 starting from 8 and purified using
column chromatography with EtOAc/Hex 1:2 (v/v) as eluent. The compound was
obtained as a yellow oil (212 mg, 78 %): Rf = 0.48 (EtOAc/Hex, 1:1); 1H NMR (200
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MHz, CDCl3): δ = 2.71-2.81 (m, 2H), 3.70 (s, 3H), 4.05 ppm (t, J = 6.5 Hz, 2H); 13C
NMR (50 MHz, CDCl3): δ = 33.4, 38.2, 52.3, 130.6, 149.4, 160.3, 171.1 ppm; HPLC:
purity 98%, RT = 11.5 min, mobile phase: H2O:CH3CN:TFA 50:50:0.1; HRMS: m/z
[M+H]+ calcd for C7H835Cl2NO4S: 271.9546, found: 271.9544.
2-tert-butyl-5-(dodecylthio)isothiazol-3(2H)-one-1-oxide (11)
Dodecane-1-thiol (1.2 mmol, 0.28 mL,) was added to a solution of 2-tert-butyl-5-
chloroisothiazol-3(2H)-one-1-oxide (1.2 mmol, 0.25 mg) in dry dichloromethane at
room temperature. Triethylamine (1.2 mmol, 0.15 mL) was added dropwise, and the
mixture was stirred for 3 h at room temperature. Dichloromethane (50.0 mL) was
added, and the organic layer was extracted with H2O (3 x 50 mL) and brine (1 x 50
mL), and dried with Na2SO4. The solvent was evaporated under reduced pressure,
and the residue was purified by column chromatography using EtOAc/Hex 1:25 (v/v)
as eluent. The compound was obtained as a white solid (241 mg, 57%): Rf = 0.42
(EtOAc/Hex, 1:4); mp: 62 oC; 1H NMR (200 MHz, CDCl3): δ = 0.87 (t, J = 6.5 Hz, 3H),
1.20-1.50 (m, 18H), 1.62 (s, 9H), 1.65-1.85 (m, 2H), 2.98 (t, J = 7.3 Hz, 2H), 6.07 ppm
(s, 1H). 13C NMR (50 MHz, CDCl3): δ = 14.3, 22.8, 28.3, 28.9, 29.1, 29.3, 29.5, 29.6,
29.7, 32.0, 33.6, 58.9, 118.0, 165.5, 167.2 ppm. MS (ESI): m/z 374.1 [M+H]+.
Methyl 3-[5-(dodecylthio)-1-oxido-3-oxoisothiazol-2(3H)-yl] propanoate (12)
The product was obtained using the same procedure as for compound 11 starting
from dodecane-1-thiol and methyl 3-(5-chloro-1-oxido-3-oxoisothiazol-2(3H)-
yl)propanoate (6). The compound was purified using column chromatography with
EtOAc/Hex (v/v) 1:10 as eluent and was obtained as a white solid (335 mg, 69%): Rf
= 0.39 (EtOAc/Hex, 1:2); mp: 55.7 oC;. 1H NMR (200 MHz, CDCl3): δ = 0.86 (t, J = 6.5
Hz, 3H), 1.20-1.50 (m, 18H), 1.65-1.85 (m, 2H), 2.72 (dt, J = 4.0, 7.1 Hz, 2H), 3.01 (t,
J = 7.3 Hz, 2H), 3.69 (s, 3H), 3.98 (t, J = 6.8 Hz, 2H) 6.15 ppm (s, 1H). 13C NMR (50
MHz, CDCl3): δ = 14.23, 22.8, 28.2, 28.8, 29.1, 29.4, 29.5, 29.6, 29.7, 32.0, 33.8, 33.9,




The product was obtained using procedure 1 starting from 12 and was purified using
column chromatography with EtOAc/Hex 1:10 (v/v) as eluent. The compound was
obtained as a colorless oil (254 mg ,58%): Rf = 0.49 (EtOAc/Hex, 1:2); 1H NMR (200
MHz, CDCl3): δ = 0.86 (t, J = 6.5 Hz, 3H), 1.20-1.80 (m, 20H), 1.65-1.85 (m, 2H), 2.65-
2.80 (m, 2H), 2.85-3.00 (m, 2H), 3.69 (s, 3H), 3.95-4.10 ppm (m, 2H). 13C NMR (50
MHz, CDCl3): δ =14.4, 28.8, 29.0, 29.2, 29.3, 29.6, 29.7, 29.8, 30.9, 32.1, 33.2, 38.4,
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39.9, 40.7, 52.4, 95.8, 167.8, 169.5, 171.2 ppm; HRMS: m/z [M+H]+ calcd for
C19H3335ClNO4S2: 438.1534, found: 438.1532.
3-(acetylthio)-2-methylpropanoic acid (15)
Methacrylic acid (40 mmol, 3.39 mL) was dissolved in 50 mL cyclohexane. Thioacetic
acid (120 mmol, 8.58 mL) was slowly added, and the reaction mixture was stirred at
reflux overnight. The reaction mixture was cooled to room temperature, and the
solvent was evaporated under reduced pressure. The residue was dissolved in 50 mL
ethylacetate, and extracted with HCl 1N (3 x 50 mL) and brine (1 x 30 mL). The
organic layer was dried with Na2SO4, and the solvent evaporated under reduced
pressure. The product was purified by column chromatography with
ethylacetate:hexane 1:4 (v/v) as eluent to give a colorless oil (3.24 g, 50%). Rf = 0.60
(EtOAc/Hex 2:1); 1H NMR (200 MHz, CD3OD): δ = 1.21 (d, J = 7 Hz, 3H), 2.32 (s,
3H), 2.61-2.67 (m, 1H), 3.03-3.09 ppm (m, 2H); 13C NMR (50 MHz, CD3OD): δ = 17.1,
30.4, 32.6, 41.0, 178.2, 196.9; MS (ESI): m/z 161.2 [M+H]+.
3,3'-dithiobis(2-methylpropanoic acid) (16)
3-(acetylthio)-2-methylpropanoic acid (15) (15 mmol, 2.40 g) was suspended in 20 mL
HCl 6N and refluxed for 4h. The mixture was cooled to room temperature, hydrogen
peroxide sol 35% (15 mmol, 1.28 mL) was added at 0 ˚C and the mixture stirred for
15 min. The H2O2 was quenched with few milligrams of sodium bisulfite and the
mixture extracted with ethylacetate (3 x 30 mL). The organic layers were collected,
extracted with brine (1 x 50mL) and dried over Na2SO4. The solvent was evaporated
under reduced pressure to give the product that was used for the next step without
any further purification. The compound was obtained as a pale yellow oil (1.40 g, 39
%): Rf = 0.44 (EtOAc/Hex 2:1); 1H NMR (200 MHz, CD3OD): δ = 1.22-1.36 (m, 6H),
2.78-3.03 (m, 4H), 3.53-3.56 (m, 1H), 3.88-3.92 ppm (m, 1H).
3,3'-dithiobis(N-ethyl-2-methylpropanamide) (17)
The 3,3'-dithiobis(2-methylpropanoic acid) (16) (19 mmol, 4.0 g) was suspended in 15
mL SOCl2 and the resulting mixture was heated to reflux until complete dissolution
of the acid. The solvent was evaporated under reduced pressure to furnish the
diacidchloride as a pale yellow oil. Triethylamine (76 mmol, 10.5 mL) was added to a
solution of Ethylamine*HCl (38 mmol, 3.10 g) in 80 mL of dry dichloromethane and
the resulting mixture was cooled to 0 oC. A previously prepared solution of the
diacidchloride in dichloromethane was added dropwise and the mixture was stirred
at 0 oC overnight. The mixture was extracted with brine (1 x 50 mL), the organic
layer was dried with Na2SO4 and the solvent evaporated under reduced pressure to
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give the product as an orange oil. The crude product was used for the next step
without purification.
3,3'-dithiobis[N-(methyl 2-aminoethanoate)-2methylpropanamide] (18)
3,3'-dithiobis(2-methylpropanoic acid) (16) (5 mmol, 1.05 g) was suspended in 5 mL
SOCl2, and the resulting mixture was heated to reflux until complete dissolution of
the acid. The solvent was evaporated under reduced pressure to furnish the
diacidchloride as pale yellow oil. Triethylamine (22 mmol, 3.05 mL) was added to a
solution of methyl 3-aminopropionate*HCl (10 mmol, 1.40 g) in 25 mL of dry
dichloromethane, and the resulting mixture was cooled to 0 oC. A previously
prepared solution of the diacidchloride in dichloromethane was added dropwise, and
the mixture was stirred at 0 oC overnight. The mixture was extracted with brine (2 x
30 mL), and the organic layer was dried on Na2SO4, and the solvent evaporated
under reduced pressure to give the product as a brown gum. The crude product was
used for the next step without purification.
5-chloro-2-ethyl-4-methylisothiazol-3(2H)-one (19)
The product was obtained using general procedure 3 starting from 3,3’-dithiobis(N-
ethyl-2-methylpropanamide) and was purified using column chromatography with
EtOAc/Hex 1:6 (v/v) as eluent. The compound was obtained as a yellow liquid (64 mg,
38%): Rf = 0.34 (EtOAc/Hex, 1:2); 1H NMR (200 MHz, CDCl3): δ = 1.26 (t, J = 7.2,
3H), 1.97 (s, 3H), 3.78 ppm (q, J = 7.3, 2H). 13C NMR (50 MHz, CDCl3): δ 10.9, 14.8,
39.0, 122.0, 138.4, 166.5 ppm; HPLC: purity 98%, RT = 9.2, mobile phase:
H2O:CH3CN:TFA 60:40:0.1; HRMS: m/z [M+H]+ calcd for C6H935ClNOS: 178.0088,
found: 178.0088.
Methyl 3-(5-chloro-4-methyl-3-oxoisothiazol-2(3H)-yl)propanoate (20)
The product was obtained using general procedure 3 starting from 3,3'-dithiobis[N-
(methyl 2-aminopropionate)-2-methylpropanamide] and purified using column
chromatography with EtOAc/Hex 1:4 (v/v) as eluent. The compound was obtained as
a yellow gum (122 mg, 52%): Rf = 0.44 (EtOAc/Hex, 1:1); 1H NMR (200 MHz, CDCl3):
δ = 1.98 (s, 3H), 2.71 (t, J = 6.2 2H), 3.70 (s, 3H), 4.02 ppm (t, J = 6.3 2H). 13C NMR
(50 MHz, CDCl3): δ = 10.9, 33.8, 39.8, 52.2, 121.5, 139.6, 166.9, 171.7; HPLC: purity
99%, RT = 11.4 min, mobile phase: H2O:CH3CN:TFA 60:40:0.1; HRMS: m/z [M+H]+
calcd for C8H1135ClNO3S: 236.0142, found: 236.0141.
5-chloro-2-ethyl-4-methylisothiazol-3(2H)-one-1-oxide (21)
The product was obtained using procedure 1 starting from 19 and purified using
column chromatography with EtOAc/Hex 1:2 (v/v) as eluent. The compound was
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obtained as a colorless liquid (159 mg, 82%): Rf = 0.72 (EtOAc/Hex, 1:1); 1H NMR
(200 MHz, CDCl3): δ = 1.32 (t, J = 7.3, 3H), 2.05 (s, 3H), 3.69-3.87 ppm (m, 2H). 13C
NMR (50 MHz, CDCl3): δ = 10.9, 14.8, 39.0, 122.0, 138.4, 166.5 ppm; HPLC: 98%, RT
= 11.8 min, mobile phase: H2O:CH3CN:TFA 60:40:0.1; HRMS: m/z [M+H]+ calcd for
C6H935ClNO2S: 194.0037, found: 194.0032.
Methyl 3-(5-chloro-4-methyl-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate (22)
The product was obtained using procedure 1 starting from 20 and purified using
column chromatography with EtOAc/Hex 1:4 (v/v) as eluent. The compound was
obtained as a colorless oil (181 mg, 72%): Rf = 0.56 (EtOAc/Hex, 1:1); 1H NMR (200
MHz, CDCl3): δ = 2.04 (s, 3H), 2.69-2.77 (m, 2H), 3.69 (s, 3H), 4.00 ppm (t, J = 6.7,
2H). 13C NMR (50 MHz, CDCl3): δ = 10.8, 33.6, 37.4, 52.2, 133.6, 149.8, 165.6, 171.2
ppm; HPLC: purity 97%, RT = 11.2, mobile phase H2O:CH3CN:TFA 60:40:0.1;
HRMS: m/z [M+H]+ calcd for C8H1135ClNO4S: 252.0092, found 252.0091.
Reaction of isothiazolone with propane-1-thiol
A solution 0.1 M of propane-1-thiol (3 mmol, 271 μL) in CH3CN (30 mL) was
prepared. The concentration of free thiol was quantified using 5,5'-Dithio-bis(2-
nitrobenzoic acid) (DTNB). A DTNB standard calibration curve was prepared
measuring the UV extinction, starting from 1 mM DTNB with an excess of thiol (10
mM). A sample of propane-1-thiol solution (100 μL) was mixed with 20 mM DTNB
solution (100 μL). The UV absorbance was measured and the SH content was then
calculated from the calibration curve. No significant differences were observed
between the calculated and measured concentration. For the reaction, the compound
(50 μmol) was dissolved in CH3CN (2 mL). The previously prepared solution 0.1 M of
propanethiol in CH3CN (50 μmol, 500 μL) was added, and the progress of the
reaction was followed by HPLC. As eluent, a mobile phase composition
H2O:CH3CN:TFA 50:50:0.1 was used and the compounds were identified on the basis
of their retention times.
Reaction of isothiazolone with sodium propane-1-thiolate
A solution of sodium propane-1-thiolate in water (30mL) was prepared from
propane-1-thiol (272 μL, 3 mmol) and NaOH (108mg, 2.7 mmol). The concentration
of free thiolate was quantified using 5,5'-Dithio-bis(2-nitrobenzoic acid (DTNB) as
already described. The compound (50 μmol) was dissolved in CH3CN (2 mL). The
solution 0.1 M of sodium propane-1-thiolate (0.1, 0.5 or 1.0 equiv.) was added, and
the progress of the reaction was followed by HPLC. As eluent, a mobile phase
composition H2O:CH3CN:TFA 50:50:0.1 was used, and the compounds were




The compound (4 mmol) was dissolved in 1-octanol (1 mL). Water (1 mL) was added
and the mixture was vigorously shaken with a vortex mixer (3 x 5 min) and
centrifuged (2000g, 10 sec). The two layers were separated and analyzed by HPLC.
The logP was calculated comparing the area of the peaks of the two layers.
Enzyme inhibition studies
A fluorescent histone acetyltransferase assay described by Trievel et al. was used for
enzyme inhibition studies.112 Enzyme inhibition was measured by determination of
the residual enzyme activity after 15 min incubation with the inhibitor. The enzyme
activity was measured by detection of CoA-SH by the fluorescent dye 7-
(diethylamino)-3-(4’-maleimidylphenyl)-4-methylcoumarin (CPM). The CoA-SH
concentrations measured with no inhibitor present were around 50 μM. The
inhibitor concentrations were maximal 10 μM, so that inhibitory effects of more than
20% at 10 μM inhibitor concentration cannot be explained by direct reaction of the
inhibitors with CoA-SH. Compounds that showed more than 50% inhibition at 10
μM (n = 3) were subjected to IC50 determination (n = 3). The human recombinant
histone acetyltransferase PCAF (p300/CREB-bindingprotein Associated Factor) was
obtained from Biomol International. The histone H3 peptide (Ac-
QTARKSTGGKAPRKQLATKNH2) was purchased from Pepscan (Lelystad, NL).
Cell Growth Inhibition
All cell culture reagents were purchased from Invitrogen. The human cancer cells
HEP G2 (liver) were maintained in Dulbecco’s modified Eagles Medium with 10%
heat-inactivated fetal calf serum, 50 IU/mL penicillin, and 50 mg/mL streptomycin
at 37 ˚C in a humidified 5% CO2 incubator. Cell proliferation was measured by a
Crystal Violet assay. The cells were seeded at 5000 cells per well into 96-well plates,
grown for 24 h, and treated for an additional 48 h with the different inhibitors. The
medium was then aspirated, and the cells were fixed with 50 μL 1% crystal violet in
70% ethanol for 30 min. The cells were washed with water and the staining was
solubilized by addition of 100 μL 1% SDS in water. The plates were read at 550 nm.
A blank extinction value in which no cells were seeded was subtracted from all
determinations and cell growth with no inhibitor present was set to 100%. All
concentrations were tested in 8-fold on one plate and the GI50 values of most potent
inhibitors were measured again on a new plate.
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Several lines of evidence indicate that histone acetyltransferases (HATs) are novel
drug targets for treatment of diseases like cancer and inflammation. The natural
product anacardic acid is a starting point for development of small molecule
inhibitors of the histone acetyltransferase (HAT) p300/CBP associated factor (PCAF).
In order to optimize the inhibitory potency, a binding model for PCAF inhibition by
anacardic acid was proposed and new anacardic acid derivatives were designed. Ten
new derivatives were synthesized using a novel synthetic route. One compound
showed a two-fold improved inhibitory potency for the PCAF HAT activity and a two-
fold improved inhibition of histone acetylation in HEP G2 cells.
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INTRODUCTION
For several diseases treatment with the currently available drugs is not satisfactory,
which demonstrates the need for conceptually new drugs for new therapeutic
targets. The epigenetic regulation of gene transcription is an area of research in
which new therapeutic targets are being discovered. Gene transcription is, among
others, regulated by histone acetyltransferases (HATs) (figure 4.1).90 Deregulation of
histone acetylation has been linked to several diseases, including cancer and
inflammation, which suggests that HATs are potential anti-inflammatory
targets.89,94,128
Figure 4.1: acetylation of histone lysine residues by histone acetyltransferases provides potential
anti-inflammatory drug targets. Anacardic acid is a cell-permeable small molecule inhibitor of
the histone acetyltransferase PCAF.
Ultimately, we aim to explore the role of histone acetyltransferases in
inflammation by development of small molecule inhibitors. Inflammation involves a
variety of inflammatory mediators whose transcription is enhanced during the
disease process by global histone acetylation as well as gene specific histone
acetylation. Several studies showed a disturbed balance between HAT and HDAC
activity in inflammatory diseases. Asthma patients show increased HAT activity in
bronchial biopsies, whereas the activity and expression of HDACs are decreased.29
The same was observed in lung tissue for chronic obstructive pulmonary disease
(COPD) patients compared to healthy subjects.41 Tissue of patients with COPD
showed reduced HDAC activity and increased histone H4 acetylation in the
interleukin-8 promoter.
Nuclear factor κB (NF-κB) mediated signal transduction plays an important role
in inflammation. When activated, NF-κB translocates to the nucleus, where it binds
to the κB recognition site of target genes and to cofactors with intrinsic HAT activity
such as p300/CBP and PCAF.32 This leads to global acetylation of lysine residues in
histone H4 and opening of the chromatin structure, enabling transcription of
Chapter 4
68
proinflammatory genes, including IL-8.39 This mechanism is supported by the
observation that Legionella pneumophila-induced IL-8 release from alveolar
epithelial cells is decreased by HAT inhibition and enhanced by HDAC inhibition.
These findings suggest that restoring the HAT/HDAC balance by small molecule
inhibitors of histone acetylation provides opportunities for treatment of
inflammation.36,41,42,118
Only a few small molecule inhibitors of HATs are currently available. Potent and
selective bisubstrate inhibitors for the HATs p300 and PCAF have been described,
however the lack of cell permeability represents a disadvantage.72 Another well-
known class of inhibitors is represented by isothiazolones, which are cell-permeable
and potent; however their reactivity limits their specificity.74,119,120,129 Furthermore,
the natural products curcumin, plumbagin, garcinol and anacardic acid (AA, figure
4.1) have been reported as inhibitors of different classes of HATs.78,80,82,87
Interestingly, it has been demonstrated that anacardic acid suppresses the NF-κB
pathway, which shows the potential of this compound to suppress inflammation.79
Several benzamide derivatives of anacardic acid have been studied for inhibition of
p300, however they were either equally potent p300 HAT inhibitors compared to
anacardic acid or they activated the p300 HAT.78,130
In this study we describe hypothesis-driven optimization of the HAT inhibitory
potency of anacardic acid. We proposed a binding model for anacardic acid in the
PCAF active site using molecular modeling techniques. Based on this model, a series
of new anacardic acid derivatives was designed. A convenient synthetic route was
developed to synthesize these derivatives. We varied the 6-alkyl chain of anacardic
acid by different substituent in order to improve the potency and the drug likeness of
these inhibitors. A series of 10 anacardic acid derivatives was synthesized and their
inhibitory potency for the recombinant HAT PCAF enzyme and for histone
acetylation in HEP G2 cells was studied.
RESULTS AND DISCUSSION
Molecular docking studies
The crystal structure of PCAF in complex with Coenzyme A (CoA) has been
published previously.104 Using this structure, docking studies were performed in
order to propose a possible binding mode for anacardic acid. We hypothesized that
the salicylate group of anacardic acid mimics the pyrophosphate group of CoA, which
forms an extensive H-bond network with the backbone amide nitrogens of V582,
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G584, G586, and T587, with the sidechain hydroxyl of T587, and with the water
molecule w6 (figure 4.2a). This active site water molecule is further stabilized by an
H-bond network with the backbone of E580, K583, and Y585 (figure 4.2a). Docking
simulations including this essential water molecule indeed yielded a (highest
ranked) pose of anacardic acid similar to the CoA binding mode (figure 4.2b), in
which the carboxylic group accepts H-bonds from the backbone of K583, G584, G586,
and w6, the hydroxyl group donates a H-bond to the T587 sidechain in the
pyrophosphate binding pocket, and the long alkyl chain of anacardic acid protrudes
deep into the hydrophobic pantothenic acid binding pocket between beta strand 4
(β4) and alpha helix 4 (α4) (figure 4.2b). The anacardic acid binding mode is further
stabilized by aromatic edge-to-face stacking between the salicylate ring and Y616.
Figure 4.2: (a) binding mode of the natural substrate CoA bound to the HAT PCAF active site
(PDB code 1CM0). Only the pantothenic acid and the pyrophosphate of CoA are shown. The
substrate carbon atoms are shown in purple. Docked binding configurations of anacardic acid
(b) (carbons atoms in green), compound 4e (c) (carbon atoms in pink), and compound 6d (d)
(carbon atoms in orange). Helix 4 and beta strand 4 are represented by yellow ribbons.
Important binding residues are shown as ball-and-sticks with grey carbon atoms. Oxygen,
nitrogen sulphur, phosphor, and hydrogen atoms are colored red, blue, yellow, orange, and cyan,
respectively. Protein-ligand as well as w6-ligand and protein-w6 H-bonds described in the text
are shown as black or grey dotted lines.
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This molecular docking pose was used as starting point for the design of new
molecules and to rationalize structure-activity relationships. First of all, the role of
the hydrophobic chain in the binding to the pantothenic acid pocket between α4 and
β4 was investigated. Secondly, it was hypothesized that incorporation of a second
aromatic ring could further stabilize ligand binding via additional aromatic stacking
interactions with Y616. Thirdly, the acidity of the carboxyl group was modulated by
introduction of substituents on the salicylate ring. In silico predicted binding modes
of novel potent anacardic acid-based PCAF ligands (figure 4.2 c-d) will be discussed
in the paragraph “2.3. Enzyme inhibition assay”.
Chemistry
A convenient synthetic method was developed in order to synthesize a diverse series
of compounds with a salicylate functionality. Several syntheses of anacardic acid
have been described so far, however these routes require harsh conditions that are
not compatible with many functional groups.131-133 Therefore, a new synthetic route
was developed, in which a Sonogashira coupling is the key step (scheme 4.1).
Scheme 4.1: synthesis of anacardic acid derivatives: reagents and conditions: a) CuI,
PdCl2(PPh3)2, Et2NH, HC≡CR, CH3CN, 70 °C; b) H2, Pd/C, MeOH, 40 °C; c) KOH 5 N, THF, 55
°C
Triflate 1 was synthesized according to previously published procedures,
starting from the commercially available 2,6-dihydroxybenzoic acid.134 Different
terminal alkynes were coupled in presence of CuI, diethylamine, and PdCl2(PPh3)2 to
give the correspondent alkynyls 2. The Sonogashira reaction, performed in
acetonitrile at 70 °C on oil bath, required 2 hours to give the product with high yields
(80-90%). The same reaction was also performed in acetonitrile at 100 °C with
microwave irradiation. In this case, the product was obtained in comparable yields
after just 30 min. Hydrogenation, using palladium on activated carbon as catalyst,
was used to reduce the akynyl triple bond to a single bond. The best yields (60-80%)
were obtained if hydrogenation was performed for 16 h, with 3 atm. H2-pressure in
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methanol at 40 °C. In case of compound 2d, hydrogenation under the described
conditions gave the correspondent cis-alkene 5d (J = 12.1 Hz). To obtain the alkane
3d, it was necessary to perform hydrogenation for 40 h. The last step in this
synthetic route was the cleavage of the acetonide protecting group. This was
achieved by saponification with KOH 5 N at 55 °C with yields between 50% and 80%.
Structures of 4-hydroxy-6-alkyl-salicylates 12a and 12b (scheme 4.2) are closely
related to another natural compound known as olivetolic acid, an intermediate in the
biosynthesis of cannabinoids.135 A synthetic route towards these compounds has
been described by Dushin and Danishefsky.136 This route implicates a Sonogashira
coupling on 7, followed by hydrogenation to give the correspondent 9. Cleavage of the
acetonide 9 to yield 12 poses a challenge. Saponification by hydroxide (OH-) can only
be performed under forcing conditions due to deprotonation of the 4-hydroxy group
and concomitant electron-donation to the carboxylate. Acidic cleavage of the
acetonide will result in decarboxylation.137 We designed another route to avoid these
problems (Scheme 2). Building block 10 was employed for Sonogashira coupling to
terminal alkenes.138 The resulting alkynyls gave the desired product upon
hydrogenation concomitant with hydrogenolysis of the benzyl group.
Scheme 4.2: synthesis of olivetolic acid derivatives: reagents and conditions: a) CuI,
PdCl2(PPh3)2, Et2NH, HC≡CR, CH3CN, 70 °C; b) H2, Pd/C, MeOH, 40 °C
Anacardic acid derivatives with an alkoxy function in the 2-position were
synthesized starting from 13 (scheme 4.3). Compound 13 was converted to 14 using a
Williamson ether synthesis with benzyl bromine (yield 83%). In contrast, reaction of
13 with tetradecylchloride did not give the desired product. Compound 16 was
obtained by Mitsunobu coupling between 13 and tetradecanol (yield 29%).
Saponification of 14 and 16 provided the corresponding free carboxylic acids 15 and
17 with yields of 49% and 66% respectively. Compound 18 was synthesized from




























Scheme 4.3: reagents and conditions: a) Benzylbromide, K2CO3, DMF; b) tetradecanol, PPh3,
DIAD, THF; c) KOH 5N, THF, 55 °C; d) H2SO4, MeOH, reflux.
Enzyme inhibition assay
The synthesized compounds were tested for inhibition of the HAT PCAF using an
indirect ELISA assay in order to study their binding properties and structure-
activity relationship. The ELISA was based on detection of acetylated lysine residues
on a histone H4 peptide using an anti-acetyl-lysine antibody. Human recombinant
PCAF was used as source of HAT activity. Anacardic acid (AA) 4a showed around
40% inhibition at 1 mM (figure 4.3), which would give an estimated IC50 value
between 1 and 2 mM. The potency measured in our assay is 100-fold lower than the
estimation by Balsubramanyam et al. but in line with the IC50 reported by Wu et
al.73,78 The differences might be explained by the fact that Wu et al. used comparable
Ac-CoA concentrations, whereas Balsubramanyam et al. used lower Ac-CoA
concentrations in the enzyme inhibition assay. Furthermore, differences in assay
buffer composition or differences in the enzyme source might cause differences in
IC50 values.
Several modifications of the salicylate moiety were investigated to slightly
modulate the acidity of the carboxyl group. Compounds 12a and 12b showed
comparable potency as observed for compounds AA 4a and 4b, respectively. These
data show that the introduction of a hydroxyl group in the 4-position of the salicylate
does not influence the inhibitory properties. Introduction of an alkoxy group in the 6-
position of the salicylate ring 17 did not lead to significant changes in potency. The
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carboxylic acid for the interaction with PCAF, however the water solubility of 18 is
too low for testing at 1 mM concentration in our assay.
Figure 4.3: inhibition of the HAT PCAF by different compounds at 1 mM. Data are expressed as
percentage of PCAF activity (n=3, *P<0.05 compared to AA 4a).
The role of the hydrophobic interactions for the ligand potency was investigated
by modifications of the hydrophobic alkyl chain. Compounds 4c and 4d showed
inhibition comparable to anacardic acid, indicating that introduction of an aromatic
ring in the chain did not affect the inhibitory properties. On the other hand,
compounds 4b and 12b were less potent than the correspondent AA 4a and 12a,
indicating that one-third reduction of the chain length causes loss of potency. Also
compound 15, with a benzyl group instead of the long alkylic chain, showed less than
20% inhibition at 1mM. These data suggest that hydrophobic interactions at the end
of the CoA binding pocket are important for binding. This observation is in line with
the proposed binding mode of anacardic acid (figure 4.2b), which is stabilized by
hydrophobic interactions deep in the pantothenic acid pocket between α4 and β4
(figure 4.1a).
Interestingly, incorporation of a 3-(2-methoxyphenoxy)propyl moiety 4e provided

































2-methoxyphenoxy ring stacks between the aromatic rings of Y616 and F617,
whereas the 2-methoxy group can be accommodated in a small additional pocket
between L589, V576 and Y616. Compound 4e provides a good platform for further
structural variation in order to optimize the inhibitory potency of this compound
class.
Compound 6d is the only compound that proved to be more potent than
anacardic acid in our assay. We measured for this compound an IC50 of 662 ± 64 µM
(figure 4.4). Remarkably, compounds 4c and 4d, also including a second benzyl
group, but lacking the cis double bond, did not show increased potency compared to
anacardic acid 4a. In the highest ranked docking pose of compound 6d, the salicylate
moiety is hydrogen bonded to the pyrophosphate binding pocket as described for
anacardic acid 4a (figure 4.2d). In addition, the geometry of the cis-double bond
forces the phenoxy ring in an optimal conformation for face-to-edge aromatic
stacking with Y616 and orientates the hydrophobic tail of the molecule deep into the
hydrophobic binding cleft between α4 and β4 (figure 4.2d) . This conformational
restriction could explain the increased potency of 6d compared to 4d. Furthermore,
compound 6d has improved druglike properties compared to anacardic acid. In
conclusion, compounds 6d and 4e provide a starting point for the design of new
PCAF inhibitors.
Figure 4.4: IC50’s for inhibition of PCAF HAT activity by anacardic acid 4a and salicylate 6d.
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Cell-based study
Since compound 6d was more potent than anacardic acid 4a, we decided to test the
effects of 6d on histone acetylation in a cell-based study. Histone H4 acetylation
levels in HEP G2 cells were measured using an anti-acetyl histone H4 antibody. The
HDACs inhibitor suberoylanilide hydroxamic acid (SAHA) was used to increase the
basal histone acetylation. Cells were treated for 24 h with 5 µM SAHA and co-
treated with different concentration of 6d and anacardic acid 4a. The cells were
treated with subtoxic concentrations of the inhibitors. Figure 4.5a shows that SAHA
increased histone H4 acetylation levels significantly. Compound 6d decreased the
acetylation induced by SAHA in HEP G2 cells at 30 μM and 60 μM. The decrease is
stronger than observed for a comparable concentration of anacardic acid (AA) 4a.
Quantification of the western blot results (figure 4.5b) showed a significant increased
inhibition for compound 6d compared to AA 4a (P<0.01). These data demonstrate
that compound 6d is a useful tool to inhibit histone acetylation in cell-based studies.
Differences between the effective concentrations between the inhibition of the
recombinant enzyme and the cell-based studies might originate from factors such as
differences in the assay buffer composition, differences in the Ac-CoA concentration
or differences in the enzyme source. Furthermore, the fact that higher
concentrations of AA 4a and 6d were required to inhibit the recombinant enzyme
PCAF compared to the cell-based studies could indicate that these compounds target
different histone acetyltransferases in the cell-based studies.
CONCLUSION
In this study we describe the development of a salicylate derivative 6d with
improved inhibition of histone acetylation compared to the natural product anacardic
acid. A binding configuration of anacardic acid in the HAT PCAF active site was
proposed using molecular modeling. In this binding model, the salicylate is bounded
in the pyrophosphate binding pocket and the alkyl chain is located in the CoA
substrate binding cleft. Based on this model, new anacardic acid derivatives were
designed in order to explore the role of the alkyl chain and the importance of the
salicylate moiety. A convenient synthetic route towards anacardic acid was
developed and 10 derivatives were synthesized. Testing of the inhibitory potency for
the PCAF HAT activity showed that one derivative had a 2-fold improved inhibitory
potency for the HAT PCAF recombinant enzyme. Moreover, this derivative showed
also a 2-fold improved potency for inhibition of histone H4 acetylation in cell-based
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studies on HEP G2 cells. This is the first report on hypothesis-driven optimization of
the HAT PCAF inhibition.
Figure 4.5: cell-based studies on histone H4 acetylation levels in HEP G2 cells. a) Western blot
of histone extracts of HEP G2 cells after 24h treatment with different concentrations of the
indicated compounds. Coomassie brilliant blue staining was used to determine equal amount of
loading. b) Quantification of Histone H4 acetylation levels: values are shown in comparison to
histone acetylation levels of non-treated cells (100%) and expressed as mean ± SEM of three
independent experiments. *P<0.05, **P<0.01 compared to SAHA stimulated samples. #P<0.01
compared to SAHA - AA 4a (60 μM) treated samples.




Chemicals were purchased from Sigma–Aldrich and Acros Organics, and used
without further purification. Solvents were dried before use according to known
procedures and all the reactions were carried-out under a nitrogen atmosphere.
Analytical thin-layer chromatography (TLC) was performed on aluminum sheets of
Silica Gel 60 F254. Ultraviolet light, KMnO4 solution or ninhydrin solution were
used to visualize bands. All microwave irradiation reactions were carried out in a
Biotage Initiator™ Microwave Synthesizer. Column chromatography was performed
with MP Ecochrom Silica Gel 32–63, 60 Å. 1H and 13C NMR spectra were recorded on
a Varian Gemini-200. 13C spectra were recorded using the attached proton test (APT)
pulse sequence. Chemical shift values are reported as part per million (δ) relative to
residual solvent peaks (CDCl3, 1H δ = 7.26, 13C δ = 77.16 or CD3OD, 1H δ = 3.31, 13C δ
= 49.00). The coupling constants (J) are reported in Hertz (Hz). Electrospray
ionization mass spectra (ESI-MS) were recorded on an Applied Biosystems/SCIEX
API3000-triple quadrupole mass spectrometer. High-resolution mass spectra (HR-
MS) were recorded using a flow injection method on a LTQ-Orbitrap XL mass
spectrometer (Thermo Electron, Bremen, Germany) with a resolution of 60,000 at
m/z 400. Protonated testosterone (lock mass m/z = 289.2162) was used for internal
recalibration in real time. Melting points were determined on an Electrothermal
digital melting point apparatus and are uncorrected.
Synthetic procedure 1
Freshly distilled diethylamine (3.0 mmol, 0.30 mL) and the alkyne (2.2 mmol) were
subsequently added to a solution of the triflate (2.0 mmol), CuI (0.20 mmol, 38 mg),
and PdCl2(PPh3)2 (0.01 mmol, 70 mg) in degassed anhydrous acetonitrile (6.0 mL).
The mixture was either stirred for 2 h at 70 °C on oil bath or subjected to microwave
irradiation for 30 min at 100 °C (70W). Water (10 mL) was added and the mixture
was extracted with EtOAc (3 x 30 mL). The combined organic phases were washed
with brine (1 x 60 mL), dried over Na2SO4 and filtered. The solvent was evaporated
under reduced pressure and the residue was purified by column chromatography.
Synthetic procedure 2
A suspension of the starting material (1.5 mmol) and Pd/C (10%) (0.15 mmol) in
methanol (30 mL) was shaken overnight at 40 °C, with 3 atm. H2-pressure in a
PARR apparatus. The mixture was filtered through Celite, and the filtrate was
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concentrated under reduced pressure. The residue was purified by column
chromatography.
Synthetic procedure 3
The starting material (1.0 mmol) was dissolved in THF (2.0 mL). KOH 5 N (10 mmol,
2.0 mL) was added and the solution was stirred overnight at 55 °C. The reaction
mixture was diluted with EtOAc (10 mL) and acidified with 1 N HCl (20 mL). The
mixture was extracted with EtOAc (3 x 30 mL). The organic phases were collected,
washed with brine (1 x 50 mL), dried over Na2SO4 and filtered. The solvent was
evaporated and the product was purified by column chromatography or
crystallization.
2,2-dimethyl-5-(pentadec-1-ynyl)-4H-benzo[d][1,3]dioxin-4-one (2a)
The product was obtained using procedure 1 starting from 1 (0.65 g, 2.0 mmol) and
1-pentadecyne (0.46 g, 2.2 mmol), using oil bath heating. The crude product was
purified using column chromatography with EtOAc/Hex 1:6 (v/v) as eluent to yield
2a (0.65 g, 85%) as a brown solid; Rf = 0.60 (EtOAc/Hex 1:2); 1H NMR (200 MHz,
CDCl3): δ = 0.87 (3H, t, J = 6.5 Hz), 1.20-1.65 (22H, m), 1.70 (6H, s), 2.50 (2H, t, J =
7.1 Hz), 6.85 (1H, d, J = 8.5Hz), 7.18 (1H, d, J = 7.6Hz), 7.38 ppm (1H, t, J = 7.9Hz);
13C NMR (50 MHz, CDCl3): δ = 14.3, 20.2, 22.9, 25.9, 28.7, 29.2, 29.4, 29.6, 29.7, 29.9,
32.1, 78.9, 98.8, 105.7, 114.2, 116.6, 126.5, 129.1, 134.9, 156.6, 161.6 ppm; MS (ESI):
m/z 385.5 [M+H]+.
2,2-dimethyl-5-(dec-1-ynyl)-4H-benzo[d][1,3]dioxin-4-one (2b)
The product was obtained using procedure 1 starting from 1 (0.65 g, 2.0 mmol) and
1-decyne (0.30 mg, 2.2 mmol) using oil bath heating. It was purified by column
chromatography using EtOAc/Hex 1:5 (v/v) as eluent. The product was obtained as a
brown solid (0.52 g, 86%); Rf = 0.58 (EtOAc/Hex 1:1); 1H NMR (200 MHz, CDCl3): δ =
0.86 (3H, t, J = 6.5 Hz), 1.27-1.65 (12H, m), 1.68 (6H, s), 2.48 (2H, t, J = 6.9 Hz), 6.84
(1H, d, J = 8.2 Hz), 7.17 (1H, d, J = 7.6 Hz), 7.38 ppm (1H, t, J = 8.1 Hz); 13C NMR
(50 MHz, CDCl3): δ = 14.2, 20.1, 22.8, 25.8, 28.6, 29.1, 29.2, 29.3, 32.0, 78.8, 98.7,
105.5, 114.2, 116.5, 126.5, 129.0, 134.8, 156.6, 159.1 ppm; MS (ESI): m/z 315.3
[M+H]+.
5-((4-heptylphenyl)ethynyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (2c)
The product was obtained using procedure 1 starting from 1 (0.65 g, 2.0 mmol)
and 1-ethynyl-4-heptylbenzene (0.44 g, 2.2 mmol) using oil bath heating. The residue
was purified by column chromatography using EtOAc/Hex 1:14 (v/v) as eluent. The
product was obtained as a brown solid (0.66 g, 88%); Rf = 0.62 (EtOAc/Hex 1:5); 1H
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NMR (200 MHz, CDCl3): δ = 0.88 (3H, t, J = 6.6 Hz), 1.26-1.73 (8H, m), 1.59 (2H, m),
1.73 (6H, m), 2.62 (2H, t, J = 7.65 Hz), 6.89-6.93 (1H, m), 7.17 (2H, d, J = 8.2 Hz),
7.28-7.33 (1H, m), 7.42-7.46 (1H, m), 7.50-7.57 ppm (2H, d, J = 8.2 Hz); 13C NMR (50
MHz, CDCl3): δ = 14.2, 22.8, 25.9, 29.2, 29.3, 31,3, 31.9, 36.1, 87.2, 96.8, 105.7, 114.0,




The product was obtained using procedure 1 starting from 1 (0.65 g, 2.0 mmol) and
1-eth-1-ynyl-4-(pentyloxy)benzene (0.41 g, 2.2 mmol) using either oil bath heating or
microwave irradiation. The residue was purified by column chromatography using
EtOAc/Hex 1:6 (v/v) as eluent. The product was obtained as brown oil. The yield was
80% (0.58 g) after oil bath heating and 84% (0.61 g) after microwave irradiation; Rf =
0.57 (EtOAc/Hex 1:2); 1H NMR (200 MHz, CDCl3): δ = 0.72 (3H, t, J = 6.9 Hz), 1.21-
1.17 (4H, m), 1.50-1.52 (8H, m), 3.74 (2H, t, J = 6.6 Hz), 6.62-6.68 (3H, m), 7.03-7.08
(1H, m), 7.20 (1H, d, J = 7.9 Hz), 7.31-7.36 ppm (2H, m); 13C NMR (50 MHz, CDCl3):
δ = 14.1, 22.5, 25.8, 28.2, 29.0, 68.1, 86.7, 96.9, 105.7, 113.8, 114.6, 114.9, 116.7,




The product was obtained using procedure 1 starting from 1 (0.65 g, 2.0 mmol) and
1-methoxy-2-(prop-2-yn-1-yloxy)benzene (0.36 g, 2.2 mmol) using either oil bath
heating or microwave irradiation. The residue was purified by column
chromatography using EtOAc/Hex 1:5 (v/v) as eluent. The product was obtained as
yellow oil in 88% yield (0.60 g) after bath heating and 86% yield (0.58 g) after
microwave irradiation; Rf = 0.43 (EtOAc/Hex 1:2); 1H NMR (200 MHz, CDCl3): δ =
1.79 (6H, s), 3.97 (3H, s), 5.16 (2H, s), 6.98-7.07 (4H, m), 7.29-7.35 (2H, m), 7.46-7.54
ppm (1H, m); 13C NMR (50 MHz, CDCl3): δ = 25.8, 56.0, 57.9, 85.1, 91.2, 105.8, 111.8,
115.0, 117.8, 121.0, 122.2, 124.6, 129.3, 135.0, 147.2, 149.8, 156.6, 158.8 ppm; MS
(ESI) m/z: 356.2 [M+NH4]+.
2,2-dimethyl-5-pentadecyl-4H-benzo[d][1,3]dioxin-4-one (3a)
The product was obtained using procedure 2 starting from 2a and it was purified by
column chromatography using EtOAc/Hex 1:6 (v/v) as eluent. The product was
obtained as colourless solid (0.31 g, 60%); Rf = 0.61 (EtOAc/Hex 1:2); 1H NMR (200
MHz, CDCl3): δ = 0.87 (3H, t, J = 6.5 Hz), 1.20-1.60 (26H, m), 1.69 (6H, s), 3.08 (2H,
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t, J = 7,6 Hz), 6.79 (1H, d, J = 8.2 Hz), 6.92 (1H, d, J = 7.6 Hz), 7.38 ppm (1H, t, J =
7.9 Hz). 13C NMR (50 MHz, CDCl3): δ = 14.3, 22.8, 25.8, 29.5, 29.6, 29.8, 31.3, 32.1,
34.5, 105.1, 112.2, 115.2, 125.2, 135.2, 148.7, 157.2, 160.3ppm; MS (ESI): m/z 389.5
[M+H]+.
2,2-dimethyl-5-decyl-4H-benzo[d][1,3]dioxin-4-one (3b)
The product was obtained using procedure 2 starting from 2b and it was purified by
column chromatography using EtOAc/Hex 1:5 as eluent. The product was obtained
as a white solid (0.29 g, 65%); Rf = 0.60 (EtOAc/Hex 1:1); 1H NMR (200 MHz, CDCl3):
δ = 0.87 (3H, t, J = 6.8 Hz), 1.25-1.66 (16H, m), 1.69 (6H, s), 3.08 (2H, t, J = 7.6 Hz),
6.78 (1H, d, J = 8.2 Hz), 6.92 (1H, d, J = 7.6 Hz), 7.38 ppm (1H, t, J = 7.9 Hz); 13C
NMR (50 MHz, CDCl3): δ = 14.3, 22.8, 25.8, 28.7, 29.5, 29.6, 29.8, 31.3, 32.1, 33.4,
34.5, 105.1, 112.2, 115.2, 125.2, 135.2, 148.7, 157.2, 160.4 ppm; MS (ESI): m/z 319.3
[M+H]+.
5-(4-heptylphenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (3c)
The product was obtained using procedure 2 starting from 2c and it was purified by
column chromatography using EtOAc/Hex 1:12 as eluent. The product was obtained
as dark yellow solid (0.55 g, 97%); Rf = 0.41 (EtOAc/Hex 1:5); 1H NMR (200 MHz,
CDCl3): δ = 0.88 (3H, t, J = 6.5 Hz), 1.30 (8H, m), 1.60 (2H, m), 1.69 (6H, m), 2.56
(2H, t, J = 7.6), 2.86 (2H, t, J = 8.0), 3.38 (2H, t, J = 8.0), 6.79-6.90 (2H, m), 7.06-7.19
(4H, m), 7.34-7.42 ppm (1H, m); 13C NMR (50 MHz, CDCl3 ): δ = 14.2, 22.8, 25.8, 29.3,
29.4, 31.7, 31.9, 35.7, 36.8, 37.2, 105.1, 105.2, 112.3, 115.5, 125.5, 125.9, 127.2, 128.4,
128.6, 128.9, 135.2, 139.0, 140.6, 147.4, 157.2, 160.4 ppm; MS (ESI): m/z 381.3
[M+H]+.
2,2-dimethyl-5-(4-(pentyloxy)phenethyl)-4H-benzo[d][1,3]dioxin-4-one (3d)
A suspension of the starting material 2d (0.55 g, 1.5 mmol) and Pd/C (10%) (16 mg,
0.15 mmol) in methanol (30 mL) was stirred under 3 atm. H2 pressure at 40 °C for 36
h in a PARR apparatus. The mixture was filtered through Celite and the filtrate was
concentrated under reduced pressure. The residue was purified by column
chromatography using EtOAc/Hex 1:14 (v/v) as eluent. The product was obtained as
yellow oil (0.51 g, 93%); Rf = 0.38 (EtOAc/Hex 1:10); 1H NMR (200 MHz, CDCl3): δ =
0.88 (3H, t, J = 3.5 Hz), 1.38-1.44 (4H, m), 1.70 (6H, s), 1.73-1.79 (2H, m), 2.84 (2H, t,
J = 8.1 Hz), 3.36 (2H, t, J = 7.9 Hz), 3.93 (2H, t, J = 6.8 Hz), 6.80-6.84 (m, 2H), 6.86
(1H, d, J = 7.7 Hz), 7.06 (1H, d, J = 8.5 Hz), 7.14-7.16 (m, 2H), 7.35-7.39 ppm (m,
1H); 13C NMR (50 MHz, CDCl3 ): δ = 14.1, 22.5, 25.7, 28.3, 29.1, 34.9, 36.7, 36.9, 68.0,
105.1, 112.2, 114.4, 115.4, 125.5, 129.3, 129.6, 133.7, 135.2, 147.2, 157.2 157.4, 160.0
ppm; MS (ESI): m/z 369.4 [M+H]+.




The product was obtained using procedure 2 starting from 2e and it was purified by
column chromatography using EtOAc/Hex 1:8 (v/v) as eluent. The product was
obtained as yellow oil (0.46 g, 90%); Rf = 0.49 (EtOAc/Hex 1:2); 1H NMR (200 MHz,
CDCl3): δ = 1.70 (3H, m), 2.13-2.24 (2H, m), 3.28 (2H, t, J = 7.6 Hz), 3.87 (3H, s), 4.09
(2H, t, J = 6.6 Hz), 6.82 (1H, d, J = 7.0 Hz), 6.90 (4H, m), 6.98 (1H, d, J = 7.6 Hz),
7.36-7.44 ppm (1H, t, J = 7.9 Hz); 13C NMR (50 MHz, CDCl3): δ = 26.4, 31.1, 31.5,
56.7, 69.1, 105.8, 112.7, 114.1, 116.2, 121.7, 126.1, 126.1, 135.9, 147.7, 149.3, 150.3,
158.0, 161.0 ppm; MS (ESI) m/z 360.3 [M+H]+.
2-pentadecyl-6-hydroxybenzoic acid (anacardic acid, 4a)
The product was obtained using procedure 3 starting from 3a and it was purified by
crystallization from EtOAc/Hex 1:6 (v/v) at 4 °C. The product was obtained as a
white solid (0.30 g, 85%); Rf = 0.31 (100% EtOAc); mp: 90-91 °C ; 1H NMR (200 MHz,
CDCl3): δ = 0.88 (3H, t, J = 6.5 Hz), 1.20-1.50 (24H, m), 1.55-1.60 (2H, m), 2.97 (2H,
t, J = 7.6 Hz), 6.77 (1H, d, J = 7.3 Hz), 6.87 (1H, d, J = 8.2 Hz), 7.36 ppm (1H, t, J =
7.9 Hz); 13C NMR (50 MHz, CDCl3 ): δ = 14.4, 22.9, 29.6, 29.7, 29.9, 30.1, 32.2, 32.3,
36.7, 110.6, 116.1, 123.0, 135.7, 148.1, 163.9, 176.4 ppm; HRMS: m/z [M-H]-, calcd for
C22H35O3 347.2586, found 347.2576.
2-decyl-6-hydroxybenzoic acid (4b)
The product was obtained using procedure 3 starting from 3b and it was purified by
column chromatography using EtOAc/Hex 1:6 (v/v) as eluent. The product was
obtained as pale yellow solid (0.14 g, 51%); Rf = 0.53 (100% EtOAc); mp: 81-82 °C; 1H
NMR (200 MHz, CDCl3): δ = 0.87 (3H, t, J = 6.5 Hz), 1.20-1.45 (14H, m), 1.50-1.60
(2H, m), 2.98 (2H, t, J = 7,6 Hz), 6.78 (1H, d, J = 7.6 Hz), 6.87 (1H, d, J = 7.6Hz), 7.36
ppm (1H, t, J = 7.9 Hz); 13C NMR (50 MHz, CDCl3): δ = 14.3, 22.8, 29.4, 29.5, 29.6,
29.8, 30.0, 32.1, 32.2, 36.6, 110.5, 116.0, 122.9, 135.6, 148.0, 163.8, 176.3 ppm;
HRMS: m/z [M-H]- calcd for C17H25O3 277.1804, found 277.1807.
2-(4-heptylphenethyl)-6-hydroxybenzoic acid (4c)
The product was obtained using procedure 3 starting from 3c and it was purified by
column chromatography using EtOAc/Hex 1:2 (v/v) as eluent. The product was
obtained as white powder (0.23 g, 67%); Rf = 0.4 (100% EtOAc); mp: 110-111 °C; 1H
NMR (200 MHz, CDCl3): δ = 1.03 (3H, t, J = 5.5 Hz), 1.43-1.46 (8H, m), 1.71-1.78
(2H, m), 2.72 (2H, t, J = 7.6 Hz), 3.00-3.08 (2H, m), 3.40-3.48 (2H, m), 6.86 (1H, d, J
= 7.5 Hz), 7.06 (1H, d, J = 7.5 Hz), 7.20 (4H, m), 7.39-7.56 ppm (1H, m); 13C NMR (50
MHz, CDCl3 ): δ = 14.2, 22.8, 29.3, 29.5, 31.7, 32.0, 35.7, 38.0, 38.7, 110.6, 116.4,
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123.2, 127.0, 128.4, 128.5, 129.0, 135.8, 139.0, 140.8, 146.7, 163.8, 176.1 ppm; HRMS:
m/z [M-H]- calcd for C22H27O3 339.1965, found 339.1969.
2-hydroxy-6-(4-(pentyloxy)phenethyl)benzoic acid (4d)
The product was obtained using procedure 3 starting from 3d and it was purified by
column chromatography using EtOAc/Hex 1:5 (v/v) as eluent. The product was
obtained as yellow solid (0.17 g, 51%); Rf = 0.43 (100% EtOAc); mp: 98-99 °C; 1H
NMR (200 MHz, CD3OD): δ = 0.94 (3H, t, J = 7.0 Hz), 1.38-1.45 (m, 4H), 1.72-1.75
(m, 2H), 2.70-2.85 (2H, m), 3.10-3.20 (2H, m), 3.92 (t, J = 6.5 Hz), 6.66-6.80 (m, 4H),
7.08 (2H, d, J = 8.5 Hz), 7.23-7.27 ppm (m, 1H); 13C NMR (50 MHz, CD3OD): δ =
13.4, 22.5, 28.4, 29.2, 37.7, 38.7, 68.0, 106.4, 114.3, 115.1, 122.2, 129.2, 133.2, 134.4,
144.9, 157.8, 161.7, 171.7 ppm; HRMS m/z [M-H]+ calcd for C20H23O4 327.1601, found
327.1614.
2-hydroxy-6-(3-(2-methoxyphenoxy)propyl)benzoic acid (4e)
The product was obtained using procedure 3 starting from 3e and it was purified by
column chromatography using EtOAc/Hex 1:4 (v/v) as eluent. The product was
obtained as white powder (0.22 g, 73%); Rf = 0.42 (EtOAc); mp: 147-148 °C; 1H NMR
(200 MHz, CD3OD): δ = 2.03-2.11 (2H, m), 3.09 (2H, t, J = 7.6 Hz), 3.83 (3H, s), 3.98
(2H, t, J = 6.5 Hz), 6.75-6.79 (2H, m), 6.89-6.94 (4H, m), 7.12-7.29 ppm (1H, m); 13C
NMR (50 MHz, CD3OD): δ = 32.4, 21.7, 56.6, 69.7, 106.4, 113.6, 115.1, 116.1, 122.2,
122.4, 123.2, 134.3, 145.6, 149.9, 151.0, 162.5, 174.1; HRMS m/z [M-H]+ calcd for
C17H17O5 301.1081, found 301.1074.
(Z)-2,2-dimethyl-5-(4-(pentyloxy)styryl)-4H-benzo[d][1,3]dioxin-4-one (5d)
The product was obtained using the procedure 2 starting from 2d and purified by
column chromatography using EtOAc/Hex 1:14 (v/v) as eluent. The product was
obtained as yellow oil (0.44 g, 80%); Rf = 0.51 (EtOAc/Hex 1:2); 1H NMR (200 MHz,
CDCl3): δ = 1.10-1.19 (3H, m), 1.54-1.67 (4H, m), 1.92-2.07 (8H, m), 4.09-4.18 (2H,
m), 6.90-6.93 (2H, m), 7.01-7.10 (2H, m), 7.16-7.23 (3H, m), 7.23-7.25 (1H, m), 7.35-
7.39 ppm (1H, m); 13C NMR (50 MHz, CDCl3): δ = 14.8, 23.2, 26.5, 28.9, 29.7, 68.6,
106.2, 112.8, 114.8, 115.1, 116.1, 116.6, 126.1, 128.3, 129.7, 131.1, 131.2, 134.4,
135.7, 143.0, 159.0, 161.0 ppm; MS (ESI): m/z 367.3 [M+H]+.
(Z)-2-hydroxy-6-(4-(pentyloxy)styryl)benzoic acid (6d)
The product was obtained using procedure 3 starting from 5d and it was purified by
column chromatography using EtOAc/Hex 1:5 (v/v) as eluent. The product was
obtained as yellow solid (0.18 g, 55%); Rf = 0.67 (100% EtOAc); mp: 94-95 °C; 1H
NMR (400 MHz, CDCl3): δ = 0.91 (3H, t, J = 7.0 Hz), 1.33-1.42 (4H, m), 1.71-1.78(2H,
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m), 3.89 (2H, t, J = 6.4), 6.58 (1H, d, J = 12.1), 6.68 (2H, d, J = 8.4), 6.77 (1H, d, J =
8.3), 6.83 (1H, d, J = 12.1), 6.93 (1H, d, J =8.2), 7.00 (2H, d, J = 8.4), 7.27-7.32 ppm
(1H, m); 13C NMR (50 MHz, CDCl3): δ = 14.1, 22.6, 28.3, 29.0, 68.0, 110.3, 114.2,
114.6, 116.9, 122.9, 128.7, 129.0, 129.3, 130.6, 135.8, 142.6, 158.4, 163.6, 175.5 ppm;
HRMS: m/z [M-H]+ calcd for C20H21O4 325.1445, found 325.1443.
Benzyl 2,4-bis(benzyloxy)-6-(((trifluoromethyl)sulfonyl)oxy) benzoate (10)
Triflic anhydride (35 mmol, 5.9 mL) was added dropwise to a solution of benzyl 2,4-
bis(benzyloxy)-6-hydroxybenzoate (30 mmol, 13 g) and pyridine (0.11 mol, 8.1 mL) in
dry dichloromethane (30 mL) at 0 °C. The resulting mixture was stirred for 1.5 hours
at 0 °C. The excess of triflic anhydride was quenched by dropwise addition of water
(5 mL). The mixture was slowly poured into a saturated solution of NaHCO3 (50
mL), the two layers were separated in a separation funnel, and the organic layer was
collected. The water layer was washed with dichloromethane (2 x 50 mL). The
combined organic layers were washed with water (1 x 100 mL), brine (1 x 100 mL),
and dried over Na2SO4 and concentrated under reduced pressure. The crude product
was purified by column chromatography using EtOAc/Hex 1:10 (v/v) as eluent to
yield the product as a white solid (9.6 g, 56%); Rf = 0.46 (EtOAc/Hex 1:4); 1H NMR
(400 MHz, CDCl3): δ = 5.04 (s, 2H), 5.05 (s, 2H) 5.33 (s, 2H), 6.54 (s, 1H), 6.59 (s, 1H),
7.34 ppm (m, 15H); 13C NMR (50 MHz, CDCl3): δ = 67.9, 71.1, 71.3, 100.7, 100.8,
110.9, 127.5, 127.8, 128.5, 128.7, 128.8, 128.9, 129.1, 135.5, 135.7, 148.3, 158.8,
161.6, 163.3 ppm; MS (ESI): m/z 590.2 [M+NH4]+.
Benzyl 2,4-bis(benzyloxy)-6-(pentadec-1-yn-1-yl)benzoate (11a)
The product was obtained using procedure 1 starting from 10 (1.2 g, 2.0 mmol) and
1-pentadecyne (0.46 mg, 2.2 mmol) using either oil bath heating or microwave
irradiation. It was purified by column chromatography using EtOAc/Hex 1:25 (v/v)
as eluent. The product was obtained as colorless oil in 83% yield (1.1 g) for oil bath
heating and 88% (1.1 g) for microwave irradiation; Rf = 0.53 (EtOAc/Hex 1:7 v/v); 1H
NMR (400 MHz, CDCl3): δ = 0.88 (3H, t, J = 6.3 Hz,), 1.20-1.60 (22H, m), 2.28 (2H, t,
J = 6.6 Hz,), 5.00 (1H, s), 5.02 (1H, s), 5.33 (1H, s), 6.50 (1H, d, J = 2.4 Hz), 6.63 (1H,
d, J = 2.4 Hz), 7.24-7.39 ppm (15H, m); 13C NMR (50 MHz, CDCl3): δ = 14.2, 19.5,
22.7, 28.6, 29.0, 29.2, 29.4, 29.6, 29.7, 31.9, 66.9, 70.2, 70.5, 77.8, 94.6, 101.1, 109.6,
119.8, 124.1, 127.1, 127.6, 127.9, 128.0, 128.2, 128.4, 128.5, 128.7, 136.0, 136.2,
136.3, 156.8, 160.2, 166.9 ppm; MS (ESI): m/z 631.4 [M+H]+.
Benzyl 2,4-bis(benzyloxy)-6-(dec-1-yn-1-yl)benzoate (11b)
The product was obtained using procedure 1 starting from 10 (1.2 g, 2.0 mmol) and
1-decyne (0.30 g, 2.2 mmol) using microwave irradiation. It was purified by column
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chromatography using EtOAc/Hex 1:20 (v/v) as eluent. The product was obtained as
brown oil (0.89 g, 79%); Rf = 0.66 (EtOAc/Hex 1:4); 1H NMR (400 MHz, CDCl3): δ =
0.88 (t, J = 6.6, 3H), 1.27-1.55 (m, 12H), 2.28 (t, J = 6.9, 2H), 4.99 (s, 2H), 5.02 (s,
2H), 5.33 (s, 2H), 6.50 (1H, d, J = 4.3 Hz), 6.62 (1H, d, J = 4.3 Hz), 7.27-7.40 ppm (m,
15H); 13C NMR (50 MHz, CDCl3): δ = 14.1, 19.4, 22.6, 28.5, 28.9, 29.1, 29.2, 31.8,
66.9, 70.2, 70.5, 94.6, 101.1, 109.6, 119.8, 124.1, 127.0, 127.5, 127.8, 127.9, 128.2,
128.3, 128.5, 128.6, 135.9, 136.2, 136.3, 156.8, 160.2, 166.9 ppm; MS (ESI): m/z
561.4 [M+H]+.
2,4-Dihydroxy-6-pentadecylbenzoic acid (12a)
The product was obtained using procedure 2 starting from 10a and purified by
column chromatography using EtOAc/Hex 1:3 (v/v) as eluent. The product was
obtained as a white solid (0.49 g, 89.5%); Rf = 0.19 (100% EtOAc); mp: 124-125 °C; 1H
NMR (400 MHz, CD3OD): δ = 0.88 (3H ,t, J = 6.8 Hz), 1.22-1.31 (24H, m), 1.51-1.56
(2H, m), 2.86 (2H, t, J = 7.7 Hz), 6.14 (1H, d, J = 2.2 Hz), 6.18 ppm (1H, d, J = 2.2
Hz); 13C NMR (50 MHz, CD3OD): δ = 13.1, 22.4, 29.1, 29.2, 29.4, 29.6, 31.7, 31.8,
36.2, 100.3, 103.5, 110.4, 148.7, 162.2, 165.5, 173.4 ppm; MS (ESI): m/z 363.4; [M-H]-;
HRMS: m/z [M-H]- calcd for C22H35O4 363.2540, found 363.2542.
2-decyl-4,6-dihydroxybenzoic acid (12b)
The product was obtained using procedure 2 starting from 10b and it was purified by
column chromatography using EtOAc/Hex 1:3 (v/v) as eluent. The product was
obtained as a pale orange solid (0.34 g, 76.5%); Rf =0.48 (100% EtOAc); mp: 107-108
°C; 1H NMR (400 MHz, CD3OD): δ = 0.90 (3H, t, J = 6.8 Hz), 1.29-1.33 (m, 14H),
1.54-1.57 (2H, m), 2.86-2.90 (2H t, J = 7.9 Hz), 6.14 (1H d, J = 2.6 Hz), 6.19 ppm (1H
d, J = 2.6 Hz); 13C NMR (50 MHz, CD3OD): δ = 14.4, 23.7, 30.5, 30.7, 30.8, 30.9, 33.1,
33.2, 37.6, 101.7, 111.4, 111.7, 150.2, 163.5, 166.8, 173.5 ppm; HRMS: m/z [M-H]-
calcd for C17H25O4 293.1758, found 293.1761.
5-(benzyloxy)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (14)
The starting material 13 (2.2 g, 11 mmol) was dissolved in DMF (20 mL), and cooled
to 0 °C. K2CO3 (3.1 g, 22 mmol) was added and benzylbromide (1.5 mL, 12 mmol)
was added dropwise, and the mixture was stirred for 1h at 0 °C and then overnight
at room temperature. The reaction mixture was extracted with EtOAc (3 x 20 mL),
and the combined organic layers were washed with brine (1 x 40 mL), dried with
MgSO4, and filtered. The solvent was evaporated to give the pure compound as a
yellow solid (2.6 g, 84%); Rf = 0.23 (EtOAc/Hex 1:5); 1H NMR (200 MHz, CDCl3): δ =
1.71 (6H, s), 5.25 (2H, s), 6.53 (1H, d, J = 8.2 Hz), 6.63 (1H, d, J = 8.5 Hz), 7.26-7.43
(5H, m), 7.53-7.57 ppm (1H, m); 13C NMR (50 MHz, CDCl3): δ = 25.8, 70.8, 104.2,
Improved histone acetylation inhibition
85
105.1, 105.4, 107.3, 109.6, 126.8, 127.9, 128.7, 136.4, 158.0, 158.2, 160.5 ppm; MS
(ESI): m/z 285.2 [M+H]+.
2-(benzyloxy)-6-hydroxybenzoic acid (15)
The product was obtained using procedure 3 starting from 14 and it was purified by
column chromatography using EtOAc/Hex 1:2 (v/v) as eluent. The product was
obtained as white solid (0.12 g, 49%); Rf = 0.39 (100% EtOAc); mp: 122-123 °C; 1H
NMR (200 MHz, CD3OD): δ = 5.27 (2H, s), 6.59 (1H, d, J = 8.2), 6.67 (1H, d, J = 8.2),
7.35 (5H, m), 7.48-7.53 ppm (1H, m). 13C NMR (50 MHz, CD3OD): δ = 73.0, 105.2,
112.0, 112.2, 121.1, 129.8, 130.1, 136.4, 137.8, 160.5, 164.5, 171.5 ppm; HRMS: m/z
[M-H]- calcd for C14H11O4 243.0662, found 243.0666.
2,2-dimethyl-5-(tetradecyloxy)-4H-benzo[d][1,3]dioxin-4-one (16)
5-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (13) (0.99 g, 5.1 mmol) and 1-
tetradecanol (1.6 g, 7.5 mmol) were dissolved in dry THF (15 mL), and the reaction
mixture was cooled down to 0 °C. PPh3 (2.0 g, 7.5 mmol) and DIAD (1.5 mL, 7.5
mmol) were added, and the mixture was first stirred for 1 h at 0 °C and then
overnight at room temperature. The reaction mixture was concentrated under
reduced pressure, and the compound was purified by column chromatography using
EtOAc/Hex 1:12 as eluent. The product was obtained as white solid (0.54 g, 27%); Rf
= 0.33 (EtOAc/Hex 1:10); 1H NMR (200 MHz, CDCl3): δ = 0.84 (3H, m), 1.09-1.33
(22H, m), 1.51 (2H, m), 1.70 (6H, s), 4.03 (2H, t, J = 6.8 Hz), 6.50 (1H, d, J = 7.4 Hz),
6.57 (1H, d, J = 8.5 Hz), 7.32-7.39 ppm (1H, m); 13C NMR (50 MHz, CDCl3): δ =
14.09, 22.8, 25.7, 25.9, 26.8, 27.5, 29.1, 29.5, 29.6, 29.7, 32.2, 69.5, 103.6, 105.2,
106.5, 109., 136.3, 157.9, 158.0, 161.2 ppm; MS (ESI): m/z 391.3 [M+H]+.
2-hydroxy-6-(tetradecyloxy)benzoic acid (17)
The product was obtained using procedure 3 starting from 16 and it was purified by
column chromatography using EtOAc/ Hex 1:5 (v/v) as eluent. The product was
obtained as pale pink solid (0.23 g, 66%); Rf = 0.63 (100% EtOAc); mp: 93-94 °C; 1H
NMR (200 MHz, CDCl3): δ = 0.87 (3H, t, J = 6.8 Hz), 1.21-1.26 (22H, m), 1.86-1.90
(2H, m), 4.21 (2H, t, J = 6.2), 6.46 (1H, d, J = 8.2), 6.69 (1H, d, J = 8.5), 7.33-7.41
ppm (1H, m). 13C NMR (50 MHz, CDCl3): δ = 14.2, 22.8, 25.9, 26.0, 26.7, 27.5, 28.9,
29.2 29.5, 29.6, 29.7, 32.1, 70.9, 101.8, 102.3, 112.2, 134.2, 135.6, 158.2, 171.0 ppm;
HRMS: m/z [M-H]- calcd for C21H33O4 349.2384, found 349.2383.
Methyl 2-hydroxy-6-pentadecylbenzoate (18)
The starting material 4a (0.17 g, 0.5 mmol) was dissolved in 5 mL methanol.
Concentrated H2SO4 (0.5 mL) was slowly added and the solution was stirred for 4h
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at reflux. The mixture was then cooled down to room temperature, diluted with 20
mL dichloromethane and extracted with NaOH 1M (3 x 20 mL). The organic layer
was washed with brine (1 x 15 mL), dried over Na2SO4 and filtered. The solvent was
evaporated to give the pure product as a pale yellow solid (0.12 g, 65%); Rf = 0.73
(EtOAc/Hex 1:6); mp: 77-78 °C; 1H NMR (200 MHz, CD3OD): δ = 0.85-0.88 (3H, m),
1.26-1.53 (26H, m), 2.88 (2H, t, J = 7.6), 3.96 (3H, s), 6.72 (1H, d, J = 6.8), 6.82 (1H,
d, J = 7.8), 7.25-7.29 ppm (1H, m); 13C NMR (50 MHz, CD3OD): δ = 14.3, 22.8, 25.1,
25.7, 29.5, 29.7, 29.8, 30.0, 32.1, 32.3, 34.1, 36.8, 52.2, 112.0, 115.7, 122.6, 134.3,
146.3, 162.7, 172.1 ppm; HRMS: m/z [M-H]- calcd for C23H37O3 361.2746, found
361.2748.
Cell culture and histone extraction
All cell culture reagents were purchased from Invitrogen. The human cancer cell line
HEP G2 (liver) was cultured in Dulbecco’s modified Eagle Medium (DMEM)
containing 10% heat-inactivated fetal serum bovine (FBS), 50 IU/mL penicillin, and
50 mg/mL streptomycin at 37 °C in a humidified atmosphere containing 5% CO2. For
the experiments, cells were seeded in T-175 flasks, allowed to grow until about 70%
confluency and FBS-starved for 16 hours. Cells were then treated at sub-toxic (see
supplementary data) concentration of inhibitor for 24 hours. The histone extraction
was performed as previously described in literature with minor modifications.139
Protein concentrations of samples were determined using the Bradford Assay using
BSA as a standard for calibration.
Immunoblot protocol
Approximately 5 μg of extracted histones were loaded on a 12.5% polyacrylamide gel,
resolved by SDS-PAGE electrophoresis and electroblotted to PVDF membranes. The
membranes were incubated with rabbit anti-acetyl-Histone H4 antibody (Millipore,
06-598) followed by a swine anti-rabbit HRP conjugated antibody (DakoCytomation,
P0217). Bands were visualized using AEC detection kit (Sigma). Bands were
scanned using a BioRad GS-710 densitometer and quantified using ImageJ
quantification software. Equal amount of loading were determined by Coomassie
blue staining. The experiments were performed in triplicate.
Histone acetyltransferase assay
An indirect ELISA was used to test the inhibition of the HAT PCAF activity. A
solution 0.1% of bovine serum albumin (BSA) in 100 mM HEPES 7.4 was used as
buffer unless differently specified. C96 Maxisorp 96-well plate (Nunc) was coated
overnight at 4 °C with 50 μL per well of a solution 19 μg/mL streptavidin in 0.2 M
Na2CO3 pH 9.4. After washing with buffer, the wells were blocked with 200 μL of a
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solution 3% BSA in buffer for 1 h at room temperature (RT). The plate was washed
with buffer, and then coated with 50 μL per well of a solution 300 nM biotinylated
histone H4 peptide (Millipore, 12-372) for 1h at RT. After washing, 40 μL reaction
buffer (0.1% BSA + 0.8% Triton X-100 in 100 mM  HEPES pH 7.4) was added to the
wells, followed by 20 μL recombinant PCAF 240 nM in reaction buffer, and 10 μL of
the selected inhibitor solution at different concentration in reaction buffer. After 15
min incubation, 10 μL solution 40 μM AcCoA in reaction buffer was added to the
well, except for the negative control. The enzymatic reaction was allowed to proceed
for 15 min before washing. Each well was then incubated for 1h with 50 μL rabbit
anti-acetyl-Lys antibody (Millipore, AB3879) dilution 1:1800. After washing, wells
were incubated with 50 μL swine anti-rabbit HRP-conjugated dilution 1:1000
(DakoCytomation, P0217). The plate was washed with buffer and incubated with 100
μL per well of chromogen solution (0.1 mg/ml 3,3’,5,5’-tetramethyl benzidine +
0.003% H2O2 in 0.1 M Acetate buffer pH 5.5). The reaction was terminated by
addition of 100 μL H2SO4 1.0 M and the optical extinction read at 450 nm. The
positive controls were the values of wells with no inhibitor, which were set as 100%.
The negative controls were the values of wells with no AcCoA and were set as 0%.
Stock solutions of inhibitors were prepared in dimethyl sulfoxide (DMSO) and
diluted in reaction buffer. The final concentration of DMSO was tested not to have
any effect on the assay. Each compound was tested in triplicate on one plate.
Molecular docking
The Crystal structure of PCAF chain B was downloaded from Protein Data Bank
(code 1CM0). All molecules were drawn using Chemaxon MarvinSketch
(www.chemaxon.com) and prepared (structure recognition and protonation) using
SPORES (www.tcd.uni-konstanz.de/research/spores.php). Molecular docking
simulations were performed using PLANTS v1.6.140,141 The docking site center was
determined by considering all residues within 5 Å from the co-crystallized CoA. One
active site water molecule (pdb ID6) was kept for the docking. Fifteen poses were
generated for each compound. The docking results were analyzed using MOE
2008.10 (www.chemcomp.com) and Molegro Virtual Docker (www.molegro.com).
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Histone acetyltransferases are important enzymes that regulate various cellular
functions, such as epigenetic control of DNA transcription. Development of HAT
inhibitors with high selectivity and potency will provide powerful mechanistic tools
for the elucidation of the biological functions of HATs and may also have
pharmacological value for potential new therapies. In this work, analogs of the known
HAT inhibitor anacardic acid were synthesized and evaluated for inhibition of HAT
activity. Biochemical assays revealed novel anacardic acid analogs that inhibit the
human recombinant enzyme Tip60 selectively compared to PCAF and p300. Enzyme
kinetics studies demonstrated that inhibition of Tip60 by one such novel anacardic
acid derive, 20, was essentially competitive with Ac-CoA and noncompetitive with the
histone substrate. In addition, these HAT inhibitors effectively inhibited
acetyltransferase activity of cellular nuclear extracts on the histone H3 and H4 at
micromolar concentrations.
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INTRODUCTION
The plant natural product anacardic acid (AA, 6-pentadecylsalicylic acid) is isolated
from cashew nut shell liquid and is used in traditional medicine.142 It exerts
beneficial biological effects such as antitumor activity and antioxidant activity.143,144
AA was also shown to inhibit the activity of oxidative enzymes, such as tyrosinase,
cyclooxygenase, and lipoxygenase.145-147 Interestingly, AA and its derivatives were
reported to modulate the enzymatic activity of histone acetyltransferases (HATs)
such as p300 and p300/CBP-associated factor (PCAF) and affect HAT-dependent
gene transcription.78,130,148,149
HATs are grouped into distinct families based on their sequence and structural
homology.95 The best studied families are the GNAT (GCN5-related N-
acetyltransferase) family that includes PCAF and GCN5, the p300/CBP family that
includes p300, and the MYST family that includes Tip60 (TAT-interacting protein 60)
and MOF (Maleless On the First). Acetylation of histones and other proteins by
HATs regulates chromatin restructuring, protein stability, enzyme activity, protein-
protein interaction, metabolism, etc.150-154 On the chromatin template, generally,
histone acetylation is connected to activation of gene transcription, whereas
acetylation of transcription factors can either activate or inactive gene
transcription.128 Combinations of acetylation and other posttranslational
modifications regulate gene transcription in response to extra- and intracellular
stimuli. Moreover, accumulating evidence reveals that HAT activities are
deregulated in many diseases, which highlights the pharmacologic importance of
HATs as potential drug targets.97,155 Acetylations of the nuclear factor κB (NF-κB)
transcription factor as well as the histones play a crucial role in activation of this
pathway.156 Recent years have seen great efforts for designing and screening
chemical HAT modulators.93,157,158 The known HAT inhibitor AA has been shown to
inhibit NF-κB mediated gene transcription, presumably by inhibition of the HAT
p300.79 Furthermore, it has been shown that AA inhibits Tip60, which is one key
member of the MYST family. AA blocks the Tip60-dependent activation of the ataxia
telangiectasia mutated (ATM) protein kinase and the DNA-dependent protein kinase,
catalytic subunit (DNA–PKcs) by DNA damage and sensitizes human tumor cells to
the cytotoxic effects of ionizing radiation.159 This indicates that HAT inhibition by
small molecules provides a potential novel therapeutic approach for cancer and
inflammatory diseases.
The molecular mechanism by which AA and its analogs inhibit HAT activity
remains, however, poorly understood. It has been suggested that the salicylate
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functionality of anacardic acid binds to the same pocket as the Ac-CoA
pyrophosphate, which suggest competitive binding in respect to Ac-CoA.148 In
contrast, some studies suggested noncompetitive inhibition for AA against Ac-CoA in
p300 and PCAF assays, which implicates a different inhibitory mechanism for p300
and PCAF.78,160
Herein, we describe the design and synthesis of a series of AA analogs and the
evaluation of their regulatory activity on the human recombinant HATs p300, PCAF,
and Tip60 as well as cellular HAT activity. We aim to develop potent and selective
inhibitors for recombinant HATs that also inhibit cellular HATs. Furthermore, we
aim to gain a better understanding of the HAT inhibitory mechanism of AA analogs.
RESULTS AND DISCUSSION
Synthesis
A focused compound collection based on AA was synthesized using a versatile route
in which Sonogashira couplings are the key steps. The Sonogashira couplings were
performed under microwave irradiation, which provided fast conversion with
moderate to high yields. Arylbromides were alkylated using alkylhalides to give the
products 2a-2d in high yields (> 90%) (Scheme 1). Alkylation of 1c provided the N-
alkylated product 2e as the main product in 55% yield. The O-alkylated product was
isolated in minor amounts. The N-alkylated product 2e showed a characteristic
amide carbonyl signal in the IR spectrum, whereas this signal was absent in the
corresponding O-alkylated product. Subsequently, the arylbromides were coupled to
trimethylsilylacetylene by a Sonogashira coupling to yield the corresponding
trimethylsilylalkynes in yields between 36 and 76%. The trimethylsilyl protective
group was cleaved to give the corresponding alkynes 3a-3e.
Alkynes 3a-3e were coupled to triflate 4 using Sonogashira couplings to provide
compounds 5a-5e in yields between 49 and 82% (Scheme 2). Hydrogenation of the
alkynes using Pd/C under H2 atmosphere and hydrolysis of the acetonide using KOH
in THF provided compounds 6a-6c and 6f. Hydrogenation of 5c using higher catalyst
loading resulted in partial or complete reduction of the acetyl group to give either
the ethyl (6e) or hydroxyethyl (6d) functionality. Furthermore, hydrogenation of
alkyne 5e resulted in reduction of the pentylpyridin-2(1H)-one functionality (5e) to
give a pentylpiperidin-2-one functionality (6g).
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Scheme 5.1: synthesis of acetylene building blocks for Sonogashira coupling. a) R-halide,
K2CO3, DMF, b) TMS-acetylene, PdCl2(PPh3)2, Et2NH, CuI, PPh3, CH3CN, c) TBAF, THF.
Compounds 9, 12 and 15 (Scheme 2) present variations to the 6-alkyl
substitution pattern of AA. These compounds were synthesized by Sonogashira
couplings of alkynes on building blocks 7, 10 and 13. Products 8, 11 and 14 were
obtained in yields around 60%. These alkynes were hydrogenated using Pd/C under
H2 atmosphere. The methyl ester and methoxy functionality in 8 were
simultaneously deprotected using BBr3 and the methyl ester in 11 was hydrolyzed
using KOH in THF. Hydrogenation of 14 provided the final product 15 in one step.
Scheme 5.2: Sonogashira coupling and subsequent hydrogenation and deprotection to give
anacardic acid derivatives 6a-6h. a) PdCl2(PPh3)2, Et2NH, CuI, PPh3, CH3CN, b) H2, Pd/C,
MeOH, c) KOH, THF.
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Inhibitory potency of the AA analogs on three major
HAT proteins
The potencies of AA and its analogs to modulate the acetyltransferase activities of
recombinant HATs were evaluated using human recombinant Tip60, PCAF and
p300, which represent the three major HAT families in mammalian cells. Standard
radioisotope-labeled histone acetyltransferase assays were carried out with 14C-
labeled Ac-CoA as the acetyl donor. Histone N-terminal peptides were used as the
acetyl acceptor of the HAT reaction: H4-20 for p300 and Tip60 catalysis, and H3-20
for PCAF catalysis. The compounds shown in Scheme 1, 2 and in table 5.1 were
screened for inhibition of HAT activity. The compounds in table 5.1 were published
previously 148. The activities of the three HATs in the presence of 200 μM of each
compound are collectively shown in figure 5.1. Clearly, the effect of the AA analogs
on the enzymatic activity of the three HAT enzymes varies significantly from one
another, which offers the opportunity to derive structure-activity relationship (SAR).
Table 5.1: previously published anacardic acid (16) derivatives that were applied in this
study.148
R1 R2 R3
16 H H -(CH2)14CH3
17 H H -(CH2)9CH3
18 H OH -(CH2)14CH3
19 H OH -(CH2)9CH3
20 H H
21 H H
22 CH3 H -(CH2)14CH3
23 H H
24 H H
25 H H -O(CH2)13CH3
26 H H -OCH2Ph
O
O
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Figure 5.1: the effect of AA (16) and its analogs on the HAT activity of the enzymes Tip60, p300,
and PCAF. The inhibitors were applied at a concentration of 200 μM. For the Tip60 assay, the
reaction mixture contained 100 nM Tip60, 10 μM Ac-CoA, 100 μM H4-20. For the p300 assay,
the reaction mixture contained 5 nM p300, 10 μM Ac-CoA, and 100 μM H4-20. For the PCAF
assay, the reaction mixture contained 5 nM PCAF, 10 μMAc-CoA, and 100 μM H3-20.
The overall observation is that the AA analogs show stronger inhibitory potency
for Tip60 compared to p300 and PCAF, suggesting that the studied AA analogs have
a general tendency for specific inhibition for the MYST HATs. In particular,
compounds 6c, 16, 17, 18, 19, 6a, and 20 inhibited more than 76% of the Tip60
activity at 200 µM, whereas their inhibitory effect on the activity of p300 and PCAF
was little or very modest (≤35%). All these compounds have the conserved 6-
substituted salicylate functionality, which highlights that this motif is critical for
Tip60 inhibition. In contrast to AA that inhibits the Tip60 activity almost completely,
compound 22, in which the carboxylate is replaced for a methyl ester, completely lost
its inhibitory potency. Moreover, all the compounds with more than 70% inhibitory
activity at 200 μM have an extended hydrophobic substituent in 6-position. In
contrast, compounds with hydrophilic substituents, e.g. 6b and 6d, very weakly
inhibit Tip60 at 200 μM. This indicates that hydrophobic substitution in the
salicylate 6-position is indispensable for Tip60 inhibition. Compounds 16, 17 and 6h
show that aliphatic side chains with 10 to 15 carbon atoms (16, 17) in the salicylate
6-position provide good inhibition potency in contrast to aliphatic chains with 5
carbon atoms (6h). These data indicate that side chains that correspond to the
length of a linear aliphatic chain with 10 to 15 carbon atoms provide good inhibitory
potency. Also, it seems plausible that the first atom of the side chain adjacent to the

























hydrophilic oxygen greatly diminished inhibitory activity of the compounds. This
was exemplified in 25 that contains an alpha-oxygen and shows only modest
inhibitory activity.
Of interest, some of the AA analogs showed activation of the acetyltransferase
activity of p300 and PCAF in contrast with the observed inhibitory effect on Tip60.
For example, 21 and 24 enhance the PCAF activity significantly. Our observation is
not unique: the activation of HAT activity by several AA analogs was also observed
previously.78,161,162 The exact mechanism by which certain AA analogs activate HAT
activity is not clear, however it is not likely that this behavior is caused by
competitive binding to the Ac-CoA binding pocket.89 Therefore, binding to an
alternative binding pocket can be presumed. Future investigation of the binding
pocket that presumably causes activation is required for rational design of optimized
HAT activators.
Among the effective Tip60 inhibitors, there are three salicylates with a
phenethyl substitution in the 6-position, 6a, 6c and 20. These inhibitors have
calculated logD values at pH 7.4 of respectively 4.53, 3.07 and 4.19, which are lower
than the calculated value 5.21 for AA (calculated using MarvinSketch v5.4). The
high logD value for AA is generally considered to be a disadvantage for its bioactivity
and therefore the inhibitors with the 6-phenethyl salicylate type can considered to be
improved leads for development of Tip60 inhibitors. Inhibitor 20 inhibited the Tip60
activity by 88% at 200 μM and had no observable inhibitory effect on p300 and PCAF,
in contrast to AA that shows about 20% inhibition of these enzymes at 200 μM. We
therefore selected this inhibitor for further evaluation in order to understand the
potency and selectivity of this AA analog for HAT inhibition. We determined the IC50
value for inhibition of the HAT activity of Tip60 and MOF for 20 and compared that
with AA. MOF is another MYST family HAT that is relevant in eukaryotic gene
transcription. The IC50 was determined as the concentration of the inhibitor at which
half of the enzyme activity was inhibited. The results are shown in table 5.2. Under
these experimental conditions, IC50 of AA and 20 are 64 μM and 74 μM for Tip60,
and 43 μM and 47 μM for MOF. In contrast, IC50 of both AA and 20 are higher than
200 μM for p300 and PCAF (the exact IC50 values cannot be determined due to
compound insolubility at high concentrations). These data indicate that AA and the
other tested AA analogs tend to be specific inhibitors for the MYST family HATs.
This is exemplified by 20, which inhibited about 90% of Tip60 activity but had no
appreciable inhibitory impact on p300 and PCAF (figure 5.1). The comparable
inhibitory potency for the MYST family HATs Tip60 and MOF can be explained by
the 67% sequence similarity in their catalytic region (Blast sequence alignment).163
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Table 5.2: IC50 data of AA and 20 for the inhibition of HATs.
IC50 of AA IC50 of 20
Tip60 64 ± 15 μM 74 ± 20 μM
PCAF > 200 μM (60% retained) > 200 μM (97% retained)
p300 > 200 μM (60% retained) > 200 μM (70% retained)
MOF 43 ± 2 μM 47 ± 14 μM
For the Tip60 assay, the reaction contained 10 nM Tip60, 1 μM Ac-CoA, 100 μM H4-20 andthe reaction time was 7 min; For the PCAF assay, the reaction contained 1 nM PCAF, 1μM Ac-CoA, 100 μM H3-20 and the reaction time was 3.5 min; For the p300 assay, thereaction contained 5 nM p300, 1 μM Ac-CoA, 100 μM H4-20 and the reaction time was 5min; For the MOF assay, the reaction contained 1 nM MOF, 1 μM Ac-CoA, 100 μM H4-20and the reaction time was 5 min.
Kinetic pattern of Tip60 inhibition by compound 20
We carried out steady-state kinetic characterization of 20 for inhibition of Tip60 with
respect to Ac-CoA and the H4 peptide to understand the mechanism by which the
AA analogs inhibit the HAT activity of Tip60. The inhibition pattern was analyzed
by measuring initial velocities of Tip60 at different concentrations of one substrate, a
fixed concentration of the second substrate, and several selected concentrations of 20
(i.e. 0, 80, 120 µM). The Michaelis-Menten plots and the Lineweaver-Burk double
reciprocal plots are shown in figure 5.2. In the primary double reciprocal plot of E/V
versus 1/[Ac-CoA] a series of straight lines intersect at a point very close to the
ordinate. The Michaelis-Menten data were fit to the nonlinear noncompetitive
inhibition equation and yielded Kis of 54 μM and Kii of 572 μM.73 Because Kis is 10-
fold smaller than Kii, it is concluded that the inhibition of Tip60 by 20 is essentially
competitive with respect to Ac-CoA, binding to the same enzyme form. The
measurable Kii may be an indication that 20 has additional weak binding site(s) in
Tip60. On the other hand, the intersecting point in the double reciprocal plot of E/V
versus 1/[H4-20] is clearly positioned to the left of the ordinate. The kinetic data
fitting yielded Kis of > 660 μM and Kii of 78 μM. Therefore, 20 is noncompetitive
against the peptide substrate, preferentially binding to the enzyme form which is
different from that the peptide binds to. The inhibitory pattern of 20 also offers
insight into the kinetic mechanism of Tip60 catalysis. It suggests a likely ordered
substrate binding pathway: Ac-CoA binds to Tip60 first and the peptide binds at a
point downstream of Ac-CoA binding.
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Figure 5.2: steady-state kinetic characterization of Tip60 inhibition by 20. (a) and (b)
Michaelis-Menten and Lineweaver–Burk plots showing relation of Tip60 activity versus Ac-CoA
concentration at three selected concentrations of 20 (0 μM, 80 μM, 120 μM). The reaction
contained 50 nM Tip60 and 100 μM H4-20. (c) and (d) Michaelis-Menten and Lineweaver–Burk
plots showing function of Tip60 activity versus H4-20 concentration at three selected
concentrations of 20 (0 μM, 80 μM, 120 μM). The reaction contained 25 nM Tip60 and 2 μM Ac-
CoA.
Docking study
To elucidate the structural basis of Tip60 inhibition by the AA analogs, we
performed a docking study of 20 with the crystal structure of Tip60 HAT domain
(PDB ID 2OU2). As showed in figure 5.3, the 50 structural poses of the ligand were
found to be located at four different regions in the Tip60 structure. In particular, half
of the generated poses are located in the Ac-CoA binding pocket of Tip60 (i.e. region
I). A further zoom-in examination reveals that in this site 20 and the adenine group
of Ac-CoA interacts with several common amino acid residues of the Tip60, such as
Ser364, Lys331, and Arg326. It is also interesting that the hydrophobic tail in
molecule 20 shows a similar orientation as the long chain of Ac-CoA. These docking
results suggest that 20 targets the active site of Tip60, which coincides well with the
aforementioned steady-state kinetic analysis showing that inhibition by 20 is
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predominantly competitive in respect to Ac-CoA. The docking model provides a
structural basis for future optimization to obtain more potent and selective AA
analog inhibitors.
Figure 5.3: docking of 20 in the crystal structure (2OU2) of Tip60 HAT domain.
Inhibition of cellular HAT activity
The inhibition of HAT activity in nuclear extracts from HeLa cells or tissue samples
from different brains regions from rats was studied using an ELISA assay. In this
assay either the biotinylated histone H3 (aa 1-21) or histone H4 (aa 2-24) peptides
were linked to a 96-well plate via streptavidin. The histone peptides were subjected
to acetylation by using nuclear extracts as enzyme source and histone acetylation
was detected using an anti-acetyl Lysine antibody. Most of the studied 6-
alkylsalicylates show concentration dependent inhibition of histone H4 acetylation
(figure 5.4). Compounds with a polar chain in the salicylate 6-position have a
strongly reduced HAT inhibitory potency (6b, 6g, 6h, 23, 26). Also methylation of
the salicylate carboxylate (22) is detrimental for the HAT inhibitory activity. An
aliphatic substituent in the salicylate 6-position is beneficial for inhibition of HAT
activity (16, 17, 18, 19). Interestingly, compound 21 that has been described
previously to be a more potent inhibitor of histone acetylation than AA in HEP G2
cells also showed high inhibitory activity on HeLa nuclear extracts.148
It is of note that, the inhibition profile of the AA analogs on nuclear extract
acetyltransferase activity correlates well with the assay on recombinant Tip60. For
instance, the compound that inhibited the cellular HAT activity more than 50% at
200 μM, e.g. 6a, 6c, 6f, 11, 12, 16, 17, 18, 19, 20, 21, 24, and 25, also inhibited the
Tip60 HAT activity. On the other hand, most of the compounds that showed poor
inhibition of HeLa nuclear extract activity, 6b, 6g, 6h, 22, 23, and 26, were also very
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poor inhibitors in for the recombinant enzyme. The compounds 6d, 6e and 15 are
exceptions because they seem to be more potent on HeLa nuclear extracts than for
the recombinant Tip60. This is an indication for the presence of multiple HATs in
nuclear extracts.
Figure 5.4: inhibition of HAT activity of HeLa nuclear extract measured with ELISA assay.
Averages and standard deviations of triplicates are reported relative to the positive control in
which no inhibitor was present and the negative control where no enzyme was present. a)
Concentration dependent inhibition of HAT activity by AA analogs. The ELISA plate was coated
with histone H4; b) Inhibition of HAT activity by AA analogs (50 μM). The ELISA plate was
coated with either histone H3 or histone H4.
The inhibitory potency of the compound collection on histone H3 acetylation by
HeLa nuclear extracts was investigated at 50 µM concentrations and compared to
histone H4 acetylation (figure 5.4b). Interestingly, a change in inhibitory potency
was observed between histone H3 and histone H4. For example 16 and 17 show
almost equal potency for both histones, whereas for example, 6a, 6f, 15, 18 and 20,
are more potent for histone H3 compared to histone H4. The opposite is true for
compounds like 21, 24 and 25. Given the complexity of HAT enzyme composition,
distribution, and catalytic turnover rates of each HAT complex in the nucleus, it
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acetylation and H4 acetylation. However, the data shown here indicate that selective
inhibitors towards histone H3 or H4 acetylation could be developed.
The HAT activity of nuclear extracts of brain tissue samples from rats showed
no significant difference between HAT activity in brain tissue in different brain
regions (n = 3, p > 0.05) (figure 5.5). Studies on two different animals showed no
significant deviations between the animals (n = 2, p > 0.05). The inhibitors 16 and 20
both inhibited the HAT activity of the nuclear extracts of different regions
significantly (p < 0.05). Compound 20 showed slightly impaired inhibition compared
to 16, which is statistically significant for the hippocampus (p < 0.05).
Figure 5.5: acetyltransferase activity of nuclear extract from tissue samples from different brain
regions in mice. The acetyltransferase activity was determined using an ELISA assay with
histone H3 as acetyl acceptor. The inhibitors AA and 20 were applied in a concentration of 30
μM. Experiments were performed in triplicate for two different animals. The averages and
standard deviations for the two animals are shown and blank values were subtracted. * p <
0.05.
CONCLUSION
AA analogs with various 2-phenylethane substituents in the salicylate 6-position
were synthesized and tested for modulating enzymatic activities of three major types
of mammalian HAT proteins. The recombinant enzyme inhibition assays
demonstrated that inhibitors 18, 19, 20 and 21 are selective for Tip60 in comparison
with PCAF and p300. Compounds that inhibit Tip60 show in most cases also
inhibition of HAT activity in HeLa nuclear extracts, which suggests that MYST type
HATs play an important role in the HAT activity of the studied extracts. Inhibitor 20
was subjected to further investigation because its logD value is lower than AA,



























is maintained. Enzyme kinetics showed that inhibition of Tip60 by 20 is competitive
to Ac-CoA and non-competitive to histone H4, which supports the hypothesis that
AA derivatives bind to the Ac-CoA binding pocket. Inhibitor 20 showed also equal
potency to AA in nuclear extracts of tissue samples from different brain regions of




Chemicals were purchased from commerical suppliers and used without further
purification. If required, solvents were dried before use according to known
procedures. Pd-catalysed cross-couplings were carried-out under a nitrogen
atmosphere. Analytical thin-layer chromatography (TLC) was performed on
aluminum sheets of Silica Gel 60 F254. Spots on TLC were detected by ultraviolet
light or KMnO4 solution. Column chromatography was performed with MP
Ecochrom Silica Gel 32–63, 60 Å. Reactions under microwave irradiation reactions
were carried out in a Biotage Initiator™ Microwave Synthesizer. 1H and 13C NMR
spectra were recorded on a Varian Gemini-200. 13C spectra were recorded using the
attached proton test (APT) pulse sequence. Chemical shift values are reported as
part per million (δ) relative to residual solvent peaks (CDCl3, 1H δ = 7.26, 13C δ =
77.16, CD3OD, 1H δ = 3.31, 13C δ = 49.00, CD3CN 1H δ = 1.94, 13C δ = 118.26 DMSO
1H δ = 2.50, 13C δ = 39.52). The coupling constants (J) are reported in Hertz (Hz).
Electrospray ionization mass spectra (ESI-MS) were recorded on an Applied
Biosystems/SCIEX API3000-triple quadrupole mass spectrometer. Infrared (IR)
spectra were recorder on a Thermo Nicolet 380 Smart Orbit ATR FTIR apparatus.
Melting points were determined on an Electrothermal digital melting point
apparatus and are uncorrected. High-resolution mass spectra (HR-MS) were
recorded using a flow injection method on a LTQ-Orbitrap XL mass spectrometer
(Thermo Electron, Bremen, Germany) with a resolution of 60,000 at m/z 400.
Protonated testosterone (lock mass m/z = 289.2162) was used for internal
recalibration in real time.
General procedure 1
K2CO3 (18 mmol, 2.5 g) was suspended in 15 mL of DMF. The phenol (6.0 mmol) and
the alkyl halide (6.6 mmol) were added subsequentially and the suspension was
stirred overnight at 60 °C. The reaction mixture was diluted with 50 mL demiwater
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and the resulting reaction mixture was extracted with with EtOAc (3 x 30 mL). The
combined organic layers were, washed with brine (1 x 50 mL), dried over Na2SO4 and
filtered. The solvent was evaporated under reduced pressure to give the product in
high purity.
General procedure 2
Freshly distilled diethylamine (23 mmol, 2.3 mL) and trimethylsilylacetylene (5.5
mmol, 0.78 mL) were subsequently added to a solution of the aryl halide (5.0 mmol),
CuI (0.25 mmol, 48 mg), PPh3 (1 mmol, 0.26 g) and PdCl2(PPh3)2 (0.25 mmol, 0,17 g)
in degassed anhydrous acetonitrile (2.0 mL). The mixture was stirred under
microwave irradiation for 30 min at 120 °C . The mixture was diluted with EtOAc
(30 mL), extracted with water (3 x 30 mL), and brine (1 x 30 mL). The resulting
solution was dried over Na2SO4 and filtered. The solvent was evaporated under
reduced pressure and the residue was purified by column chromatography.
General procedure 3
The starting material (3.0 mmol) was dissolved in THF (10 mL) and solution was
cooled down to 0 °C. A solution 1 M of tetra-n-butylammonium fluoride (TBAF) in
THF (3.3 mmol, 3.3 mL) was added slowly and the reaction mixture was stirred for
30 min at 0 °C. The solution was diluted with satured solution of NH4Cl (15 mL) and
extracted with diethyl ether (3 x 30 mL). The combined organic layers were dried
over Na2SO4 and filtered.The solvent was evaporated under reduced pressure to give
the product in high purity.
General procedure 4
Freshly distilled diethylamine (5.0 mmol, 0.52 mL) and the alkyne (2.7 mmol) were
subsequently added to a solution of aryl triflate 4 or 13 or jodide 7 or 10 (2.5 mmol ),
CuI (0.25 mmol, 48 mg), and PdCl2(PPh3)2 (0.13 mmol, 88 mg) in degassed
anhydrous acetonitrile (1.5 mL). The mixture was stirred under microwave
irradiation for 30 min at 100 °C. The mixture was diluted with EtOAc (20 mL),
extracted with water (3 x 20 mL), and brine (1 x 20 mL). The resulting solution was
dried over Na2SO4 and filtered. The solvent was evaporated under reduced pressure
and the residue was purified by column chromatography.
General procedure 5
A suspension of the starting material (1.5 mmol) and Pd/C (10%) (0.15 mmol, 10
mol%) in methanol (30 mL) was shaken overnight at 40 °C, with 3 atm. H2-pressure
in a Parr apparatus. The mixture was filtered through Celite, and the filtrate was




The starting material (1.0 mmol) was dissolved in THF (2.0 mL). KOH 5 N (10 mmol,
2.0 mL) was added and the mixture was stirred overnight at 55 °C. The reaction
mixture was diluted with EtOAc (10 mL) and acidified with 1 N HCl (20 mL). The
mixture was extracted with EtOAc (3 x 30 mL). The organic phases were collected,
washed with brine (1 x 50 mL), dried over Na2SO4 and filtered. The solvent was
evaporated and the product was purified by column chromatography or
crystallization
1-bromo-4-((3,7-dimethyloctyl)oxy)benzene (2a)
The product was obtained using procedure 1 starting from 4-bromophenol (6.0 mmol,
1.0 g) and 1-bromo-3,7-dimethyloctane (6.6 mmol, 1.4 mL). The product was obtained
as colorless oil (1.7 g, 93%). Rf = 0.88 (EtOAc/Hex 1:2). 1H NMR (200 MHz, CDCl3): δ
= 0.87 (6H, d, J = 6.5 Hz), 0.93 (3H, d, J = 6.5 Hz), 1.13-1.35 (6H, m), 1.52-1.58 (2H,
m), 1.60-1.65 (1H, m), 1.80-1.85 (1H, m), 3.92-3.97 (2H, m), 6.77 (2H, d, J = 8.8 Hz),
7.36 (2H, d, J = 8.8 Hz). 13C NMR (50 MHz, CDCl3 ): δ = 19.6, 22.6, 22.7, 24.6, 28.0,
29.8, 36.1, 37.3, 39.2, 66.6, 112.5, 116.3, 132.2, 158.2. MS (ESI): m/z 330.3 and 332.2
(ratio 1:1) [M+NH4]+.
1-bromo-4-(2-methoxyethoxy)benzene (2b)
The product was obtained using procedure 1 starting from 4-bromophenol (6.0 mmol,
1.0 g) and 1-bromo-2-methoxyethane (6.6 mmol, 0.54 mL). The product was obtained
as colorless liquid (1.3 g, 96%). Rf = 0.48 (EtOAc/Hex 1:2). 1H NMR (200 MHz,
CDCl3): δ = 3.44 (3H, s), 3.74 (2H, t, J = 8.0 Hz), 4.08 (2H, t, J = 8.0 Hz), 6.80 (2H, d,
J = 6.5 Hz), 7.36 (2H, d, J = 6.5 Hz). 13C NMR (50 MHz, CDCl3 ): δ = 59.2, 67.5, 70.9,
112.4, 116.4, 132.2, 157.8. MS (ESI): m/z 248.1 [M+NH4]+.
1-(5-bromo-2-(pentyloxy)phenyl)ethanone (2c)
The product was obtained using procedure 1 starting from 1-(5-bromo-2-
hydroxyphenyl)ethanone (6.0 mmol, 1.3 g) and 1-bromopentane (6.6 mmol, 1.0 mL)
The product was obtained as a pale yellow solid (1.6 g, 98%). Rf= 0.49 (EtOAc/Hex
1:2). 1H NMR (400 MHz, CDCl3) δ 0.94 (3H, t, J = 7.2 Hz), 1.38-1.48 (4H, m), 1.81-
1.87 (2H, m), 2.61 (3H, s), 4.03 (2H, t, J = 6.5 Hz), 6.83 (1H, d, J = 8.8 Hz), 7.51 (1H,
dd, J = 2.6, 8.8 Hz), 7.83 (1H, d, J = 2.6 Hz). 13C NMR (100 MHz, CDCl3) δ 14.1, 22.5,
28.4, 28.9, 32.1, 69.0, 112.5, 114.4, 128.4, 134.5, 137.2, 158.7, 199.0. MS (ESI): (m/z)
285.2 and 287.2 (ratio 1:1) [M+H]+.
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1-(5-bromo-2-(heptyloxy)phenyl)ethanone (2d)
The product was obtained using procedure 1 starting from 1-(5-bromo-2-
hydroxyphenyl)ethanone (6.0 mmol, 1.3 g) and 1-bromo-heptane (6.6 mmol, 1.0 mL).
The product was obtained as pale yellow solid (1.7 g, 92%). Rf = 0.71 (EtOAc/Hex
1:2). 1H NMR (200 MHz, CDCl3): δ = 0.89 (3H, t, J = 6.5 Hz), 1.30-1.49 (8H, m), 1.80-
1.87 (2H, m), 2.60 (3H, s), 4.02 (2H, t, J = 6.5 Hz), 6.82 (1H, d, J = 8.5 Hz), 7.49 (1H,
dd, J = 2.6, 6.2 Hz), 7.82 (1H, d, J = 2.6 Hz). 13C NMR (50 MHz, CDCl3 ): δ = 14.2,
22.7, 26.2, 29.1, 29.2, 31.8, 32.0, 69.1,112.9, 114.3, 129.7, 133.1, 136.1, 157.6, 198.4.
MS (ESI): m/z 313.0 and 315.0 (ratio 1:1) [M+H]+.
5-bromo-1-pentylpyridin-2(1H)-one (2e)
The product was obtained using procedure 1 starting from 5-bromo-2-
hydroxypyridine (6.0 mmol, 1.0 g) and 1-bromo-pentane (6.6 mmol, 0.82 mL). The
product was obtained as pale yellow solid (0.81 g, 55%). Rf = 0.33 (EtOAc/Hex 1:2).
1H NMR (200 MHz, CDCl3): δ = 0.87 (3H, t, J = 6.8 Hz), 1.26-1.33 (4H, m), 1.66-1.74
(2H, m), 3.85 (2H, t, J = 7.5 Hz), 6.45 (1H, d, J = 9.7 Hz), 7.28-7.37 (2H, m). 13C NMR
(50 MHz, CDCl3 ): δ = 13.9, 22.3, 28.6, 28.9, 50.1, 97.7, 122.2, 137.4, 142.2, 160.9. MS
(ESI): m/z 244.2 and 246.2 (ration 1:1) [M+H]+. IR (neat): νmax = 823, 1152, 1436,
1525, 1581, 1651. The O-alkylated product 5-bromo-2-(pentyloxy)pyridine lacks the
amide carbonyl signal at 1651.
((4-((3,7-dimethyloctyl)oxy)phenyl)ethynyl)trimethylsilane
The product was obtained using procedure 2 starting from 1-bromo-4-((3,7-
dimethyloctyl)oxy)benzene (5.0 mmol, 1.6 g). After work-up, the reaction product was
dissolved in EtOAc/Hex 1:1 (v/v) and filtered over Celite. The solvent was evaporated
to get the crude product that was used for the next step with further purification.
((4-(2-methoxyethoxy)phenyl)ethynyl)trimethylsilane
The product was obtained using procedure 2 starting from 1-bromo-4-(2-
methoxyethoxy)benzene (5.0 mmol, 1.2 g). It was purified by column chromatography
using EtOAc/Hex 1:8 (v/v) as eluent. The product was obtained as orange oil (0.50 g,
40%). Rf = 0.45 (EtOAc/Hex 1:2). 1H NMR (200 MHz, CDCl3): δ = 0.08 (9H, s), 3.29
(3H, s), 3.58 (2H, d, J = 8.0 Hz), 3.92 (2H, d, J = 8.0 Hz), 6.63-6.71 (2H, m), 7.19-7.23
(2H, m). 13C NMR (50 MHz, CDCl3 ): δ =  0.1, 59.2, 67.2, 70.9, 92.5, 105.1, 113.1,
114.4, 116.4, 132.2, 133.4, 157.9. MS (ESI): m/z 249.2 [M+H]+.
1-(2-(pentyloxy)-5-((trimethylsilyl)ethynyl)phenyl)ethanone
The product was obtained using procedure 2 starting from 1-(5-bromo-2-
(pentyloxy)phenyl)ethanone (5.0 mmol, 1.4 g). The product was purified by column
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chromatography using EtOAc/Hex 1:10 (v/v) as eluent. The product was obtained as
yellow solid (1.1 g, 76%). Rf= 0.62 (EtOAc/Hex 1:2 ). 1H NMR (400 MHz, CDCl3) δ
0.22 (9H, s), 0.93 (3H, t, J = 7 Hz), 1.34-1.50 (4H, m), 1.81-1.88 (2H, m), 2.60 (3H, s),
4.05 (2H, t, J = 6.7 Hz), 6.85 (1H, d, J = 8.8 Hz), 7.50 (1H, dd, J = 2.3, 8.8 Hz), 7.84
(1H, d, J = 2.3 Hz). 13C NMR (100 MHz, CDCl3) δ 0.0, 14.0, 22.4, 28.3, 28.8, 31.9,
68.8, 93.3, 104.0, 112.2, 115.4, 128.1, 134.3, 136.8, 158.3, 198.9. MS (ESI): (m/z)
303.2 [M+H]+.
1-(2-(heptyloxy)-5-((trimethylsilyl)ethynyl)phenyl)ethanone
The product was obtained using procedure 2 starting from 1-(5-bromo-2-
(heptyloxy)phenyl)ethanone (5.0 mmol, 1.6 g). Purification was performed by column
chromatography using 100% hexane as eluent. The product was obtained as yellow
solid (0.60 g, 36%). Rf = 0.59 (EtOAc/Hex 1:2). 1H NMR (200 MHz, CDCl3): δ = 0.21-
0.24 (9H, s), 0.89 (3H, t, J = 6.5 Hz) 1.30-1.43 (8H, m), 1.80-1.84 (2H, m), 2.60 (3H, s),
4.05 (2H, t, J = 6.5 Hz), 6.85 (1H, d, J = 8.5 Hz), 7.50 (1H, dd, J =  2.3, 6.2 Hz), 7.84
(1H, d, J = 2.4 Hz). 13C NMR (50 MHz, CDCl3 ): δ = 0.1, 14.2, 22.7, 26.2, 29.1, 29.2,
31.8, 32.1, 68.9, 93.5, 104.2, 112.4, 115.5, 128.2, 134.5, 136.9, 158.5, 199.0. MS (ESI):
m/z 331.3 [M+H]+.
1-pentyl-5-((trimethylsilyl)ethynyl)pyridin-2(1H)-one
The product was obtained using procedure 2 starting from 5-bromo-1-pentylpyridin-
2(1H)-one (5.0 mmol, 1.2 g). The product was purified by column chromatography
using EtOAc/Hex 1:6 (v/v) as eluent. The product was obtained as orange oil (0.61 g,
47%). Rf = 0.56 (EtOAc/Hex 1:2). 1H NMR (200 MHz, CDCl3): δ = 0.13-0.23 (9H, s),
0.89 (3H, t, J = 6.7 Hz), 1.28-1.35 (4H, m), 1.65-1.76 (2H, m), 3.87 (2H, t, J = 7.4 Hz),
6.47 (1H, d, J = 9.4 Hz), 7.30 (1H, dd, J = 2.4, 7.0 Hz), 7.48 (1H, d, J = 2.4 Hz). 13C
NMR (50 MHz, CDCl3 ): δ =  0.1, 14.0, 22.4, 28.8, 29.1, 50.3, 94.9, 100.7, 102.4, 120.8,
135.2, 141.7, 161.1. MS (ESI): m/z 262.3 [M+H]+.
1-((3,7-dimethyloctyl)oxy)-4-ethynylbenzene (3a)
The product was obtained using procedure 3 starting from ((4-((3,7-
dimethyloctyl)oxy)phenyl)ethynyl)trimethylsilane (3.0 mmol, 1.0 g). The product was
purified by column chromatography using Hexane as eluent. It was obtained as
yellow solid (0.74 g, 95%). Rf= 0.59 (EtOAc/Hex 1:8). 1H NMR (200 MHz, CDCl3): δ =
0.87 (6H, d, J = 6.7 Hz), 0.94 (3H, d, J = 6.4 Hz), 1.14-1.36 (6H, m), 1.51-1.62 (2H,
m), 1.65-1.68 (1H, m), 1.80-1.85 (1H, m), 3.00 (1H, s), 3.96-4.01 (2H, m), 6.83 (2H, d,
J = 8.8 Hz), 7.42 (2H, d, J = 8.8 Hz). 13C NMR (50 MHz, CDCl3 ): δ = 19.6, 22.6, 22.7,
24.6, 28.0, 29.8, 36.1, 37.3, 39.2, 66.4, 75.6, 83.8, 113.9, 114.5, 133.5, 159.5. MS (ESI):
m/z 259.4 [M+H]+.
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1-ethynyl-4-(2-methoxyethoxy)benzene (3b)
The product was obtained using procedure 3 starting from ((4-(2-
methoxyethoxy)phenyl)ethynyl)trimethylsilane (3.0 mmol, 0.74 g). The product was
obtained as orange oil (0.49 g, 93%). Rf = 0.34 (EtOAc/Hex 1:2). 1H NMR (200 MHz,
CDCl3): δ = 2.91 (1H, s), 3.36 (3H, s), 3.67 (2H, t, J = 8.0 Hz), 4.03 (2H, d, J = 8.0 Hz),
6.79 (2H, d, J = 6.6 Hz), 7.33 (2H, d, J = 6.6 Hz); 13C NMR (50 MHz, CDCl3 ): δ =
59.2, 67.3, 70.9, 75.8, 83.6, 114.4, 115.2, 133.5, 159.1. MS (ESI): m/z 177.2 [M+H]+.
1-(5-ethynyl-2-(pentyloxy)phenyl)ethanone (3c)
The product was obtained using procedure 3 starting from 1-(2-(pentyloxy)-5-
((trimethylsilyl)ethynyl)phenyl)ethanone (3.0 mmol, 0.91 g). The crude product was
purified using column chromatography with EtOAc/Hex 1:30 (v/v) as eluent to yield
the product as a white solid (0.55 g, 79%). Rf= 0.60 (EtOAc/Hex 1:2 (v/v). 1H NMR
(400 Mhz, CDCl3) δ 0.94 (3H, t, J = 7.2 Hz), 1.38-1.47 (4H, m), 1.84-1.87 (2H, m), 2.61
(3H, s), 3.00 (1H, s), 4.06 (2H, t, J = 6.5 Hz), 6.88 (1H, d, J = 8.8 Hz), 7.54 (1H, dd,
2.3, 8.8 Hz), 7.86 (1H, d, J = 2.3 Hz). 13C NMR (100 MHz, CDCl3) δ 13.9, 22.3, 28.3,
28.8, 31.9, 68.8, 77.3, 82.6, 112.4, 114.2, 128.3, 134.4, 137.0, 158.6, 198.9. MS (ESI):
(m/z) 231.1 [M+H]+.
1-(5-ethynyl-2-(heptyloxy)phenyl)ethanone (3d)
The product was obtained using procedure 3 starting from 1-(2-(heptyloxy)-5-
((trimethylsilyl)ethynyl)phenyl)ethanone (3.0 mmol, 0.99 g). The product was
obtained as yellow solid (0.73 g, 94%). Rf = 0.56 (EtOAc/Hex 1:2). 1H NMR (200 MHz,
CDCl3): δ = 0.88 (3H, t, J = 6.8 Hz), 1.29-1.49 (8H, m), 1.76-1.87 (2H, m), 2.60, (3H,
s), 2.98 (1H, s), 4.04 (2H, t, J = 6.5 Hz), 6.87 (1H, d, J = 8.8 Hz), 7.52 (1H, dd, J = 6.4,
2.2 Hz), 7.84 (1H, d, J = 2.4 Hz). 13C NMR (50 MHz, CDCl3 ): δ = 14.0, 22.5, 26.1,
28.9, 29.1, 31.7, 31.9, 59.1, 68.8, 82.6, 112.4, 114.2, 128.2, 134.3, 137.0, 158.6, 198.8.
MS (ESI): m/z 259.5 [M+H]+.
5-ethynyl-1-pentylpyridin-2(1H)-one 3e)
The product was obtained using procedure 3 starting from 1-pentyl-5-
((trimethylsilyl)ethynyl)pyridin-2(1H)-one (3 mmol, 0.78 g). The product was
obtained as dark orange solid (0.55 g, 97%). Rf = 0.49 (EtOAc/Hex 1:2). 1H NMR (200
MHz, CDCl3): δ = 0.83 (3H, t, J = 6.8 Hz), 1.22-129 (4H, m), 1.66 (2H, m), 2.95 (1H,
s), 3.83 (2H, t, J = 7.5 Hz), 6.42 (1H, d, J = 9.3 Hz), 7.25 (1H, dd, J = 9.0, 2.3 Hz),
7.44 (1H, d, J = 2.4 Hz). 13C NMR (50 MHz, CDCl3 ): δ = 13.6, 19.7, 22.2, 24.1, 50.1,





The product was obtained using procedure 4 starting from 1-((3,7-dimethyloctyl)oxy)-
4-ethynylbenzene (2.7 mmol, 0.70 g) and triflate 4 (2.5 mmol, 0.82 g). The product
was purified by column chromatography using EtOAc/Hex 1:16 (v/v) as eluent. The
product was obtained as brown oil (0.73 g, 67%). Rf = 0.4 (EtOAc/Hex 1:4). 1H NMR
(200 MHz, CDCl3): δ = 0.80 (6H, d, J = 6.8 Hz), 0.87 (3H, d, J = 6.2 Hz), 1.07-1.28
(6H, m), 1.43-1.64 (2H, m), 1.66 (6H, m), 1.68-1.74 (2H, m), 3.90-3.97 (2H, m), 6.78-
6.84 (3H, m), 7.19-7.24 (1H, m), 7.34-7.42 (1H, m), 7.47-7.52 (2H, m). 13C NMR (50
MHz, CDCl3): δ = 19.6, 22.6, 22.7, 25.7, 27.9, 29.8, 36.1, 37.3, 39.2, 66.4, 86.6, 96.8,
105.0 (why this peak ?), 105.6, 114.5, 114.8, 116.6, 113.7, 125.9, 128.1, 133.6, 134.8,
156.6, 159.0, 159.7. MS (ESI): m/z 435.3 [M+H]+.
5-((4-(2-methoxyethoxy)phenyl)ethynyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-
4-one (5b)
The product was obtained using procedure 4 starting from 1-ethynyl-4-(2-
methoxyethoxy)benzene (2.7 mmol, 0.48 g) and triflate 4 (2.5 mmol, 0.82 g). The
product was purified by column chromatography using EtOAc/Hex 1:4 (v/v) as
eluent. The product was obtained as yellow gum (0.65 g, 74%). Rf = 0.27 (EtOAc/Hex
1:2). 1H NMR (200 MHz, CDCl3): δ = 1.66 (6H, s), 3.39 (3H, s), 3.67-3.72 (2H, m),
4.05-4.10 (2H, m), 6.80- 6.87 (4H, m), 7.19-7.24 (1H, m), 7.35-7.39 (1H, m), 7.48-7.53
(1H, m). 13C NMR (50 MHz, CDCl3 ): δ =  25.9, 59.4, 67.4, 71.0, 86.9, 93.5, 96.8, 105.7,
114.8, 114.9, 115.5, 116.8, 125.9, 128.3, 133.8, 134.2, 135.0, 156.8, 158.9, 159,5. MS
(ESI): m/z 370.2 [M+NH4]+.
5-((3-acetyl-4-(pentyloxy)phenyl)ethynyl)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (5c)
The product was obtained using procedure 4 starting from 1-(5-ethynyl-2-
(pentyloxy)phenyl)ethanone (2.7 mmol, 0.62 g) and triflate 4 (2.5 mmol, 0.82 g).. The
crude product was purified using column chromatography with EtOAc/Hex 1:7 (v/v)
as eluent to yield the compound as a pale yellow solid (0.54 g, 49%). Rf = 0.42
EtOAc/Hex 1:2 (v/v). 1H NMR (400 MHz, CDCl3) δ 0.93 (3H, t, J = 7.2 Hz), 1.36-1.49
(4H, m), 1.72 (6H, s), 1.82-1.87 (2H, m), 2.62 (3H, s), 4.08 (2H, t, J = 6.5 Hz), 6.89-
6.94 (2H, m), 7.28 (1H, dd, J = 1.0, 8.0 Hz), 7.46 (1H, t, J = 8.1 Hz), 7.72 (1H, dd, J =
2.4, 8.5 Hz), 7.96 (1H, d, J = 2.1 Hz). 13C NMR (100 MHz, CDCl3) δ 14.0, 22.4, 25.7,
28.3, 28.8, 31.9, 68.9, 87.1, 95.5, 105.6, 112.5, 113.8, 115.2, 117.0, 125.4, 128.3, 128.4,
134.1, 134.9, 137.2, 156.6, 158.7,159.0, 198.9. MS (ESI): (m/z) 407.2 [M+H]+.




The product was obtained using procedure 4 starting from 1-(5-ethynyl-2-
(heptyloxy)phenyl)ethanone (2.7 mmol, 0.70 g) and triflate 4 (2.5 mmol, 0.82 g)..
Purification was performed by column chromatography using EtOAc/Hex 1:7 (v/v) as
eluent. The product was obtained as yellow oil (0.84 g, 83%). Rf = 0.39 (EtOAc/Hex
1:2). 1H NMR (200 MHz, CDCl3): δ = 0.89 (3H, t, J = 6.4 Hz), 1.31-1.65 (8H, m), 1.73-
1.75 (6H, m), 1.82-1.93 (2H, m), 2.62 (3H, s), 4.08 (2H, t, J = 6.5 Hz), 6.88-7.05 (2H,
m), 7.26-7.30 (1H, m), 7.42-7.50 (1H, m), 7.73 (1H, dd, J = 2.2, 6.5 Hz), 7.96 (1H, d, J
= 2.35 Hz). 13C NMR (50 MHz, CDCl3): δ = 14.0, 22.6, 25.6, 26.1, 29.0, 29.1, 31.7,
31.9, 68.8, 87.1, 95.5, 105.6, 106.8, 112.5, 115.2, 116.9, 122.4, 125.5, 128.3, 128.4,
134.1, 134.9, 137.2, 156.6, 158.7, 159.0, 198.9. MS (ESI): m/z 452.3 [M+NH4]+.
5-((2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)ethynyl)-1-pentylpyridin-
2(1H)-one (5e)
The product was obtained using procedure 4 starting from 5-ethynyl-2-
(pentyloxy)pyridine (2.7 mmol, 0.51 g) and triflate 4 (2.5 mmol, 0.82 g). The product
was purified by column chromatography using EtOAc/Hex 1:4 (v/v) as eluent. The
product was obtained as yellow solid (0.68 g, 69%). Rf = 0.31 (EtOAc/Hex 1:1). 1H
NMR (200 MHz, CDCl3): δ = 0.84 (3H, t, J = 6.5 Hz), 1.18-1.31 (6H, m), 3.87 (2H, t, J
= 7.5 Hz), 6.50 (1H, d, J = 9.4 Hz), 6.85 (1H, d, J = 7.0 Hz), 7.18-7.19 (1H, m), 7.36-
7.45 (2H, m), 7.63 (1H, d, J = 2.4 Hz). 13C NMR (50 MHz, CDCl3): δ = 13.9, 22.3, 25.7,
28.7, 29.0, 50.3, 88.4, 92.1, 102.4, 105.8, 113.5, 117.1, 120.6, 125.0, 127.7, 135.2,
141.4, 142.1, 156.7, 159.1, 161.3. MS (ESI): m/z 366.2 [M+H]+.
2,2-dimethyl-5-(pent-1-yn-1-yl)-4H-benzo[d][1,3]dioxin-4-one (5f)
The product was obtained using procedure 4 starting from 1-pentyne (2.7 mmol, 0.23
mL) and triflate 4 (2.5 mmol, 0.82 g). The product was purified by column
chromatography using with EtOAc/Hex 1:9 (v/v) as eluent. The compound was
obtained as yellow solid (0.48 g, 82%). Rf = 0.44 EtOAc/Hex 1:2 (v/v). 1H NMR (400
MHz, CDCl3) δ 1.08 (3H, t, J = 7.3), 1.65-1.70 (8H, m), 2.48 (2H, t, J = 7.0 Hz), 6.85
(1H, dd, 0.9, 7.3 Hz), 7.18 (1H, dd, J = 0.88, 6.7 Hz), 7.39 (1H, t, J = 7.9 Hz). 13C
NMR (100 MHz, CDCl3) δ 13.6, 22.0, 25.7, 78.9, 98.4, 105.5, 114.1, 116.4, 126.3,
128.9, 134.7, 156.5, 159.0. MS (ESI): (m/z) 245.1 [M+H]+.
5-(4-((3,7-dimethyloctyl)oxy)phenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-
4-one




mmol, 0.65 g). The product was purified by column chromatography using
EtOAc/Hex 1:18 (v/v) as eluent. The product was obtained as brown solid (0.62 g,
94%). Rf = 0.57 (EtOAc/Hex 1:4). 1H NMR (200 MHz, CDCl3): δ = 0.87 (6H, d, J = 6.8
Hz), 0.94 (3H, d, J = 6.5 Hz), 1.10-1.37 (6H, m), 1.47-1.64 (2H, m), 1.69 (6H, s), 1.73-
1.77 (2H, m), 2.80-2.88 (2H, m), 3.32-3.40 (2H, m), 3.96 (2H, t, J = 6.0 Hz), 6.79-6.88
(4H, m), 7.12-7.26 (2H, m), 7.37 (1H, t, J = 7.9 Hz ). 13C NMR (50 MHz, CDCl3 ): δ =
19.7, 22.6, 22.7, 24.6, 25.6, 28.0, 29.9, 36.3, 36.6, 36.9, 37.3, 39.2, 66.3, 105.0, 112.1,
114.3, 115.4, 125.4, 129.5, 133.6, 135.1, 147.2, 157.1, 157.4, 160.3. MS (ESI): m/z
439.2 [M+H]+.
5-(4-(2-methoxyethoxy)phenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one
The product was obtained using procedure 5 starting from 5-((4-(2-
methoxyethoxy)phenyl)ethynyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.5
mmol, 0.53 g). The product was purified by column chromatography using
EtOAc/Hex 1:5 (v/v) as eluent. The product was obtained as white solid (0.49 g, 92%).
Rf = 0.61 (EtOAc/Hex 1:1). 1H NMR (200 MHz, CDCl3): δ = 1.69 (6H, m), 2.79-2.87
(2H, m), 3.31-3.35 (2H, m), 3.45 (3H, s), 3.71-3.74 (2H, m), 4.08-4.11 (2H, m), 6.79-
6.85 (4H, m), 7.12-7.16 (2H, m), 7.36 (1H, t, J = 7.9 Hz). 13C NMR (50 MHz, CDCl3 ):
δ = 25.6, 36.6, 36.9, 59.2, 67.2, 71.1, 105.0, 112.1, 114.4, 115.4, 125.5, 129.2, 134.1,
135.1, 147.1, 157.1, 160.3, 173.4. MS (ESI): m/z 374.2 [M+H]+.
5-(3-acetyl-4-(pentyloxy)phenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one
The product was obtained using procedure 5 starting from 5-((3-acetyl-4-
(pentyloxy)phenyl)ethynyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.5 mmol,
0.61 g). The product was purified by column chromatography using EtOAc/Hex 1:10
(v/v) as eluent. The product was obtained as a white solid (0.25 g, 40%). Rf = 0.52
(EtOAc/Hex 1:2). 1H NMR (400 MHz, CDCl3): δ 0.94 (3H, t, J = 7.2 Hz), 1.39-1.47
(4H, m), 1.70 (6H, s), 1,82-1,84 (2H, m), 2.62 (3H, s), 2,83-2.87(2H, m), 3,31-3.35 (2H,
m), 4,03 (2H, t, J = 6.5 Hz), 6.81-6.88 (3H, m), 7.36 (2H, m), 7,57 (1H, d, J = 2.4 Hz).
13C NMR (100 MHz, CDCl3) δ 14.0, 22.4, 25.6, 28.9, 32.1, 36.3, 36.8, 68.6, 105.1,
112.0, 112.4, 115.6, 125.4, 127.8, 130.2, 133.6, 134.0, 135.3, 146.8, 157.0, 157.2,
160.3, 200.1. MS (ESI): (m/z) 411.2 [M+H]+.
5-(3-(1-hydroxyethyl)-4-(pentyloxy)phenethyl)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one
The product was obtained using procedure 5 starting from 5-((3-acetyl-4-
(pentyloxy)phenyl)ethynyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.5 mmol,
0.61 g) using 20 % (w/w) Pd/C 10% mol  (which percentage ?). The product was
obtained as yellow solid (0.53 g, 86%): Rf = 0.52 (EtOAc/Hex 1:2); 1H NMR (MHz,
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CDCl3): δ 0.93 (3H, t, J = 7.2 Hz), 1.36-1.47 (4H, m), 1.50 (3H, d, J = 6.5 Hz), 1.60
(3H, s), 1.80 (3H, s), 1,77-1,84 (2H, m), 2.84 (2H, t, J = 7.9 Hz), 3,33-3.37 (2H, m),
3.98 (2H, t, J = 6.4 Hz), 5.03 (1H, q, J = 6.5 Hz), 6.76-6.87 (3H, m), 7.10 (1H, dd, J =
2.4, 10.6 Hz), 7,15 (1H, d, J = 2.34 Hz), 7.37 (1H, t, J = 7.9 Hz) ppm. 13C NMR (100
MHz, CDCl3) δ 14.0, 22.4, 22.9, 25.6, 25.7, 28.4, 29.0, 36.7, 36.9, 67.2, 68.0, 105.1,
111.2, 112.1, 115.4, 125.5, 126.6, 128.1, 133.0, 133.8, 135.1, 147.1, 154.4, 157.2 ppm.
MS (ESI): (m/z) 430.3 [M+NH4]+.
5-(3-ethyl-4-(pentyloxy)phenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one
The product was obtained using procedure 2 starting from 5-((3-acetyl-4-
(pentyloxy)phenyl)ethynyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.5 mmol,
0.61 g) using 40 % (w/w) Pd/C 10% mol (which percentage ?). The product was
obtained as yellow solid (0.40 g, 98%): Rf = 0.78 (EtOAc/Hex 1:2); 1H NMR (400MHz,
CDCl3): δ 0.94 (3H, t, J = 7.2 Hz), 1.18 (3H, t J = 7.5Hz), 1,36-1,48 (4H, m), 1.70 (6H,
s), 1.77-1.81 (2H, m), 2.61 (2H, q, J = 7,5 Hz), 2,82 (2H, t, J = 7,9 Hz), 3.36 (2H, t, 7.9
Hz), 3.93 (2H, t, J = 6.4 Hz), 6.73 (1H, d, 8.8 Hz), 6.81 (1H, d, J = 8.2 Hz), 6.87 (1H,
d, J = 7.6 Hz), 7.00-7.02 (2H, m), 7.38 (1H, t, 7.9 Hz) ppm. 13C NMR (100 MHz,
CDCl3) δ 14.0, 14.3, 22.4, 23.4, 25.6, 28.4, 29.1, 36.8, 37.0, 67.9, 105.0, 111.0, 112.1,
115.3, 125.5, 126.6, 129.4, 132.5, 133.3, 135.1, 147.4, 155.1, 157.1, 160.3 ppm. MS
(ESI): (m/z) 397.2 [M+H]+.
5-((3-acetyl-4-(heptyloxy)phenyl)ethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-
one
The product was obtained using procedure 5 starting from 5-((3-acetyl-4-
(heptyloxy)phenyl)ethynyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.5 mmol,
0.61 g). Purification was performed by column chromatography using EtOAc/Hex 1:8
(v/v) as eluent. The product was obtained as yellow oil (0.52 g, 84%); Rf = 0.51
(EtOAc/Hex 1:2); 1H NMR (200 MHz, CDCl3): δ = 0.81 (3H, t, J = 6.4 Hz), 1.22-1.40
(8H, m), 1.60 (6H, s), 1.71-1.78 (2H, m), 2.53 (3H, s), 2.72-2.80 (2H, m), 3.21-3.29
(2H, m), 3.93, (2H, t, J = 5.1 Hz), 6.70-6.80 (3H, m), 7.25-7.32 (2H, m), 7.48 (1H, d, J
= 2.4 Hz); 13C NMR (50 MHz, CDCl3 ): δ = 14.1, 22.6, 25.6, 26.2, 29.0, 29.3, 31.8, 32.1,
36.3, 36.8, 68.6, 105.1, 112.0, 112.4, 115.6, 125.4, 127.8, 130.2, 133.6, 134.1, 135.3,
146.8, 157.0, 157.2, 160.3, 200.0 ppm; MS (ESI): m/z 456.3 [M+NH4]+.
5-(2-(2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)ethyl)-1-pentylpiperidin-
2-one
The product was obtained using procedure 5 starting from 2-dimethyl-5-((6-
(pentyloxy)pyridin-3-yl)ethynyl)-4H-benzo[d][1,3]dioxin-4-one (1.5 mmol, 0.55 g). The
product was purified by column chromatography using EtOAc/Hex 1:1 (v/v) as
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eluent. The product was obtained as orange oil (0.44 g, 80%); Rf = 0.30 (EtOAc/Hex
3:1); 1H NMR (200 MHz, CDCl3): δ = 0.87 (3H, t, J = 6.7 Hz), 1.11-1.36 (6H, m), 1.43-
1.59 (5H, m), 1.68 (6H, s), 1.88-1.95 (2H, m), 2.30-2.49 (2H, m), 3.02-3.08 (2H, m),
3.31-3.37 (2H, m), 6.79-6.91 (2H, m), 7.40 (1H, t, J = 7.9 Hz). 13C NMR (50 MHz,
CDCl3 ): δ = 14.0, 22.5, 25.6, 26.7, 27.3, 29.1, 31.5, 32.0, 34.1, 34.9, 47.3, 53.0, 105.1,
111.8, 115.6, 125.0, 135.4, 147.3, 157.2, 160.3, 169.5 ppm; MS (ESI): m/z 374.4
[M+H]+.
2,2-dimethyl-5-pentyl-4H-benzo[d][1,3]dioxin-4-one
The product was obtained using procedure 5 starting from 2-dimethyl-5-(pent-1-yn-
1-yl)-4H-benzo[d][1,3]dioxin-4-one (1.5 mmol, 0.37g). The product was obtained as
pale yellow solid (0.31 g, 85%): Rf = 0.54 (EtOAc/Hex 1:2); 1H NMR (400 MHz,
CDCl3): δ 0.88 (3H, t, J = 7.2 Hz), 1.30-1.38 (4H, m), 1.56-1.70 (8H, m), 3.08 (2H, t, J
= 7.8 Hz), 6.78 (1H, dd, J = 1.2, 8.2 Hz), 6.91 (1H, dd, J = 1.0, 8.5 Hz), 7.38 (1H, t, J =
7.9 Hz) ppm. 13C NMR (100 MHz, CDCl3) δ 14.0, 22.5, 25.6, 30.8, 31.8, 34.3, 104.9,
112.1, 115.0, 125.1, 135.0, 148.5, 157.1, 160.2 ppm. MS (ESI): (m/z) 249.3 [M+H]
2-(4-((3,7-dimethyloctyl)oxy)phenethyl)-6-hydroxybenzoic acid (6a)
The product was obtained using procedure 6 starting from 5-(4-((3,7-
dimethyloctyl)oxy)phenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1 mmol,
0.44 g). The product was purified by column chromatography using EtOAc/Hex 1:6
(v/v) as eluent. The product was obtained as yellow solid (0.0.37 g, 93%); Rf = 0.38
(EtOAc/Hex 1:1); 1H NMR (200 MHz, CDCl3): δ = 0.83 (6H, d, J = 6.8 Hz), 0.94 (3H,
d, J = 6.5 Hz), 1.07-1.25 (6H, m), 1.43-1.46 (2H, m), 1.50-1.56 (2H, m), 2.11-2.82 (2H,
m), 3.15-3.23 (2H, m), 3.89 (2H, t, J = 6.0 Hz), 6.64 (1H, d, J = 7.6 Hz), 6.73-7.00 (3H,
m), 7.04-7.19 (2H, m), 7.28 (1H, t, J = 8.1 Hz), 13C NMR (50 MHz, (CD3)2SO): δ =
19.6, 22.6, 22.7, 24.7, 28.0, 29.9, 36.3, 37.3, 37.4, 38.8, 39.2, 66.4, 110.5, 114.5, 116.2,
123.0, 129.3, 133.6, 135.6, 146.4, 157.4, 163.7, 175.7 ppm; HRMS: m/z [M-H]-, calcd
for C25H33O4 397.2379, found 397.2381.
2-hydroxy-6-(4-(2-methoxyethoxy)phenethyl)benzoic acid (6b)
The product was obtained using procedure 6 starting from 5-(4-(2-
methoxyethoxy)phenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1 mmol, 0.36
g). The product was purified by column chromatography using EtOAc/Hex 1:4 (v/v)
as eluent. The product was obtained as white solid (0.18 g, 58%); Rf = 0.49 (100
%EtOAc); 1H NMR (200 MHz, CD3CN): δ = 2.74-2.81 (2H, m), 3.11-3.19 (2H, m), 3.36
(3H, s), 3.65-3.70 (2H, m), 4.03-4.08 (2H, m), 6.73-6.85 (4H, m), 7.09-7.14 (2H, m),
7.28-7.35 (1H, m); 13C NMR (50 MHz, CD3CN): δ = 42.3, 43.6, 63.3, 72.4, 76.1, 117.6,
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119.6, 120.6, 127.7, 134.7, 139.5, 139.7, 150.7, 162.4, 167.7, 177.8 ppm; HRMS: m/z
[M-H]-, calcd for C18H19O5 315.1238, found 315.1239.
2-(3-acetyl-4-(pentyloxy)phenethyl)-6-hydroxybenzoic acid (6c)
The product was obtained using procedure 6 starting from 5-(3-acetyl-4-
(pentyloxy)phenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.0 mmol, 0.41 g).
The product was obtained a pale green solid (0.26 g, 71%); mp:106 ˚C; Rf = 0.46
(EtOAc 100%); 1H NMR (400MHz, CD3CN): δ 0.95 (3H, t, J = 7.2 Hz), 1.41-1.50 (4H,
m), 1.82-1.87 (2H, m), 2.59 (3H, s), 2.84 (2H, t, J = 8.2 Hz), 3.18 (2H, t, J = 8,2 Hz),
4.09 (2H, t, J = 6.64 Hz), 6.78 (1H, d, J = 7.3 Hz), 6.83 (1H, dd, J =  1.2, 8.2 Hz), 7.01
(1H, d, J =  8.5 Hz), 7.32-7.36 (2H, m), 7.49 (1H, d, J = 2.3 Hz) ppm. 13C NMR (50
MHz, CD3OD) δ 14.4, 23.5, 29.6, 30.1, 32.2, 38.4, 39.4, 69.8, 113.8, 114.9, 116.3,
123.3, 128.8, 130.8, 134.5, 135.2, 135.3, 145.6, 158.5, 162.9, 174.2, 202.3 ppm. HRMS:
m/z [M-H]-, calcd for C22H25O5 369.1708, found 369.1711.
2-hydroxy-6-(3-(1-hydroxyethyl)-4-(pentyloxy)phenethyl)benzoic acid (6d)
The product was obtained using procedure 6 starting from 5-(3-(1-hydroxyethyl)-4-
(pentyloxy)phenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.0 mmol, 0.41 g).
The compound was obtained as white solid (0.14 g, 38%); mp: 113 ˚C; Rf = 0.46
(EtOAc 100%); 1H NMR (400MHz, CD3OD): δ 0.94 (3H, t, J = 6.9 Hz), 1.36-1.46 (7H,
m), 1.75-1.78 (2H, m), 2.79 (2H, t, J = 7.9 Hz), 3.07-3.17 (2H, m), 3.93 (2H, d, J = 3.5
Hz), 5.16 (1H, q, J = 6.2 Hz), 6.68 (1H, d, J = 7.3 Hz), 6.75-6.78 (2H, m), 6.98 (1H, d,
J = 7.3 Hz), 7.21-7.27 (2H, m) ppm. 13C NMR (50 MHz, CD3OD) δ 13.0, 22.1, 23.1,
28.2, 28.8, 37.5, 38.1, 64.0, 67.7, 110.8, 114.0, 114.6, 121.9, 125.1, 127.2, 132.9, 133.8,
134.0, 144.5, 153.5, 161.0, 172.9 ppm. HRMS: m/z [M-H]-, calcd for C22H27O5
371.1864, found 371.1867.
2-(3-ethyl-4-(pentyloxy)phenethyl)-6-hydroxybenzoic acid (6e)
The product was obtained using procedure 6 starting from 5-(3-ethyl-4-
(pentyloxy)phenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.0 mmol, 0.39 g).
The compound was obtained as white solid (0.11 g, 32%); mp: 96 ˚C; Rf = 0.65 (EtOAc
100%); 1H NMR (400MHz, CD3OD): δ 0.95 (3H, t, J = 7.2 Hz), 1.16 (3H, t, J = 7.5
Hz), 1.38-1.51 (4H, m), 1.76-1.81 (2H, m), 2.59 (2H, q, J = 7.4 Hz), 2.78 (2H, t, J = 7.8
Hz), 3.16-3.20 (2H, m), 3.95 (2H, t, J = 6.3 Hz), 6.76-6.83 (3H, m), 6.98-7.00 (2H, m),
7.33 (1H, t, J = 7.9 Hz) ppm. 13C NMR (50 MHz, CD3OD) δ 13.4, 14.0, 22.2, 23.1,
28.1, 28.9, 37.2, 38.4, 67.9, 111.3, 112.3, 115.3, 122.3, 126.5, 126.6, 129.2, 129.3,
132.2, 133.8, 134.1, 145.6, 155.1, 162.6, 172.7 ppm. HRMS: m/z [M-H]-, calcd for




The product was obtained using procedure 6 starting from 5-(3-acetyl-4-
(heptyloxy)phenethyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.0 mmol, 0.41 g).
Purification was performed by column chromatography using EtOAc/Hex 1:5 (v/v) as
eluent. The product was obtained as pale yellow solid (0.21 g, 58%); Rf = 0.47 (100%
EtOAc); 1H NMR (200 MHz, CDCl3): δ = 0.82 (3H, t, J = 6.6 Hz), 1.23-1.30 (8H, m),
1.72-1.76 (2H, m), 2.61 (3H, s), 2.78-2.82 (2H, m), 3.13-3.17 (2H, m), 3.95 (2H, t, J =
6.5 Hz), 6.65 (1H, d, J = 6.5 Hz), 6.75-6.84 (2H, m), 7.15-7.30 (2H, m), 7.62 (1H, d, J
= 2.4 Hz); 13C NMR (50 MHz, CDCl3 ): δ = 14.1, 22.6, 26.2, 29.0, 29.2, 31.7, 32.1, 37.3,
38.8, 68.7, 110.9, 112.3, 116.2, 122.7, 127.6, 130.3, 133.8, 134.1, 135.1, 145.8, 157.3,
163.6, 174.6, 201.5 ppm; HRMS: m/z [M-H]-, calcd for C24H29O5 397.2021, found
397.2018.
2-(2-(1-butyl-6-oxopiperidin-3-yl)ethyl)-6-hydroxybenzoic acid (6g)
The product was obtained using procedure 6 starting from 2,2-dimethyl-5-(2-(6-
(pentyloxy)-2,3,4,5-tetrahydropyridin-3-yl)ethyl)-4H-benzo[d][1,3]dioxin-4-one (1
mmol, 0.37 g). The product was purified by column chromatography using
DCM/MeOH 9:1 (v/v) as eluent. The product was obtained as white solid (0.24 g,
73%); Rf = 0.60 (DCM/MeOH 2:1); 1H NMR (200 MHz, (CD3)2SO): δ = 0.87 (3H, t, J =
6.9 Hz), 1.16-1.59 (9H, m), 1.78-1.84 (2H, m), 2.17-2.24 (2H, m), 2.63-2.69 (2H, m),
2.87-2.98 (2H, m), 3.13-3.30 (2H, m), 6.70-6.75 (2H, m), 7.14-7.22 (1H, m); 13C NMR
(50 MHz, (CD3)2SO): δ = 14.4, 22.3, 26.6, 27.2, 29.0, 31.5, 33.6, 35.1, 46.5, 52.7, 114.1,
120.5, 120.1, 131.1, 141.6, 156.4, 168.5, 170.7 ppm; HRMS: m/z [M-H]-, calcd for
C19H26O4N1 332.1867, found 332.1869.
2-hydroxy-6-pentylbenzoic acid (6H)
The product was obtained using procedure 6 starting from 2,2-dimethyl-5-pentyl-4H-
benzo[d][1,3]dioxin-4-one (1.0 mmol, 0.25 g). The product was obtained as white solid
(0.19 g, 90%); mp:84 ˚C; Rf = 0.57 (EtOAc 100%); 1H NMR (400MHz, CDCl3): δ 0.89
(3H, t, J = 7.0 Hz), 1.30-1.36 (4H, m), 1.55-1.59 (2H, m), 2.87 (2H, t, J = 7.8 Hz), 6.69-
6.73 (2H, m), 7.22 (1H, t, J = 7.9 Hz). NMR (50 MHz, CDCl3) δ 13.0, 22.1, 31.5, 31.7,
35.2, 105.0, 114.2, 121.4, 132.4, 145.4, 160.7, 173.2 ppm. HRMS: m/z [M-H]-, calcd for
C12H15O3 207.1027, found 207.1028
Methyl 5-(dec-1-ynyl)-2-methoxybenzoate (8)
The product was obtained using procedure 4 starting from dec-1-yne (2.7 mmol, 0.48
mL) and methyl 5-iodo-2-methoxybenzoate (2.5 mmol, 0.73 g). The product was
purified by column chromatography using EtOAc/Hex 1:8 (v/v) as eluent. The
product was obtained as orange solid (0.53 g, 68%); Rf = 0.40 (EtOAc/Hex 1:3); 1H
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NMR (200 MHz, CDCl3): δ = 0.85-0.91 (3H, m), 1.25-1.31 (8H, m), 1.39-1.44 (2H, m),
1.51-1.56 (2H, m), 2.37 (2H, t, J = 6.9 Hz), 3.87 (3H, s), 3.89 (3H, s), 6.88 (1H, d, J =
8.7 Hz), 7.47 (1H, dd, J = 8.6, 2.2 Hz), 7.83 (1H, d, J = 2.2 Hz); 13C NMR (50 MHz,
CDCl3 ): δ = 14.1, 19.3, 22.6, 28.7, 28.9, 29.1, 29.2, 31.8, 52.0, 56.1, 79.2, 89.8, 111.9,
116.1, 120.0, 134.9, 136.4, 158.3, 165.9 ppm; MS (ESI): m/z 303.2 [M+H]+.
Methyl 5-decyl-2-methoxybenzoate
The product was obtained using procedure 5 starting from methyl 5-(dec-1-yn-1-yl)-
2-methoxybenzoate (1.5 mmol, 0.47 g). The product was obtained as dark yellow oil
(0.45 g, 95%); Rf = 0.45  (EtOAc/Hex 1:3); 1H NMR (200 MHz, CDCl3): δ =0.76 (3H, t,
J = 6.5 Hz), 1.26 (14H, m), 1.58-1.64 (2H, m), 2.55 (2H, t, J = 7.4 Hz), 3.87 (3H, s),
3.88 (3H, s), 6.88 (1H, d, J = 8.5 Hz), 7.26 (1H, dd, J = 8.5, 2.4 Hz), 7.60 (1H, d, J =
2.3 Hz) ; 13C NMR (50 MHz, CDCl3 ): δ = 14.1, 22.7, 29.2, 29.3, 29.5, 29.6, 29.7, 31.5,
31.9, 34.8, 51.9, 56.1, 112.0, 119.6, 131.3, 133.3, 134.6, 157.2, 166.9 ppm; MS (ESI):
m/z 307.2 [M+H]+
5-decyl-2-hydroxybenzoic acid (9)
Methyl 5-decyl-2-methoxybenzoate (1 mmol, 0.32 g) was dissolved in dry CH2Cl2 (20
mL) and the solution was cooled to -78 °C. A solution 1 M of boron tribromide (BBr3)
in CH2Cl2 (5.0 mmol, 5.0 mL) was slowly added and the reaction mixture was stirred
for 5 h at room temperature. The reaction mixture was quenched with few drops of
water and extract with a saturated Na2CO3 solution (30 mL). The water layer was
acidified with HCl 1 N and extracted with EtOAc (3 x 50 mL). The organic layers
were collected, washed with brine (1 x 50 mL), dried over Na2SO4 and filtered. The
solvent was evaporated and the product was purified by column chromatography
using EtOAc/Hex 1:3 (v/v) as eluent. The product was obtained as pink solid (0.20 g,
73%); Rf = 0.32 (100 % EtOAc); 1H NMR (200 MHz, CDCl3): δ = 0.88 (3H, t, J = 6.5
Hz), 1.26 (14H, m), 1.55-1.62 (2H, m), 2.56 (2H, t, J = 7.4 Hz), 6.93 (1H, d, J = 8.5
Hz), 7.34 (1H, dd, J = 8.5, 2.3 Hz), 7.71 (1H, d, J = 2.1 Hz); 13C NMR (50 MHz, CDCl3
): δ = 14.1, 22.7, 29.1, 29.3, 29.4, 29.6, 31.4, 31.9, 34.8, 45.8, 110.8, 117.5, 129.9,
134.0, 137.3, 160.3, 174.4 ppm; HRMS: m/z [M-H]-, calcd for C17H25O3 277.1809,
found 277.1811.
Methyl 2-(pentadec-1-ynyl)benzoate (11)
The product was obtained using procedure 4 starting from pentadec-1-yne (1.1 mmol,
0.27 mL) and methyl 2-iodobenzoate (0.95 mmol, 0.25 g). The reaction mixture was
subjected to microwave irradiation at 100 oC (85 W) for 45 minutes. The mixture was
extracted with diethyl ether (3 x 50mL) and the solvents were evaporated under
reduced pressure. The reaction mixture was separated by column chromatography
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on silica using diethyl ether/pentane 1:4 (v/v) as solvent. The product was obtained
as brown oil (0.20 g, 62%): Rf = 0,67 (diethyl ether/pentane 1:10); 1H NMR (400 MHz,
CDCl3) δ 0.88 (3H, t, J = 6.9 Hz), 1.21-1.65 (22H, m), 2.47 (2H, t, J = 7.1 Hz), 3.91
(3H, s), 7.30 (1H, td, J = 1.3, 7.7 Hz), 7.41 (1H, td, J = 1.4, 7.6 Hz), 7.50 (1H, dd, J =
1.1, 7.8 Hz), 7.88 (1H, dd, J = 7.9, 1.1); 13C NMR (50 MHz, CDCl3) δ 14.1, 19.8, 22.7,
28.7, 29.0, 29.2, 29.4, 29.6, 29.6, 29.7, 31.9, 52.1, 105.0, 114.1, 127.1, 130.1, 131.5,
134.2, 144.8.
Methyl 2-pentadecylbenzoate
The product was obtained using procedure 5 starting from methyl 2-(pentadec-1-yn-
1-yl)benzoate (0.51 g, 1.5 mmol). The product was obtained as colorless oil (0.40 g, 78
%): Rf = 0.87 (diethyl ether/ pentane 1:4); 1H NMR (400 MHz, CDCl3) δ 0.88 (3H, t, J
= 6.9), 1.15-1.70 (26H, m), 2.85-2.99 (2H, m), 3.89 (3H, s), 7.14-7.29 (2H, m), 7.31-
7.50 (1H, m), 7.84 (1H, dd, J = 1.2, 7.7); 13C NMR (50 MHz, CDCl3) δ 14.1, 22.7, 29.4,
29.5, 29.7, 29.8, 31.8, 31.9, 34.5, 51.9, 125.6, 130.5, 130.9, 131.8, 144.7.
2-pentadecylbenzoic acid (12)
Methyl 2-pentadecylbenzoate (0.40 mmol, 0.15 g) and LiOH (2.2 mmol, 0.050 g,)
were dissolved in THF/Methanol/H2O 3:1:1 (5 mL) and refluxed overnight in a round
bottom flask equipped with a condenser. The solvents were evaporated under
reduced pressure. Water (50 mL) was added and the mixture was acidified to pH 2
with aqueous HCl 2 M. The mixture was extracted with diethyl ether (3 x 50 mL)
and the combined organic layers were dried over MgSO4.The solvent was evaporated
under reduced pressure to give the product as pale yellow solid (0.13 g, 91%): Rf: 0.49
(diethyl ether/pentane 1:4); 1H NMR (400 MHz, CDCl3) δ 0.89 (3H, t, J = 6.9 Hz),
1.07-1.70 (26H, m), 2.99-3.10 (2H, m), 7.23-7.33 (2H, m), 7.47 (1H, td, J = 1.4, 7.8
Hz), 8.06 (1H, dd, J = 1.2, 8.4 Hz); 13C NMR (101 MHz, CDCl3) δ 14.1, 22.7, 29.4,
29.5, 29.6, 29.7, 31.8, 31.9, 34.6, 125.8, 128.1, 131.2, 131.6, 132.8, 146.0, 173.6.
Benzyl 2,4-bis(benzyloxy)-6-((4-heptylphenyl)ethynyl)benzoate (14)
The product was obtained using procedure 4 starting from 1-ethynyl-4-
heptylbenzene (2.7 mmol, 0.59 g) and 13 (0.95 mmol, 0.25 g). The product was
purified by column chromatography using EtOAc/Hex 1:9 (v/v) as eluent. The
product was obtained as brown oil (0.97 g, 62%); Rf = 0.43 (EtOAc/Hex 1:3); 1H NMR
(200 MHz, CDCl3): δ = 0.81 (3H, t, J = 6.4 Hz), 1.21-1.23 (8H, m), 1.49-1.53 (2H, m),
2.53 (2H, t, J = 7.4 Hz), 4.96 (2H, s), 4.99 (2H, s), 5.29 (2H, s), 6.48 (1H, d, J = 2.4
Hz), 6.7 (1H, d, J = 2.4 Hz), 7.02-7.31 (19H, m); 13C NMR (50 MHz, CDCl3): δ = 14.2,
22.2, 22.8, 29.2, 31.4, 31.9, 36.1, 67.2, 70.4, 70.7, 86.2, 93.4, 101.9, 109.6, 119.8,
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120.0, 123.8, 127.2, 127.7, 128.0, 128.1, 128.3, 128.4, 128.5, 128.6, 128.8, 131.8,
136.0, 136.3, 136.4, 144.0, 157.2, 160.5, 166.8 ppm; MS (ESI): m/z 623.3 [M+H]+.
2-(4-heptylphenethyl)-4,6-dihydroxybenzoic acid (15)
The product was obtained using procedure 5 starting from benzyl 2,4-bis(benzyloxy)-
6-((4-heptylphenyl)ethynyl) benzoate (1.5 mmol, 0.94 g). The product was purified by
column chromatography using EtOAc/Hex 1:5 (v/v) as eluent. The product was
obtained as white solid (0.40 g, 74%); Rf = 0.60 (100 % EtOAc); 1H NMR (200 MHz,
CDCl3): δ = 0.85 (3H, t, J = 6.4 Hz), 1.25-1.31 (8H, m), 1.58-1.62 (2H, m), 2.58 (2H, t,
J = 7.4 Hz), 2.83-2.91 (2H, m), 3.18-3.27 (2H, m), 6.25-6.34 (1H, m), 7.09-7.40 (4H,
m), 7.40 (1H, s); 13C NMR (50 MHz, CDCl3): δ = 14.2, 22.8, 29.3, 29.5, 31.7, 32.0, 35.7,
60.8, 70.1, 100.2, 104.5, 112.0, 127.7, 128.4, 128.5, 128.8, 136.1, 139.1, 140.6, 161.5,
163.9, 172.0. HRMS: m/z [M-H]-, calcd for C22H27O4 355.1915, found 355.1918.
Protein expression
His-tagged PCAF HAT domain (493-658) was expressed with the pET28a vector.
His-tagged full length Tip60 was expressed with the pET21a(+) vector. Recombinant
p300 HAT domain was a gift from Dr. Philip Cole. Human MOF (125-458) was
expressed with the pET19 vector. All the protein expression was carried out with E.
coli BL21(DE3). The His-tagged proteins were purified on Ni-NTA beads. Protein
concentrations were determined using the Bradford assay. Proteins were flash frozen
in a storage buffer containing 25 mM HEPES pH=7.0, 500 mM NaCl, 10 mM DTT, 1
mM EDTA and 10% Glycerol, and stored at -80°C.
Biochemical inhibition assays
Radioisotope-labeled acetyltransferase assays were carried out at 30 °C in a reaction
volume of 30 μL. The reaction buffer contained 50 mM HEPES at pH 8.0, 0.1 mM
EDTA, 50 μg/mL BSA, 1 mM dithiothreitol, 0.1% Triton-X100, and 2% DMSO. 14C-
labeled Ac-CoA (Perkin Elmer) was used as the acetyl donor. The peptide containing
the N-terminal 20-amino acid sequence of histone H4 (i.e. H4-20) was used as
substrate for p300 and Tip60, and the peptide containing the N-terminal 20-amino
acid sequence of histone H3 (i.e. H3-20) was employed as substrate for PCAF. For
IC50 determination, a range of at least seven inhibitor concentrations varied at least
20-fold around the IC50 were tested. The reaction was initiated with the HAT
enzyme after the other components (Ac-CoA, peptide substrate, and the inhibitor)
were equilibrated at 30 °C for 5 min. Rate measurements were based on initial
conditions (generally less than 15% consumption of the limiting substrate). After the
reaction, the mixture was loaded onto a Waterman P81 filter paper and then washed
with 50 mM sodium bicarbonate (pH 9.0) for three times. The paper was air dried
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and the amount of radioactivity incorporated into the peptide substrate was
quantified by liquid scintillation counting. In all the cases, background acetylation
(in the absence of enzyme) was subtracted from the total signals. The IC50 was
determined as the concentration of an inhibitor at which half of the enzyme activity
was inhibited. All the assays were performed at least twice, and duplicates generally
agreed within 20%.
Acetyltransferase assays with nuclear extracts
Nuclear extracts were prepared from HeLa cells or tissue samples for distinct brain
regions using procedures described by Dignam et al.164 The HAT activity in the
nuclear extracts was determined using an ELISA assay in which either a
biotinylated histone H3 peptide (aa 1 to 21, Anaspec – 61702) or a histone H4
peptide (aa 2-24, Millipore, 12-372) was immobilized using steptavidin-biotin
linkage. The ELISA was performed as described previously 148. The buffer for the
enzymatic reaction contained 0.01% Triton X-100, 0.1 mM EDTA, 50 μg/mL BSA,
1mM DTT and 50 mM HEPES pH 7.4. The nuclear extracts were standardized based
on the protein concentration. The final protein concentration of the HeLa nuclear
extract in the enzyme reaction was 2.5 μg/mL. For nuclear extracts of brain tissue
samples the concentration was 40 μg/mL. The reaction time for the enzymatic
reaction was 15 min. The brain tissue samples were obtained from Prof. Dr. B.
Roozendaal, Neurosciences, UMCG, Groningen, The Netherlands. The samples were
obtained from animal experiments that were approved by the animal experiment
committee (Dier Experimenten Commissie, DEC) from this institute according to
national regulations described in the ‘law for animal experiments’.
Modeling
The PDB file of Tip60 structure (2OU2) was modified with Maestro 9.0.211 software
to add hydrogens and delete the water and Ac-CoA molecules. The 3-dimensional
structure of 20 was also constructed with Maestro 9.0.211. AutoDock Version 4.2
was then employed to generate PDBQT files for both the ligand and the
macromolecule for docking. AutoGrid was used to generate a grid box covering the
whole protein unit for docking processing. The Genetic Algorithm with 2500,000
maximum numbers of evaluations and 50 generations for picking individuals was
selected as the docking parameters. Structural analysis with PyMOL was performed
following the docking process
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The use of small molecule modulators of epigenetic modifications, in order to
regulate the expression of certain genes during disease manifestations, represents a
new potential therapeutic approach. Furthermore, it provides a new powerful
investigation tool for pharmacological studies.
Several inhibitors of enzymes involved in epigenetic modifications have been
identified and have played an important role in elucidating epigenetic regulatory
mechanisms. Several DNA methylation inhibitors and HDAC inhibitors are under
investigation in clinical trials. Some of them are already available for clinical use in
the United States. On the contrary, the development of HAT inhibitors has proved
more challenging. Despite significant efforts, HAT inhibitors have still limited
efficacy, selectivity or low cell-permeability. The design of new and improved HAT
inhibitors is necessary because of the potential applications of this class of
compounds in the field of inflammation and cancer. Recent studies clearly
demonstrate that inappropriate or excessive inflammatory responses are often
accompanied by hyperacetylation of histones and non-histone proteins involved in
the transcription of pro-inflammatory genes. Similarly, increasing evidences suggest
that dysfunctions of acetylation processes are often associated with development of
numerous cancer types.
The work described in this thesis focuses on the synthesis and biological
evaluation of novel HAT inhibitors. The major challenge is to find potent and
selective HAT inhibitors that show biological activity in cells. We report the design of
potent isothiazolone-based inhibitors of the HAT PCAF, which are also cytotoxic for
different cancer cell lines. We develop an anacardic acid (AA) derivative that is a
potent inhibitor of histone acetylation in cells. Furthermore, we identify a 6-
alkylsalicylate derivative that is a selective inhibitor of the recombinant HAT Tip60
in comparison with the HATs PCAF and p300. In conclusion, we provide new
chemical tools for pharmacological studies to validate HATs inhibitors as potential
new drugs for treatment of cancer and inflammation.
ISOTHIAZOLONES ASHAT INHIBITORS
The first part of this thesis describes the design of new HAT inhibitors based on the
isothiazolone scaffold. In chapter 2 we described the synthesis of a small collection
of isothiazolone derivatives, which were screened in vitro for the inhibition of the
recombinant HAT PCAF in order to resolve the structure-activity relationship (SAR).
In this study we identified compound 2.2e (figure 6.1) as the most potent inhibitor,
which suggests that a methyl ester at two carbon atoms distance from the
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isothiazolone ring provides additional interactions with PCAF. Interestingly, we also
observed that a chloride in the 5-position of N-aliphatic substituted isothiazolones
was essential for their inhibitory properties. In contrast, there were no pronounced
differences in PCAF inhibitory potency between N-aromatic substituted 5-
chloroisothiazolones and isothiazolones. The small differences between the IC50
values of different 5-chloroiosthiazolones indicate that the reactivity of these
compounds towards the thiolates in the enzyme active site plays a predominant role
in enzyme inhibition. In addition, we found that compound 2.4e (figure 6.1) also
inhibited PCAF, which identifies 5-chloroisothiazolone-1-oxide as a novel class of
HAT inhibitors.
Figure 6.1: novel isothiazolone-based HAT inhibitors described in this thesis.
In chapter 3 we investigated the reaction of isothiazolones derivatives with
thiols and thiolates to better understand the chemical reactivity of these compounds.
We showed that 5-chloroisothiazolones reacted quickly with thiolates providing
multiple products. In contrast, the reaction of 5-chloroisothiazolone-1-oxides with
thiolates occurred through addition in the 5-position and elimination of the chloride
to give the correspondent 5-alkylthioisothiazolone-1-oxides. This supports the
hypothesis that the inhibition of HATs by isothiazolone derivatives is due to their
reactivity towards thiolates. The elucidation of chemical reactivity confirms that
isothiazolones might find applications in ABPP because they react with thiolates.
In addition, we explored synthetic modifications of the isothiazolone ring in
order to modulate its reactivity and we tested the effects of these modifications on
the in vitro inhibition of the recombinant HAT PCAF. The isothiazolone reactivity
could be modulated by introduction of electron- donating or electron-withdrawing
groups in the 4-position. We showed that the introduction of a methyl group in the 4-
position of the isothiazolone ring caused a significant drop in inhibitory potency. On
the other hand, introduction of a chlorine atom in the 4-position did not affect the
inhibitory properties of 5-chloroisothiazolones, whereas it caused a drop in inhibitory
potency of 5-chloroisothiazolone-1-oxides. The relationship between thiolate
reactivity and HAT inhibition cannot easily be  derived, because changes in
inhibitory potency might originate both from their binding properties to the enzyme
active site as well as from their reactivity. Nevertheless, this study demonstrates
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that the inhibitory potency of 5-chloroisothiazolones cannot easily be improved by
introduction of substituent in the 4-position.
In chapter 2 and 3 we explored the growth inhibition of several cancer cell lines
upon treatment with isothiazolones to explore the toxicity of these compounds. These
studies showed that N-aliphatic substituted 5-chloroisothiazolones inhibited
proliferation of the cancer cell lines HEP G2, A2780 and HEK 293 at micromolar
concentrations. Little or no growth inhibition was observed with other classes of
isothiazolone derivatives. In general, the differences in PCAF inhibitory potency
were not reflected in the inhibition of cell proliferation. This might be due to
differences in cell membrane permeability between the compounds, even though
other mechanisms might be involved. Nevertheless, the cytotoxic effects exerted by
N-aliphatic substituted 5-chloroisothiazolones suggest possible anticancer properties
for these compounds.
ANACARDIC ACID DERIVATIVES ASHAT INHIBITORS
The second part of this thesis describes the development of novel HAT inhibitors
using the natural product AA as starting point. In chapter 4 we proposed a binding
model for AA in the HAT PCAF active site in which the salicylate is bound in the
pyrophosphate binding pocket and the alkyl chain is located in the CoA substrate
binding cleft. This binding model can be used as starting point for the design of new
molecules in order to optimize the inhibitory potency. We design several AA
derivatives and synthesized them using a novel, convenient and versatile synthetic
route. We investigated the in vitro inhibitory potency of these derivatives towards
the recombinant HAT PCAF to elucidate the SAR. In general, the synthesized
compounds showed poor inhibition of PCAF, with potencies comparable to or lower
than AA. An important consideration is that AA has poor drug-like properties, such
as a log P value higher than 5. Our new inhibitors represent an improvement from
this point of view. Compound 4.6d (figure 6.2) was the only compound that proved to
be more potent than AA in the enzyme inhibition studies. Moreover, this derivative
showed also a two-fold improved potency for inhibition of histone H4 acetylation in
cell-based studies. Therefore, compound 4.6d represents a novel pharmacological
probe to study inhibition of histone acetylation in cells. It is interesting to point out
that 4.6d was the only compound with a cis double bond in the substituent on
salicylate 6-position. This conformational restriction could explain the increase in
inhibitory potency. However, more compounds with a cis double bond have to be
evaluated to confirm this possible correlation.
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Figure 6.2: novel anacardic acid-based HAT inhibitors described in this thesis.
In chapter 5 we addressed the issue of specificity of AA derivatives among
different classes of HATs. We synthesized several compounds with various 2-
phenylethane substituents in the salicylate 6-position in order to enhance binding by
providing specific interactions with the enzymes. All the salicylate derivatives were
screened for the inhibition of the recombinant HATs Tip60, PCAF and p300, which
represent the three major HAT families in mammalian cells. In general, the
synthesized compounds showed stronger inhibitory potency for Tip60 compared to
p300 and PCAF. Compound 5.20 (figure 6.2) showed the highest selectivity for
Tip60. Moreover its calculated logP value is significantly lower than that of AA,
which represents an advantage for the bioactivity. Altogether, 5.20 is a novel HAT
inhibitor with improved isoenzyme selectivity and drug-like properties. This
compound could be used in cell-based study to explore Tip60 biological functions and
implications in pathologies.
Compounds that inhibited the recombinant HAT Tip60 also inhibited HAT
activity of nuclear extract from HeLa cells, with comparable potency. This suggests
that Tip60 or closely related HATs are a major source of HAT activity in these cells.
Interestingly, some inhibitors showed a difference in inhibitory potency between
histone H3 and histone H4. These data indicate that selective inhibitors towards
histone H3 or H4 acetylation could be developed. These kinds of compounds would
represent new investigation tools for pharmacological studies.
We analyzed the HAT inhibitory mechanism of AA derivatives using enzyme
kinetics. These studies showed that inhibition of Tip60 by 5.20 is competitive to Ac-
CoA and non-competitive to histone H4. This supports our hypothesis that AA




Future work should be oriented towards the design of improved HAT inhibitors and
the evaluation of their biological properties in pharmacological studies.
Several isothiazolone-based PCAF inhibitors described in thesis exerted
cytotoxic effects towards different cancer cell lines. Further investigations are
necessary to study the biological mechanisms underlying the cell growth inhibition
showed by these compounds. For example, western blots analysis of histone
acetylation levels in cell lines that are treated with N-aliphatic substituted 5-
chloroisothiazolones are required to proof a connection between the PCAF HAT
inhibition and the biological activity. These studies are needed to validate HATs
inhibitors as drug candidates for cancer therapy.
We showed that compounds 2.2e and 2.4 react quickly with thiolates. Functional
groups that react covalently with thiolates have been extensively used for ABPP of
enzymes with a cysteine in the active site. 5-chloroisothiazolones and 5-
chloroisothiazolone-1-oxides might find applications in this field. HATs contain a
cysteine in the active site and therefore the reactivity of isothiazolones could be
employed for development of probes to detect the activity of HATs in cell-lysates.
However, chemical probes that are applied in ABPP need a certain level of
specificity. The evaluation of the SAR presented in this thesis is a first step towards
the development of specific isothiazolone-based HAT inhibitors. An appropriate
design and additional structure modifications are necessary before applying these
compounds in ABPP.
Docking and enzyme kinetics studies suggest that AA derivatives bind to HATs
in the Ac-CoA binding pocket. Nevertheless, the binding configuration remains to be
solved. This could be done by resolution of the crystal structure of HATs in complex
with AA or its derivatives. Detailed knowledge of the binding configuration will
provide a good basis for structure-based design of novel inhibitors with improved
affinity and selectivity. In our studies, the screening for inhibitory activity indicates
that hydrophobic interactions are extremely important for the inhibition of HATs by
6-alkylsalicylates. Not only an extended and hydrophobic substituent in the
salicylate 6-position is essential for HAT inhibition, but also the introduction of
heteroatoms causes drop in potency. At the same time, the hydrophobicity and the
amphiphilic nature of 6-alkylsalicylates are considered to be a disadvantage for the
drug-like character. Consequently, it is particularly challenging to develop 6-
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alkylsalicylates with high affinity for HATs, without compromising the drug
properties compounds.
Despite their limited potency and selectivity, currently available HAT inhibitors
have been extensively investigated as potential anticancer drugs. In contrast, the
use of HAT inhibitors in studies on inflammation is still very limited. Inflammation
is of particular interest because recent literature clearly indicates that HATs play
crucial regulatory roles in the NF-κB signaling pathway. The novel HAT inhibitors
described in this thesis could be applied in pharmacological studies to explore their
potential as anti-inflammatory drugs. Recent experiments demonstrated that both
AA and compound 2.2e inhibited histone acetylation in human airway smooth
muscle cells. Furthermore, both compounds inhibited the interleukin 8 release upon
stimulation of cells with tumor necrosis factor α (unpublished data – Department of
Molecular Pharmacology, University of Groningen). These data indicate that the
effects of HAT inhibitors on the NF-κB-mediated expression of pro-inflammatory
genes should be explored further. Ultimately, this would identify HAT inhibition as
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Dutch summary (Nederlandse samenvatting)
De modulatie van epigenetische modificaties door kleine moleculen biedt
mogelijkheden om de expressie van bepaalde ziekte gerelateerde genen te
beïnvloeden. Dit soort kleine moleculen kunnen toegepast worden voor
farmacologische studies aan specifieke ziektemodellen. Uiteindelijk zouden zulke
kleine moleculen gebruikt kunnen worden in potentiële nieuwe geneesmiddelen.
Er zijn remmers geïdentificeerd voor verschillende enzymen die betrokken zijn
bij epigenetische modificaties. Deze remmers hebben een belangrijke rol gespeeld bij
het ontrafelen van epigenetische regulatie mechanismen. Verschillende DNA-
methylatie-remmers en histone deacetylase (HDAC) remmers worden momenteel
onderzocht in klinische studies. Sommigen van hen zijn reeds beschikbaar voor
klinisch gebruik (Azacitidine, Vorinostat). De ontwikkeling van histone
acetyltransferase (HAT) remmers bleek echter een grotere uitdaging. Ondanks
aanzienlijke inspanningen hebben HAT-remmers nog steeds een beperkte
werkzaamheid, een lage selectiviteit of een beperkte cel-permeabiliteit. Het ontwerp
van nieuwe en verbeterde HAT-remmers biedt mogelijkheden voor onderzoek naar
mogelijke therapeutische toepassingen van deze klasse van remmers op het gebied
van ontstekingen en kanker. Recente studies tonen duidelijk aan dat ongepaste of
buitensporige ontstekingsreacties vaak gepaard gaan met hyperacetylering van
histonen en andere eiwitten die betrokken zijn bij de transcriptie van pro-
inflammatoire genen. Er wordt ook steeds meer bewijs gevonden dat afwijkingen in
acetyleringen vaak worden geassocieerd met de ontwikkeling van een groot aantal
vormen van kanker.
Het werk beschreven in dit proefschrift richt zich op de synthese en biologische
evaluatie van nieuwe HAT-remmers. De grote uitdaging is het vinden van krachtige
en selectieve HAT-remmers die histon acetylering remmen in cellenlijnen. Wij
rapporteren het ontwerp van krachtige isothiazolone gebaseerde remmers van het
HAT PCAF, die cytotoxisch zijn voor verschillende kankercellijnen. Verder
beschrijven we de ontwikkeling van een stoffen die afgeleid zijn van het
natuurproduct ‘anacardic acid’ (AA) dat histonacetylering in cellen remt. Verder
beschrijven we de identificatie van een nieuw 6-alkylsalicylaat derivaat als een





Het eerste deel van dit proefschrift beschrijft het ontwerp van nieuwe HAT-remmers
op basis van een isothiazolon kernstructuur. In hoofdstuk 2 beschrijven we de
synthese van een kleine verzameling van isothiazolon derivaten, die in vitro
gescreend zijn voor de remming van de recombinante HAT, PCAF waarmee de
structuur-activiteit relatie (SAR) voor deze stofklasse zijn bestudeerd. In deze studie
identificeerden we stof 2.2e (figuur a.1) als de meest krachtige remmer, wat
suggereert dat een methyl ester met een ‘spacer’ van twee koolstofatomen tussen de
isothiazolone ring extra interacties met het enzym PCAF geeft. Verder hebben we
vastgesteld dat een chloride atoom in de 5-positie van het isothiazolon met N-
alifatische substituent essentieel is voor hun remmende eigenschappen. In
tegenstelling daarmee, waren er geen uitgesproken verschillen in het PCAF
remmende vermogen tussen de 5-chloroisothiazolonen en isothiazolonen met een N-
aromatische substituent. De kleine verschillen tussen de IC50 waarden van
verschillende 5-chloroiosthiazolones geven aan dat de reactiviteit van deze
verbindingen naar het thiolaat in het actieve  van het enzym een overheersende rol
speelt in de remming van deze enzymen. Daarnaast hebben we gevonden dat stof
2.4e (figuur a.1) de HAT ook remt. Dit identificeert 5-chloroisothiazolone-1-oxides als
een nieuwe klasse van HAT-remmers.
Figuur a.1: isothiazolon derivaten.
In hoofdstuk 3 hebben we de reactie van isothiazolon derivaten met thiolen en
thiolaten beter onderzocht om meer inzicht te krijgen in de chemische reactiviteit
van deze verbindingen. We laten zien dat 5-chloroisothiazolonen snel reageren met
thiolaten en dat dit meerdere producten oplevert. In tegenstelling hiermee, levert de
reactie van een 5-chloroisothiazolone-1-oxide met een thiolaat een gedefinieerd
product op dat ontstaat door additie van het thiolaat op de 5-positie en eliminatie
van het chloride. Dit resulteert in het 5-alkylthioisothiazolone-1-oxide. Dit
ondersteunt de hypothese dat de remming van de HATs door isothiazolon derivaten
het gevolg is van hun reactiviteit ten opzichte van thiolaten. De opheldering van de
chemische reactiviteit bevestigt dat isothiazolonen toegepast kunnen worden in




Daarnaast hebben we synthetische modificaties aangebracht in de isothiazolon
ring en hebben we bestudeerd hoe dit de remming van de HAT PCAF beïnvloedt. De
reactiviteit van het isothiazolon kan worden gemoduleerd door de invoering van
elektron-zuigende of elektron-stuwende substituenten op de 4-positie. We hebben
laten zien dat de invoering van een methylgroep in de 4-positie van de isothiazolon
ring een aanzienlijke daling van de remmende potentie veroorzaakt. Aan de andere
kant, heeft de invoering van een chlooratoom in de 4-positie geen invloed op de
remmende eigenschappen van 5-chloroisothiazolonen, terwijl het wel een daling van
het remmend vermogen van 5-chloroisothiazolone-1-oxiden veroorzaakt. De relatie
tussen de thiolaat reactiviteit en HAT remming blijkt niet gemakkelijk te kunnen
worden afgeleid. Dit kan verklaard worden doordat het remmend vermogen van deze
stoffen zowel veroorzaakt wordt door hun bindende eigenschappen aan het actieve
centrum van het enzym alsook door hun reactiviteit met de thiolaat in het actieve
centrum van het enzym.
In de hoofdstukken 2 en 3 hebben we de groeiremming van verschillende
cellijnen na behandeling met isothiazolonen bestudeerd om de toxiciteit van deze
verbindingen vast te stellen. Deze studies tonen aan dat N-gesubstitueerde
alifatische 5-chloroisothiazolonen de groei remmen van de kankercellijnen HEP G2,
A2780 en HEK 293 bij micromolaire concentraties. Er wordt voor deze cellijnen
weinig of geen groeiremming waargenomen bij de andere isothiazolon derivaten. De
verschillen in de PCAF remming zijn niet gecorreleerd aan de remming van de
celgroei. Dit kan te wijten zijn aan verschillen in de celmembraan permeabiliteit
tussen de verbindingen of aan andere factoren. De waargenomen cytotoxische effect
van de N-gesubstitueerde alifatische 5-chloroisothiazolonen geeft aan dat deze
stoffen mogelijk toepassingen kunnen vinden bij het doden van tumorcellen.
Anacardic acid derivaten
Het tweede deel van dit proefschrift beschrijft de ontwikkeling van nieuwe HAT-
remmers op basis van het natuurproduct ‘anacardic acid’ (AA). In hoofdstuk 4
presenteren we een bindingsmodel voor AA aan het active centrum van de HAT
PCAF. Het salicylaat is gebonden aan de pyrofosfaat bindingsplaats en de alkylketen
is gelegen in de CoA substraat bindingsplaats. Dit bindingsmodel kan worden
gebruikt als uitgangspunt voor het ontwerp van nieuwe moleculen om het remmende
vermogen te optimaliseren. Wij hebben een aantal AA-derivaten ontworpen en
gesynthetiseerd. De synthese verliep via een nieuwe, handige en veelzijdige
synthetische route. We hebben onderzoek gedaan naar het in vitro remmend
vermogen van deze derivaten tegen de recombinante HAT PCAF. In het algemeen
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vertoonden de gesynthetiseerde verbindingen een slechte remming van de HAT
PCAF. De meeste stoffen waren even actief of minder actief dan AA. Het
natuurproduct AA heeft slechte geneesmiddel-achtige eigenschappen, zoals een log
P-waarde die hoger dan 5 is. Onze nieuwe remmers hebben een lagere log P waarde
wat gunstig is voor de geneesmiddel-achtige eigenschappen. Stof 4.6d (figuur a.2)
was de enige verbinding die actiever was dan AA in de enzymremmingstudies.
Bovendien, vertoonde dit derivaat ook een twee-voudig verbeterde potentie voor
remming van histon H4 acetylering in cel-gebaseerde studies. Daarom kan stof 4.6d
als een nieuwe remmer gebruikt worden in farmacologische studies om de remming
van histonacetylering in cellen te bestuderen. Het is een interessant punt dat stof
4.6d de enige verbinding is met een cis dubbele binding in de substituent op
salicylaat 6-positie. Deze conformationele restrictie zou de de verbeterde remming
kunnen verklaren. Echter, er moeten meer verbindingen met een cis dubbele binding
worden beoordeeld om deze mogelijke correlatie te bevestigen.
Figuur a.2: anacardic acid derivaten.
In hoofdstuk 5 hebben we de specificiteit bestudeerd van een verzameling van
salicylaat derivaten voor de verschillende klassen HATs. We hebben nieuwe
salicylaat derivaten gesynthetiseerd met verschillende 2-fenylethaan substituenten
in de salicylaat 6-positie. Het doel was om de affiniteit van deze verbindingen voor
het enzym te verbeteren door extra specifieke interacties. Alle salicylaat derivaten
werden gescreend voor de remming van de recombinante HATs Tip60, PCAF en
p300. Deze HATs zijn representatief voor de drie grote HAT families. In het
algemeen vertonen de gesynthetiseerde verbindingen een sterker remmend effect op
Tip60 in vergelijking met p300 en PCAF. Stof 5.20 (figuur a.2) laat de hoogste
selectiviteit voor Tip60 zien. Bovendien is de berekende logP waarde aanzienlijk
lager dan die van AA, wat, in het algemeen, een voordeel is voor de biologische
activiteit. Al met al, is stof 5,20 een nieuwe HAT-remmer met een verbeterd iso-
enzym selectiviteit en betere geneesmiddel-achtige eigenschappen. Deze verbinding
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kunnen gebruikt worden in cel-gebaseerde studie naar de biologische functies van
Tip60.
Verbindingen die de recombinante HAT Tip60 remmen die remmen in
vergelijkbare concentraties ook de HAT-activiteit in nucleaire extracten van HeLa
cellen. Dit suggereert dat Tip60 of nauw verwante HATs van belang zijn voor HAT-
activiteit in deze cellen. Interessant is dat sommige remmers een verschil laten zien
tussen het remmend vermogen voor histon H3 en H4. Deze gegevens suggereren dat
selectieve remmers voor histon H3 of H4 acetylering kunnen worden ontwikkeld.
We hebben het mechanisme bestudeerd van de HAT-remming door de AA-
derivaten met behulp van enzymkinetiek. Deze studies laten zien dat remming van
Tip60 door stof 5,20 competitief is met Ac-CoA en niet-competitieve naar histon H4.
Dit ondersteund onze hypothese dat AA derivaten binden aan de Ac-CoA-
bindingsplaats.
Toekomstperspectieven
Toekomstige werkzaamheden zouden zich moeten richten op het ontwerp van
verbeterde HAT-remmers en de evaluatie van hun biologische eigenschappen in
farmacologische studies.
Er zijn verschillende isothiazolon-gebaseerde PCAF remmers in dit proefschrift
beschreven die cytotoxisch zijn voor verschillende kankercellijnen. Verder onderzoek
is nodig om de biologische mechanismen die ten grondslag liggen aan de
celgroeiremming te bestuderen. Bijvoorbeeld, western blot analyse van histon
acetylering niveaus in cellijnen die zijn behandeld met HAT remmers zijn nodig om
het bewijs te leveren dat PCAF HAT inhibitie verband houdt met de groeiremming
van kankercellijnen. Deze studies zijn nodig om HAT-remmers te valideren als
kandidaat-geneesmiddelen voor de behandeling van kanker.
We hebben aangetoond dat de verbindingen 2.2e en 2.4 snel covalent binden aan
thiolaten. Functionele groepen die covalent reageren met thiolates worden vaak
gebruikt voor activity-based-protein-profiling (ABPP) van enzymen met een cysteine
in hun actieve centrum. 5-chloroisothiazolonen en 5-chloroisothiazolon-1-oxiden
kunnen worden toegepast voor ABPP van HATs die een cysteine bevatten in hun
actieve centrum. Echter, chemische detectiemoleculen die worden toegepast in ABPP
moeten over een zekere mate van specificiteit beschikken. De evaluatie van de SAR
voor remming van de HAT PCAF in dit proefschrift is een eerste stap in de




Docking studies en de enzymkinetiek suggereren dat AA derivaten een niet-
covalente binding aangaan met HATs in de Ac-CoA bindingsplaats. Het is van
belang dat de bindingsconfiguratie van deze stoffen in detail wordt opgehelderd. Dit
zou gedaan kunnen worden door het maken van een kristalstructuur van HATs in
complex met AA of derivaten daarvan. Gedetailleerde kennis van de
bindingsconfiguratie is een goede basis voor ‘structure-based design’ van nieuwe
remmers met een verbeterde affiniteit en selectiviteit. Onze studies met een
verzameling van 30 6-alkylsalicylaten geeft aan dat hydrofobe interacties uiterst
belangrijk zijn voor de remming van HATs door 6-alkylsalicylaten. Dit blijkt doordat
een lange en hydrofobe substituent in de salicylaat 6-positie essentieel is voor HAT-
remming en dat het invoeren van heteroatomen een daling veroorzaakt van hun
activiteit. Tegelijkertijd, is de hydrofobiciteit en het amfifiele karakter van 6-
alkylsalicylates een nadeel voor de geneesmiddel-achtig eigenschappen van deze
stoffen. Hieruit blijkt dat het bijzonder uitdagend is 6-alkylsalicylates te
ontwikkelen met een hoge affiniteit voor HATs, zonder afbreuk te doen aan de
geneesmiddel-achtige eigenschappen van deze verbindingen.
Ondanks hun beperkte potentie en selectiviteit zijn de momenteel beschikbare
HAT-remmers uitgebreid onderzocht als potentiële anti-kanker geneesmiddelen. In
tegenstelling daarmee is het gebruik van de HAT-remmers in onderzoek naar
onstekingen nog zeer beperkt. HAT remming is van bijzonder belang voor
onstekingen. De recente literatuur geeft duidelijk aan dat de regulatie van de NF-κB
signaal transductie route in belangrijke mate gestimuleerd wordt door de activiteit
van HATs. De HAT-remmers beschreven in dit proefschrift kunnen worden
toegepast in farmacologische studies om hun potentieel als anti-inflammatoire
geneesmiddelen te onderzoeken. Recente experimenten hebben aangetoond dat
zowel AA en stof 2.2e de histon-acetylering remmen in humane gladde spiercellen
uit de luchtwegen. Bovendien remmen beide verbindingen het vrijkomen van
interleukine 8 na de stimulatie van cellen met tumor necrose factor α
(ongepubliceerde gegevens - Afdeling Moleculaire Farmacologie, Universiteit van
Groningen). Deze gegevens wijzen erop dat de effecten van de HAT-remmers op de
NF-κB gemedieerde expressie van pro-inflammatoire genen verder moet worden
onderzocht. Uiteindelijk zou dit HAT remming kunnen identificeren als conceptueel
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